<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders - Dold, M - 2015 | Cochrane Library</title> <meta content="Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders - Dold, M - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009831.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders - Dold, M - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009831.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009831.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders" name="citation_title"/> <meta content="Markus Dold" name="citation_author"/> <meta content="markus.dold@lrz.tu-muenchen.de" name="citation_author_email"/> <meta content="Myrto T Samara" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Chunbo Li" name="citation_author"/> <meta content="Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine" name="citation_author_institution"/> <meta content="Magdolna Tardy" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Stefan Leucht" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD009831.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/01/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009831.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009831.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009831.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Antipsychotic Agents [adverse effects, *therapeutic use]; Haloperidol [adverse effects, analogs &amp; derivatives, *therapeutic use]; Loxapine [adverse effects, therapeutic use]; Psychotic Disorders [*drug therapy]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]; Trifluoperazine [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009831.pub2&amp;doi=10.1002/14651858.CD009831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="jxlIh5Me";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009831\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009831\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009831.pub2",title:"Haloperidol versus first\\u2010generation antipsychotics for the treatment of schizophrenia and other psychotic disorders",firstPublishedDate:"Jan 16, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009831.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009831.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009831.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009831.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009831.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009831.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009831.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009831.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009831.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009831.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6730 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009831.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-sec-0200"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-sec-0094"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-sec-0183"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/table_n/CD009831StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/table_n/CD009831StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information#CD009831-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Markus Dold</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information#CD009831-cr-0003">Myrto T Samara</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information#CD009831-cr-0004">Chunbo Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information#CD009831-cr-0005">Magdolna Tardy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information#CD009831-cr-0006">Stefan Leucht</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information/en#CD009831-sec-0213">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 January 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009831.pub2">https://doi.org/10.1002/14651858.CD009831.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009831-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009831-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009831-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009831-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009831-abs-0001" lang="en"> <section id="CD009831-sec-0001"> <h3 class="title" id="CD009831-sec-0001">Background</h3> <p>Haloperidol is worldwide one of the most frequently used antipsychotic drugs with a very high market share. Previous narrative, unsystematic reviews found no differences in terms of efficacy between the various first‐generation (“conventional”, "typical") antipsychotic agents. This established the unproven psychopharmacological assumption of a comparable efficacy between the first‐generation antipsychotic compounds codified in textbooks and treatment guidelines. Because this assumption contrasts with the clinical impression, a high‐quality systematic review appeared highly necessary. </p> </section> <section id="CD009831-sec-0002"> <h3 class="title" id="CD009831-sec-0002">Objectives</h3> <p>To compare the efficacy, acceptability, and tolerability of haloperidol with other first‐generation antipsychotics in schizophrenia and schizophrenia‐like psychosis. </p> </section> <section id="CD009831-sec-0003"> <h3 class="title" id="CD009831-sec-0003">Search methods</h3> <p>In October 2011 and July 2012, we searched the Cochrane Schizophrenia Group’s Trials Register, which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. To identify further relevant publications, we screened the references of all included studies and contacted the manufacturers of haloperidol for further relevant trials and missing information on identified studies. Furthermore, we contacted the corresponding authors of all included trials for missing data. </p> </section> <section id="CD009831-sec-0004"> <h3 class="title" id="CD009831-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) that compared oral haloperidol with another oral first‐generation antipsychotic drug (with the exception of the low‐potency antipsychotics chlorpromazine, chlorprothixene, levopromazine, mesoridazine, perazine, prochlorpromazine, and thioridazine) in schizophrenia and schizophrenia‐like psychosis. Clinically important response to treatment was defined as the primary outcome. Secondary outcomes were global state, mental state, behaviour, overall acceptability (measured by the number of participants leaving the study early due to any reason), overall efficacy (attrition due to inefficacy of treatment), overall tolerability (attrition due to adverse events), and specific adverse effects. </p> </section> <section id="CD009831-sec-0005"> <h3 class="title" id="CD009831-sec-0005">Data collection and analysis</h3> <p>At least two review authors independently extracted data from the included trials. The methodological quality of the included studies was assessed using The Cochrane Collaboration`s 'Risk of bias' tool. </p> <p>We analysed dichotomous outcomes with risk ratios (RR) and continuous outcomes with mean differences (MD), both with the associated 95% confidence intervals (CI). All analyses were based on a random‐effects model and we preferably used data on an intention‐to‐treat basis where possible. </p> </section> <section id="CD009831-sec-0006"> <h3 class="title" id="CD009831-sec-0006">Main results</h3> <p>The systematic review currently includes 63 randomised trials with 3675 participants. Bromperidol (n = 9), loxapine (n = 7), and trifluoperazine (n = 6) were the most frequently administered antipsychotics comparator to haloperidol. The included studies were published between 1962 and 1993, were characterised by small sample sizes (mean: 58 participants, range from 18 to 206) and the predefined outcomes were often incompletely reported. All results for the main outcomes were based on <i>very low or low quality</i> data. In many trials the mechanism of randomisation, allocation, and blinding was frequently not reported. In short‐term studies (up to 12 weeks), there was no clear evidence of a difference between haloperidol and the pooled group of the other first‐generation antipsychotic agents in terms of the primary outcome "clinically important response to treatment" (40 RCTs, n = 2132, RR 0.93 CI 0.87 to 1.00). In the medium‐term trials, haloperidol may be less effective than the other first‐generation antipsychotic group but this evidence is based on only one trial (1 RCT, n = 80, RR 0.51 CI 0.37 to 0.69). </p> <p>Based on limited evidence, haloperidol alleviated more positive symptoms of schizophrenia than the other antipsychotic drugs. There were no statistically significant between‐group differences in global state, other mental state outcomes, behaviour, leaving the study early due to any reason, due to inefficacy, as well as due to adverse effects. The only statistically significant difference in specific side effects was that haloperidol produced less akathisia in the medium term. </p> </section> <section id="CD009831-sec-0007"> <h3 class="title" id="CD009831-sec-0007">Authors' conclusions</h3> <p>The findings of the meta‐analytic calculations support the statements of previous narrative, unsystematic reviews suggesting comparable efficacy of first‐generation antipsychotics. In efficacy‐related outcomes, there was no clear evidence of a difference between the prototypal drug haloperidol and other, mainly high‐potency first‐generation antipsychotics. Additionally, we demonstrated that haloperidol is characterised by a similar risk profile compared to the other first‐generation antipsychotic compounds. The only statistically significant difference in specific side effects was that haloperidol produced less akathisia in the medium term. The results were limited by the low methodological quality in many of the included original studies. Data for the main results were <i>low or very low quality</i>. Therefore, future clinical trials with high methodological quality are required. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009831-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009831-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009831-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009831-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009831-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009831-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009831-abs-0003" lang="en"> <h3>Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia</h3> <p>Haloperidol is one of the most frequently used antipsychotic drugs worldwide. It is a first‐generation antipsychotic drug. Haloperidol is highly effective in treating the ‘positive symptoms’ of schizophrenia, such as hearing voices, seeing things and having strange beliefs. However, haloperidol also has serious side effects such as involuntary shaking, blurred vision, having a dry mouth and causing strange postures. Psychiatrists and people with schizophrenia often face a trade‐off between protection against mental illness and coping with these severe side effects. </p> <p>Previous small studies and unsystematic reviews have found no difference between the various first‐ generation antipsychotic drugs. This has led to the assumption that these drugs are similar in effectiveness (despite observations by psychiatrists and health professionals that these drugs do sometimes differ in their effectiveness and side effects). Because of high prescription‐rates, research on haloperidol is very important. </p> <p>A search for randomised trials was run in 2012. This review includes 63 trials with 3675 participants. Haloperidol was compared with a large number of other first‐generation antipsychotic drugs (including bromperidol, loxapine and trifluoperazine) to assess its effectiveness, acceptability and tolerability. The findings of the review support the evidence of previous small, narrative studies and unsystematic reviews. There was no difference between haloperidol and other mainly high‐potency first‐generation antipsychotic drugs. In addition, haloperidol was characterised by a similar risk profile and side effects to other first‐generation antipsychotic drugs. People receiving haloperidol were less likely to experience akathisia in the medium term. Occurrence of other specific side effect such as tremor, dystonia, dyskinesia and rigor were all similar between treatment groups. Psychiatrists and people with schizophrenia should know that haloperidol and other first‐generation antipsychotic drugs are similar in their effectiveness and risk of side effects. These drugs should also be similar in their acceptability for people with schizophrenia. </p> <p>However, results were limited due to the low quality of many of the included studies and low quality of evidence provided. Future studies of higher quality are required. </p> <p>This plain language summary has been written by a consumer Ben Gray: Senior Peer Researcher <a href="https://legacy.nottingham.ac.uk/OWA/redir.aspx?C=iLZxnz7hhUqT0R6I4wP35wFsjGlD0dFIp4rJjmsKe-CSeoDmt2afljQeOQn_6BMpIbIm0Jzll9c.%26URL=http%3a%2f%2fwww.mcpin.org" target="_blank">www.mcpin.org</a>. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009831-sec-0200" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009831-sec-0200">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009831-sec-0265">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009831-sec-0200"></div> <h3 class="title" id="CD009831-sec-0201">Implications for practice</h3> <section id="CD009831-sec-0201"> <section id="CD009831-sec-0202"> <h5 class="title">1. For clinicians</h5> <p>Based on the currently available randomised trial‐evidence, we found that haloperidol and the other evaluated first‐generation antipsychotic agents are characterised by a comparable efficacy for the treatment of schizophrenia and/or other psychotic disorders. Additionally, our results suggest a similar acceptability and tolerability of haloperidol and the other conventional antipsychotic drugs. However, the low methodological quality of many included studies probably confining the findings of our review should be taken into account. </p> </section> <section id="CD009831-sec-0203"> <h5 class="title">2. For people with schizophrenia</h5> <p>People with schizophrenia should know that ‐ in terms of first‐generation antipsychotics ‐ not only haloperidol is effective for the pharmacological treatment of schizophrenia and/or other psychotic disorders. The application of other first‐generation antipsychotics than haloperidol can also improve schizophrenic symptoms to a comparable extent. They are generally associated with the occurrence of a comparable number of adverse effects to that of haloperidol. In our statistics, the only clear difference in terms of side effects was that haloperidol produced less akathisia in the medium‐term trials. However, it should be taken into account as a limitation of this review that many included individual studies were characterised by a low methodological quality. Therefore, our results should be interpreted very carefully. More research is needed to appraise differences in efficacy and tolerability between haloperidol and the other first‐generation antipsychotics more accurately. Therefore, future clinical trials with a higher methodological quality are required. </p> </section> <section id="CD009831-sec-0204"> <h5 class="title">3. For managers and policy makers</h5> <p>The efficacy of other first‐generation antipsychotic drugs than haloperidol in schizophrenia and/or other psychotic disorders is supported by this systematic review. </p> </section> </section> <h3 class="title" id="CD009831-sec-0205">Implications for research</h3> <section id="CD009831-sec-0205"> <section id="CD009831-sec-0206"> <h5 class="title">1. General</h5> <p>Any future trials should consider standards of measuring outcomes and of reporting data in order to enhance the comparability of the results of clinical trials. Therefore, strict adherence to the CONSORT statement (<a href="./references#CD009831-bbs2-0187" title="SchulzKF , AltmanDG , MoherD , CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials2010;11:32. ">Schulz 2010</a>) should be ensured in future research projects. Following the CONSORT statement very closely would help to increase the amount of data for further reviews on this topic considerably. </p> </section> <section id="CD009831-sec-0207"> <h5 class="title">2. Specific</h5> <section id="CD009831-sec-0208"> <h6 class="title">2.1 Reviews</h6> <p><a href="#CD009831-tbl-0004">Table 2</a>, derived from the studies excluded for this review (please refer to <a href="./references#CD009831-sec-0220" title="">Characteristics of excluded studies</a> for details), contains suggestions for the elaboration of further reviews and for further comparisons probably relevant to reviews already existing. </p> <div class="table" id="CD009831-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies and suggestions for relevant reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Existing review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0064" title="Al HaddadMK , KamelC , SequeriaRP , MawgoodMA . Zuclopenthixol versus haloperidol in the initial treatment of schizophrenic psychoses, affective psychoses and paranoid states: a controlled clinical trial. Arab Journal of Psychiatry1996;7:44‐54. ">Al Haddad 1996</a>, <a href="./references#CD009831-bbs2-0072" title="ChinCN , HamidAR , PhilipG , RamleeT , MahmudM , ZulkifliG , et al. A double‐blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. Medical Journal of Malaysia1998;53:365‐71. ">Chin 1998</a>, <a href="./references#CD009831-bbs2-0099" title="LamureM , ToumiM , ChabannesJP , DansetteGY , BenyayaJ , HansenK . Zuclopenthixol versus haloperidol: an observational randomised pharmacoeconomic evaluation of patients with chronic schizophrenia exhibiting acute psychosis. International Journal of Psychiatry in Clinical Practice2003;7:177‐85. ">Lamure 2003</a>, <a href="./references#CD009831-bbs2-0104" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1:541‐8. ">Lublin 1991</a>, <a href="./references#CD009831-bbs2-0106" title="MosolovSN , MolodetskikhAV , EryominAV , GraikovGM , NourislamovSV . Effect and tolerability of clopixol and haloperidol in patients with acute symptoms of schizophrenia: comparative randomised investigation. Sotsial'naia I Klinicheskaia Psikhiatria2000;10:47‐52. ">Mosolov 2000</a>, <a href="./references#CD009831-bbs2-0122" title="TaymeeyapraditU , KuasirikulS . Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. Journal of the Medical Association of Thailand2002;85:1301‐8. ">Taymeeyapradit 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus zuclopenthixol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0162" title="JayakodyK , GibsonRC , KumarA , GunadasaS . Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD000525.pub3] ">Jayakody 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0066" title="AzimaH , DurostH , ArthursD . The effect of R‐1625 (haloperidol) in mental syndromes: a multiblind study. American Journal of Psychiatry1960;117:546‐7. ">Azima 1960</a>, <a href="./references#CD009831-bbs2-0076" title="CrowTJ , MacMillanJF , JohnsonAL , JohnstoneEC . A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry1986;148:120‐7. MacMillanJF , CrowTJ , JohnsonAL , JohnstoneEC . British Journal of Psychiatry. Short‐term outcome in trial entrants and trial eligible patients1986;148:128‐33. ">Crow 1986</a>, <a href="./references#CD009831-bbs2-0081" title="DurostH , LeeH , ArthursD . An early evaluation of haloperidol. In: LehmannHE , BanTA editor(s). The Butyrophenones in Psychiatry. Quebec Psychopharmacological Research Association, 1964:70‐3. ">Durost 1964</a>, <a href="./references#CD009831-bbs2-0117" title="SimpsonGM , AngusJW , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research, Clinical and Experimental1967;9:407‐12. SimpsonGM , CooperTB , BraunGA . Further studies on the effect of butyrophenones on cholesterol synthesis in humans. Current Therapeutic Research, Clinical and Experimental1967;9:413‐8. ">Simpson 1967</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0128" title="AdamsCE , BergmanH , IrvingCB , LawrieS . Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003082.pub3] ">Adams 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0069" title="BechelliLP , Navas‐FilhoF . Short term double‐blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia. L'Encephale1986;12:121‐5. ">Bechelli 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus pipothiazine palmitate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0070" title="BoyerP , PuechAJ . Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools [Modalities d'action clinique des neuroleptiques: substances, doses, instruments de mesure utilises]. Psychiatrie and Psychobiologie1987;2:296‐305. ">Boyer 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amisulpride versus placebo // amisulpride dosage // amisulpride versus fluphenazine // amisulpride versus haloperidol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0191" title="Silveira da Mota NetoJI , SoaresBGO , Silva de LimaM . Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD001357] ">Silveira 2002</a>; <a href="./references#CD009831-bbs2-0185" title="SampfordJ , SampsonS . Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010832] ">Sampford 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0074" title="ColeJO , TsuangMM . Haloperidol in geriatrics. Psychopharmacology Bulletin1970;6:86‐8. ">Cole 1970</a>, <a href="./references#CD009831-bbs2-0087" title="GerlachJ , SimmelsgaardH . Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology1978;59:105‐12. ">Gerlach 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus thioridazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0076" title="CrowTJ , MacMillanJF , JohnsonAL , JohnstoneEC . A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry1986;148:120‐7. MacMillanJF , CrowTJ , JohnsonAL , JohnstoneEC . British Journal of Psychiatry. Short‐term outcome in trial entrants and trial eligible patients1986;148:128‐33. ">Crow 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus placebo // flupenthixol versus placebo // pimozide versus placebo // trifluoperazine versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0129" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3] ">Adams 2014</a>, <a href="./references#CD009831-bbs2-0190" title="ShenX , XiaJ , AdamsCE . Flupenthixol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD009777.pub2] ">Shen 2012</a>, <a href="./references#CD009831-bbs2-0182" title="MothiM , SampsonS . Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD001949.pub3] ">Mothi 2013</a>, <a href="./references#CD009831-bbs2-0167" title="KochK , MansiK , HaynesE , AdamsCE , SampsonS , FurtadoVA . Trifluoperazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010226] ">Koch 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0075" title="CostaAMN , DeLimaMS , FariaM , FilhoSR , DeOliveiraIR , DeJesus MariJ . A naturalistic, 9‐month follow‐up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. Journal of Psychopharmacology2007;21:165‐70. ">Costa 2007</a>, <a href="./references#CD009831-bbs2-0078" title="deJesus MariJ , LimaMS , CostaAN , AlexandrinoN , Rodrigues‐FilhoS , deOliveiraIR , et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomised trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. European Archives of Psychiatry and Clinical Neuroscience2004;254:356‐61. ">de Jesus Mari 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antipsychotic drug versus olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0144" title="DugganL , FentonM , RathboneJ , DardennesR , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] ">Duggan 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0085" title="FitzgeraldCH . A double‐blind comparison of haloperidol with perphenazine. Current Therapeutic Research1969;11:515‐9. ">Fitzgerald 1969</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus perphenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0157" title="HartungB , WadaM , LauxG , LeuchtS . Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews2005, (1). [DOI: 10.1002/14651858.CD003443.pub2] ">Hartung 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0097" title="KelwalaS , BanTA , BerneySA , WilsonWH . Rapid tranquilization ‐ a comparative study of thiothixene and haloperidol. Progress in Neuropsychopharmacology and Biological Psychiatry1984;8:77‐83. ">Kelwala 1984</a>, <a href="./references#CD009831-bbs2-0101" title="LevensonAJ , BurnettGB , NottinghamJD , SermasCE , ThornbyJI . Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol. Current Therapeutic Research, Clinical and Experimental1976;20:695‐700. ">Levenson 1976</a>, <a href="./references#CD009831-bbs2-0120" title="StotskyBA . Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Diseases of the Nervous System1977;38:967‐73. ">Stotsky 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus thiothixene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0101" title="LevensonAJ , BurnettGB , NottinghamJD , SermasCE , ThornbyJI . Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol. Current Therapeutic Research, Clinical and Experimental1976;20:695‐700. ">Levenson 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine versus haloperidol // fluphenazine versus thiothixene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0103" title="LovettWC , StokesDK , TaylorLB , YoungML , FreeSM , PhelanDG . Management of behavioral symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol. Journal of Clinical Psychiatry1987;48:234‐36. ">Lovett 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus trifluoperazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0110" title="PaprockiJ , VersianiM . A double‐blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Current Therapeutic Research, Clinical and Experimental1977;21:80‐100. ">Paprocki 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus loxapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0138" title="ChakrabartiA , BagnallA , ChueP , FentonM , PalaniswamyV , WongW , et al. Loxapine for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 10. [DOI: 10.1002/14651858.CD001943.pub2] ">Chakrabarti 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0113" title="ReznikI , SirotaP , PsychM . Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. Journal of Clinical Psychopharmacology2000;20:410‐6. ">Reznik 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluvoxamine plus antipsychotic drug versus antipsychotic drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0114" title="SaletuB , KufferleB , GrunbergerJ , AndererP . Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy. Pharmacopsychiatry 19;1986:434‐7. ">Saletu 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluperlapine versus haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009831-sec-0209"> <h6 class="title">2.2 Trials</h6> <p>Although there were many randomised controlled trials carried out that compared haloperidol with other first‐generation antipsychotics, there is a need for more well‐designed randomised clinical studies. They are necessary because the methodological quality of the individual trials included in this review was low in many studies. Therefore, high‐quality trials are required to appraise the efficacy and tolerability of haloperidol in comparison to other first‐generation antipsychotics. For a suggested design of these studies please see <a href="#CD009831-tbl-0005">Table 3</a>. </p> <div class="table" id="CD009831-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggested design of study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, fully explicit description of methods of randomisation and allocation concealment.<br/> Blinding: blinded and independent raters.<br/> Duration: at least 52 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia (according to a diagnostic criteria).<br/> N = 300.*<br/> Age: adults.<br/> Sex: both. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Haloperidol. N = 150.</p> <p>2. Other first‐generation antipsychotic. N = 150.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global state: clinically important response to treatment, average score/change of the global state. </p> <p>General: time to all‐cause treatment failure marked by its discontinuation, relapse, general impression of clinician (CGI), carer/other, compliance with treatment, healthy days. </p> <p>Mental state: general measurement and specific domains (depressive symptoms, positive symptoms, negative symptoms) </p> <p>Leaving the study early (‘drop‐out’) due to any reason, due to inefficacy of treatment, and due to adverse events. </p> <p>Adverse events: any serious adverse event recorded.</p> <p>Service use: number of hospitalisation, days in hospital.<br/> Quality of life.<br/> Social functioning: return to everyday living for 80% of time.*<br/> Economic outcomes. </p> <p>Pharmacological interactions.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of ˜ 20% between groups for primary outcome with adequate degree of certainty. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CGI = Clinical Global Impression.</p> </div> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009831-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009831-sec-0015"></div> <div class="table" id="CD009831-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Haloperidol versus first‐generation antipsychotics for schizophrenia (short term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Haloperidol versus first‐generation antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia </p> <p><b>Setting:</b> inpatients and outpatients<br/> <b>Intervention:</b> haloperidol versus other first‐generation antipsychotics (short term) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>first‐generation antipsychotic drugs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> haloperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinically important response to treatment (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.93</b> <br/> (0.87 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2132<br/> (40 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>457 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>425 per 1000</b> <br/> (398 to 457) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>532 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>495 per 1000</b> <br/> (463 to 532) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to any reason as a measure of overall acceptability (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.04</b> <br/> (0.87 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1299<br/> (28 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>209 per 1000</b> <br/> (175 to 250) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>142 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> <br/> (124 to 176) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to inefficacy of treatment as a measure of overall efficacy (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.93</b> <br/> (0.4 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>507<br/> (13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> <br/> (17 to 94) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to adverse events as a measure of overall tolerability (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1</b> <br/> (0.42 to 2.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>640<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> <br/> (13 to 73) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: number of participants with at least one adverse effect (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.06</b> <br/> (0.94 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>693<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>615 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>652 per 1000</b> <br/> (578 to 738) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>588 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> <br/> (553 to 706) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.12</b> <br/> (0.95 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>998<br/> (17 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>409 per 1000</b> <br/> (347 to 479) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>410 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>459 per 1000</b> <br/> (389 to 537) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes<sup>6</sup>. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias ‐ rated 'very serious': many studies did not report the methods for sequence generation and/or allocation concealment and were not free from selective reporting.<br/> <sup>2</sup> Inconsistency ‐ rated 'no': there was no substantial level of heterogeneity (defined by an I<sup>2</sup> greater than or equal to 50% accompanied by a statistically significant Chi<sup>2</sup> test). The direction of the effect of almost all studies was the same. Therefore, the overall results are not challenged by inconsistency. </p> <p><sup>3</sup>Publication bias ‐ rated 'undetected': based on the largely symmetrical arrangement of the trials in the funnel plot the likelihood for the presence of a publication bias can be regarded as being low. </p> <p><sup>4</sup> Imprecision ‐ rated 'very serious': the 95% confidence interval around the pooled effect size includes "no effect", "appreciable benefit", and "appreciable harm". </p> <p><sup>5</sup> Imprecision ‐ rated 'serious': the 95% confidence interval around the pooled effect size includes both "no effect" and "appreciable harm".<br/> <sup>6</sup> The basis for the assumed risk was the risk in the pooled control group of the relevant studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009831-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Haloperidol versus first‐generation antipsychotics for schizophrenia (medium term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Haloperidol versus first‐generation antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia </p> <p><b>Setting:</b> inpatients and outpatients<br/> <b>Intervention:</b> haloperidol versus other first‐generation antipsychotics (medium term) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>first‐generation antipsychotic drugs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>haloperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinically important response to treatment (medium term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.51</b> <br/> (0.37 to 0.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>80<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>510 per 1000</b> <br/> (370 to 690) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>510 per 1000</b> <br/> (370 to 690) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to any reason as a measure of overall acceptability (medium term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.75 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>137<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>543 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>554 per 1000</b> <br/> (407 to 749) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>548 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>559 per 1000</b> <br/> (411 to 756) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early due to adverse events as a measure of overall tolerability (medium term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: number of participants with at least one adverse effect (medium term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.07</b> <br/> (0.58 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>137<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>657 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>703 per 1000</b> <br/> (381 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>708 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>758 per 1000</b> <br/> (411 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (medium term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.04</b> <br/> (0.62 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>80<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>421 per 1000</b> <br/> (251 to 708) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>421 per 1000</b> <br/> (251 to 709) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes<sup>7</sup>. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias ‐ rated 'very serious': many studies did not report the methods for sequence generation and/or allocation concealment and were not free from selective reporting.<br/> <sup>2</sup> Risk of bias ‐ rated 'very serious': many studies did not report the methods for sequence generation and/or allocation concealment and were not free from selective reporting. High risk of bias regarding other bias in two studies (<a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>, <a href="./references#CD009831-bbs2-0013" title="EngelhardtDM , RudorferL , RosenB . Haloperidol and thiothixene in the long‐term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment. Journal of Clinical Psychiatry1978;39:834‐40. ">Engelhardt 1978</a>) and in terms of blinding in one trial (<a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>). </p> <p><sup>3</sup> Inconsistency ‐ rated 'no': there was no substantial level of heterogeneity (defined by an I<sup>2</sup> greater than or equal to 50% accompanied by a statistically significant Chi<sup>2</sup> test). The direction of the effect of almost all studies was the same. Therefore, the overall results are not challenged by inconsistency. </p> <p><sup>4</sup> Inconsistency ‐ rated 'very serious': there was a substantial level of heterogeneity (defined by an I<sup>2</sup> greater than or equal to 50% accompanied by a statistically significant Chi<sup>2</sup> test). </p> <p><sup>5</sup> Publication bias ‐ rated 'undetected': based on the largely symmetrical arrangement of the trials in the funnel plot the likelihood for the presence of a publication bias can be regarded as being low.<br/> <sup>6</sup> Imprecision ‐ rated 'very serious': the 95% confidence interval around the pooled effect size includes "no effect", "appreciable benefit", and "appreciable harm".<br/> <sup>7</sup> The basis for the assumed risk was the risk in the pooled control group of the relevant studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009831-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009831-sec-0016">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009831-sec-0221">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD009831-sec-0016"></div> <section id="CD009831-sec-0017"> <h3 class="title" id="CD009831-sec-0017">Description of the condition</h3> <p>Schizophrenia is often a chronic and disabling psychiatric disorder. It afflicts approximately one per cent of the population worldwide with little gender differences. Schizophrenia ranks among the seven most frequent causes listed by the World Health Organization (WHO) for loss of years of life due to disability. Its typical manifestations are 'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<a href="./references#CD009831-bbs2-0137" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). The degree of suffering and disability is considerable with 80% to 90% not working (<a href="./references#CD009831-bbs2-0180" title="MarvahaS , JohnsonS . Schizophrenia and employment ? a review. Social Psychiatry and Psychiatric Epidemiology2004;39:337‐49. ">Marvaha 2004</a>) and up to 10% dying by suicide (<a href="./references#CD009831-bbs2-0198" title="TsuangMT . Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry1978;35:153‐5. ">Tsuang 1978</a>). </p> </section> <section id="CD009831-sec-0018"> <h3 class="title" id="CD009831-sec-0018">Description of the intervention</h3> <p>Antipsychotic drugs are the core treatment for schizophrenia. They can be classified according to their biochemical structure (e.g. butyrophenones, phenothiazines, thioxanthenes, etc.), their risk of producing movement disorders ('atypical' versus 'typical' antipsychotics) and the doses necessary for an antipsychotic effect (high‐potency versus low‐potency antipsychotics). They all have in common that they block to a greater or lesser extent, the transmission of dopamine in the brain. The classification into high‐potency and low‐potency compounds means that for low‐potency antipsychotic drugs higher doses are necessary to obtain the same dopamine receptor occupancy and efficacy than for high‐potency antipsychotic drugs (<a href="./references#CD009831-bbs2-0189" title="SeemanP , LeeT . Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science1975;188:1217‐9. ">Seeman 1975</a>). </p> <p>Haloperidol, the intervention in the present study, is one of the most frequently used antipsychotic compounds and still has a very high market share (<a href="./references#CD009831-bbs2-0178" title="LohseMJ , Müller‐OerlinghausenB . Psychopharmaka. In: U.Schwabe , D.Pfaffrath editor(s). Arzneimittelverordnungsreport. Heidelberg: Springer, 2009:767‐810. ">Lohse 2009</a>). It is a first‐generation ('typical', 'conventional') antipsychotic drug and belongs chemically to the butyrophenone series of neuroleptic compounds. Due to its very high antidopaminergic properties, haloperidol can be classified as a high‐potency antipsychotic agent. Its mean elimination half‐life has been reported to range from 15 to 37 hours and its bioavailability is 60% to 70% (<a href="./references#CD009831-bbs2-0168" title="KudoS , IshizakiT . Pharmacokinetics of haloperidol: an update. Clinical Pharmacokinetics1999;37:435‐56. ">Kudo 1999</a>), which indicates a high 'first‐pass‐effect'. Haloperidol is highly effective to treat schizophrenia, but on the other hand, it is associated with severe extrapyramidal adverse effects (EPS). The most predominant among these symptoms are dystonia, parkinsonian‐like syndrome, and tardive dyskinesia. Other side effects include anticholinergic effects (e.g. constipation, dry mouth, blurred vision, and urinary hesitancy), sexual dysfunction, elevations in serum prolactin, sedation and there could even be shown a relationship with sudden death. </p> <p>Therefore, clinicians and people with schizophrenia often face a trade‐off between protection against psychotic episodes and adverse effects. </p> </section> <section id="CD009831-sec-0019"> <h3 class="title" id="CD009831-sec-0019">How the intervention might work</h3> <p>The theory is that schizophrenia is caused by hyperdopaminergic states in the limbic system (<a href="./references#CD009831-bbs2-0134" title="BergerM . Psychische Erkrankungen. Klinik und Therapie. 2nd edition. München: Urban &amp; Fischer, 2003. ">Berger 2003</a>). All antipsychotic drugs block dopamine receptors. The assumption is that dopamine receptor blockade is mediating the antipsychotic effect. Therefore continuous treatment with antipsychotic compounds may be necessary to keep the dopaminergic tone low and to avoid psychotic relapses. </p> <p>There are cortical dopamine‐D2‐pathways, which seem to play an important role regarding the therapeutic and adverse effects of conventional antipsychotics: the nigrostriatal dopamine pathway (responsible for the EPS side effects), the mesolimbic and mesocortical dopamine pathways (responsible for the improvement of the positive symptoms), and the tuberoinfundibular dopamine pathway (responsible for hyperprolactinaemia). </p> <p>Because of its very high antagonism to dopamine‐D2‐receptors, haloperidol can be classified in the high‐potency antipsychotic agent group. On the other hand, compared to the other first‐generation antipsychotics, the affinity to dopamine‐D1‐receptors is relative low. </p> </section> <section id="CD009831-sec-0020"> <h3 class="title" id="CD009831-sec-0020">Why it is important to do this review</h3> <p>Haloperidol is one of the most frequently used antipsychotic drugs in Europe and the US (<a href="./references#CD009831-bbs2-0165" title="KayeJA , BradburyBD , JickH . Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population‐based observational study. British Journal of Clinical Pharmacology2003;56:569‐75. ">Kaye 2003</a>; <a href="./references#CD009831-bbs2-0184" title="PatonC , LelliottP , HarringtonM , OkochaC , SenskyT , DuffettR . Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. Journal of Psychopharmacology2003;17:223‐9. ">Paton 2003</a>). Additionally, it has been used as a standard comparator in randomised trials for the introduction of many other antipsychotics including the newer second‐generation antipsychotics. Haloperidol is also on the list of essential drugs of the WHO (<a href="./references#CD009831-bbs2-0199" title="World Health Organization (WHO). Essential drugs. WHO Drug Information2009;13:249‐92. ">WHO 2009</a>). Because of the high prescription‐rates, research on haloperidol is very important.<br/> <br/> First‐generation antipsychotic drugs are still the mainstay of treatment in countries that can not afford newer, expensive second‐generation antipsychotic drugs. But even in some industrialised countries such as Germany, conventional antipsychotic medications still have a very high market share (<a href="./references#CD009831-bbs2-0178" title="LohseMJ , Müller‐OerlinghausenB . Psychopharmaka. In: U.Schwabe , D.Pfaffrath editor(s). Arzneimittelverordnungsreport. Heidelberg: Springer, 2009:767‐810. ">Lohse 2009</a>). Recent reviews examining the more expensive second‐generation antipsychotics have also called their superiority into question (<a href="./references#CD009831-bbs2-0144" title="DugganL , FentonM , RathboneJ , DardennesR , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] ">Duggan 2005</a>; <a href="./references#CD009831-bbs2-0148" title="EssaliA , Al‐Haj HaasanN , LiC , RathboneJ . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2] ">Essali 2009</a>; <a href="./references#CD009831-bbs2-0161" title="HunterR , KennedyE , SongF , GadonL , IrvingCB . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a>; <a href="./references#CD009831-bbs2-0176" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta‐analysis comparing second‐generation and first‐generation antipsychotics for schizophrenia. Lancet2009;373:31‐41. ">Leucht 2009</a>; <a href="./references#CD009831-bbs2-0177" title="LiebermanJA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353:1209‐23. ">Lieberman 2005</a>; <a href="./references#CD009831-bbs2-0192" title="SrisurapanontM , ManeetonB , ManeetonN , LankappaS , GandhiR . Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 2. [DOI: 10.1002/14651858.CD000967.pub2] ">Srisurapanont 2004</a>). Therefore, research on the older first‐generation agents is essential. </p> <p>Previous narrative, unsystematic reviews found no differences in efficacy between conventional antipsychotics such as haloperidol (<a href="./references#CD009831-bbs2-0139" title="DavisJM , GarverDL . Neuroleptics: clinical use in psychiatry. In: L.Iversen , SIversen , S.Snyder editor(s). Handbook of Psychopharmacology. New York: Plenum Press, 1978. ">Davis 1978</a>; <a href="./references#CD009831-bbs2-0166" title="KleinDF , DavisJM . Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins, 1969. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969. ">Klein 1969</a>). This caused the unproven psychiatric assumption, codified in textbooks and guidelines (<a href="./references#CD009831-bbs2-0152" title="GaebelW , FalkaiP , WeinmannS . Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006. ">Gaebel 2006</a>; <a href="./references#CD009831-bbs2-0169" title="LehmanAF , LiebermanJA , DixonLB , McGlashanTH , MillerAL , PerkinsDO , et al. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry2004;161:1‐56. ">Lehman 2004</a>), that ‐ with the exception of clozapine ‐ there is no difference in efficacy between the available compounds. Due to this lack of evidence, treatment guidelines make statements such as “all conventional antipsychotics if adequately dosed have comparable efficacy” (German National Schizophrenia Guideline (<a href="./references#CD009831-bbs2-0152" title="GaebelW , FalkaiP , WeinmannS . Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006. ">Gaebel 2006</a>); or guideline of the World Federations of Societies of Biological Psychiatry (WFSBP) (<a href="./references#CD009831-bbs2-0149" title="FalkaiP , WobrockT , LiebermanJ , GlenthojB , GattazWF , MöllerHJ , et al. World Federation of Societies of Biological Psychiatry (WFSBP) ‐ Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry2005;6:132‐91. ">Falkai 2005</a>)).These guidelines contrast with the clinical impression that not all antipsychotic drugs are equally efficacious. This can be seen for example on the frequent selection of the high‐potency compound haloperidol for acutely ill schizophrenic patients. </p> <p>To close the empirical gap concerning this topic, we compared the standard first‐generation antipsychotic drug haloperidol with a large number of other frequently used first‐generation antipsychotic compounds. We excluded the low‐potency first‐generation drugs, because these were already addressed in other Cochrane Reviews (<a href="#CD009831-tbl-0003">Table 1</a>). We also excluded the so‐called second‐generation ('atypical') antipsychotics as comparators, because these have been extensively compared with haloperidol in other systematic reviews (e.g. <a href="./references#CD009831-bbs2-0148" title="EssaliA , Al‐Haj HaasanN , LiC , RathboneJ . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2] ">Essali 2009</a>; <a href="./references#CD009831-bbs2-0161" title="HunterR , KennedyE , SongF , GadonL , IrvingCB . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a>; <a href="./references#CD009831-bbs2-0176" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta‐analysis comparing second‐generation and first‐generation antipsychotics for schizophrenia. Lancet2009;373:31‐41. ">Leucht 2009</a>). </p> <div class="table" id="CD009831-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in this series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0175" title="LeuchtC , KitzmantelM , KaneJ , LeuchtS , ChuaWLLC . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2] ">Leucht 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol vs low‐potency first‐generation antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0193" title="TardyM , HuhnM , KisslingW , EngelRR , LeuchtS . Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009268] ">Tardy 2011a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perphenazine versus low‐potency first‐generation antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0194" title="TardyM , HuhnM , EngelRR , LeuchtS . Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD009369] ">Tardy 2011b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine versus low‐potency first‐generation antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0195" title="TardyM , HuhnM , EngelRR , LeuchtS . Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD009230] ">Tardy 2011c</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0196" title="TardyM , DoldM , EngelRR , LeuchtS . Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009396] ">Tardy 2011d</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flupenthixol versus low‐potency first‐generation antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0197" title="TardyM , DoldM , EngelRR , LeuchtS . Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD009227] ">Tardy 2011e</a> </p> </td> </tr> </tbody> </table> </div> <p>This review considers whether the statement of psychopharmacology is true that all antipsychotic drugs have the same efficacy. Thus, the findings have important impact on guidelines, clinical practise and our understanding of antipsychotic drugs. Additionally, it allows comparison of the different side effects of each compound on a large empirical basis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009831-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009831-sec-0021">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009831-sec-0226">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009831-sec-0021"></div> <p>To compare the efficacy, acceptability, and tolerability of the high‐potency first‐generation antipsychotic agent haloperidol with other first‐generation antipsychotics (with the exception of the low‐potency antipsychotics chlorpromazine, chlorprothixene, levopromazine, mesoridazine, perazine, prochlorpromazine, and thioridazine) in the pharmacotherapy of schizophrenia and other similar psychotic disorders. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009831-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009831-sec-0022">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009831-sec-0227">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009831-sec-0022"></div> <section id="CD009831-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009831-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised trials. We excluded quasi‐randomised studies such as those using allocation by day of the week, date of birth, or alternate allocation. This decision was based on the evidence of a strong relationship between allocation concealment and direction of effect (<a href="./references#CD009831-bbs2-0186" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. The Journal of the American Medical Association1995;273:408‐12. ">Schulz 1995</a>). </p> <p>Where a trial was described as 'double‐blind', but it was implied that the study was randomised, we included the trial in a sensitivity analysis. If there was no substantive difference within the primary outcome (see <a href="#CD009831-sec-0029">Types of outcome measures</a>) when these 'implied randomisation' studies were added, we included these studies in the final analysis. If there was a substantive difference, we only analysed clearly randomised trials and described the results of the sensitivity analysis in the text. </p> </section> <section id="CD009831-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included all randomised studies of participants with schizophrenia and other types of schizophrenia‐like psychoses (e.g. schizophreniform, schizoaffective, or delusional disorders), irrespective of the diagnostic system applied. There is no clear evidence that the schizophrenia‐like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<a href="./references#CD009831-bbs2-0137" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). In accordance with the general strategy of the Cochrane Schizophrenia Group (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">group module</a>), we included studies that had used other diagnostic criteria than those of the International Statistical Classification of Diseases and Related Health Problems (ICD) and the Diagnostic and Statistical Manual of Mental Disorders (DSM). These diagnostic criteria are not meticulously used in clinical routine either, so broader inclusion criteria will enhance applicability of findings. Patients were included without a restriction concerning age, gender and whether they were suffering from other conditions. </p> <p>If a study involved people with other diagnoses, we only included it if at least 75% of participants suffered from a schizophrenic syndrome or, if that was not the case, results regarding people exclusively with schizophrenia were reported. </p> <p>We included studies with participants suffering from first episode schizophrenia as well as multiple episodes. Additionally, we included trials investigating treatment‐resistant participants. We considered these different conditions by applying subgroup analyses. </p> </section> <section id="CD009831-sec-0026"> <h4 class="title">Types of interventions</h4> <section id="CD009831-sec-0027"> <h5 class="title">1. Haloperidol</h5> <p>Any oral form (oral tablets, oral liquids) at any dose. We excluded depot formulations. Injections (i.m. ‐ intramuscular, or i.v. ‐ intravenous) were allowed for initial treatment, but we included data only if people were transferred to oral medication within the first week. </p> </section> <section id="CD009831-sec-0028"> <h5 class="title">2. Control</h5> <p>Any other first‐generation antipsychotic agent that is currently available in at least one country worldwide with the exception of the low‐potency antipsychotics chlorpromazine, chlorprothixene, levopromazine, mesoridazine, perazine, prochlorpromazine, and thioridazine that were already compared with haloperidol in other Cochrane Reviews (<a href="#CD009831-tbl-0003">Table 1</a>) (<a href="./references#CD009831-bbs2-0175" title="LeuchtC , KitzmantelM , KaneJ , LeuchtS , ChuaWLLC . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2] ">Leucht 2008</a>; <a href="./references#CD009831-bbs2-0193" title="TardyM , HuhnM , KisslingW , EngelRR , LeuchtS . Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009268] ">Tardy 2011a</a>).<br/> <br/> The medication could be administered in any oral form (oral tablets, oral liquids) at any dose. We excluded depot formulations. Injections (i.m. ‐ intramuscular, or i.v. ‐ intravenous) were allowed for initial treatment, but we included data only if people were transferred to oral medication within the first week. </p> </section> </section> <section id="CD009831-sec-0029"> <h4 class="title">Types of outcome measures</h4> <p>The outcomes were analysed for different lengths of follow‐up: up to three months (short term), six months (medium term) or more than six months (long term). </p> <section id="CD009831-sec-0030"> <h5 class="title">Primary outcomes</h5> <p>Global state: Clinically important response to treatment.</p> <p>If presented, we used a cut‐off of at least 50% reduction of the baseline value of a rating scale such as the 'Positive and Negative Syndrome Scale' (PANSS; <a href="./references#CD009831-bbs2-0164" title="KaySR , FiszbeinA , OplerLA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13:261‐76. ">Kay 1987</a>) or the 'Brief Psychiatric Rating Scale' (BPRS; <a href="./references#CD009831-bbs2-0183" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>), because studies showed that this definition is clinically meaningful (<a href="./references#CD009831-bbs2-0171" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . What does the PANSS mean?. Schizophrenia Research2005;79:231‐8. ">Leucht 2005a</a>; <a href="./references#CD009831-bbs2-0172" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005b</a>; <a href="./references#CD009831-bbs2-0173" title="LeuchtS , KaneJM , EtschelE , KisslingW , HamannJ , EngelRR . Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology2006;31:2318‐25. ">Leucht 2006</a>). Otherwise we, used the definition of the original studies. </p> </section> <section id="CD009831-sec-0031"> <h5 class="title">Secondary outcomes</h5> <section id="CD009831-sec-0032"> <h6 class="title">1. Global state</h6> <p>1.1. Average score/change of the global state<br/> 1.2. Relapse ‐ as defined by each of the studies </p> </section> <section id="CD009831-sec-0033"> <h6 class="title">2. Mental state</h6> <p>2.1. General ‐ average score/change of the general mental state<br/> 2.2. Specific ‐ depersonalisation<br/> 2.3. Specific ‐ depressive symptoms<br/> 2.4. Specific ‐ manic symptoms<br/> 2.5. Specific ‐ negative symptoms<br/> 2.6. Specific ‐ positive symptoms </p> </section> <section id="CD009831-sec-0034"> <h6 class="title">3. Behaviour</h6> <p>3.1. General behaviour<br/> 3.2. Specific behaviour </p> </section> <section id="CD009831-sec-0035"> <h6 class="title">4. Leaving the study early (‘drop‐out’)</h6> <p>4.1. Due to any reason ‐ as a measure of overall acceptability<br/> 4.2. Due to inefficacy of treatment ‐ as a measure of overall efficacy<br/> 4.3. Due to adverse events ‐ as a measure of overall tolerability </p> </section> <section id="CD009831-sec-0036"> <h6 class="title">5. Adverse effects</h6> <p>5.1. General ‐ at least one adverse effect<br/> 5.2. Specific ‐ extrapyramidal/movement disorders<br/> 5.3. Specific ‐ death<br/> 5.4. Specific ‐ hypotension<br/> 5.5. Specific ‐ sedation<br/> 5.6. Specific ‐ weight gain </p> </section> <section id="CD009831-sec-0037"> <h6 class="title">6. Satisfaction with care</h6> <p>6.1. Clinically important change in satisfaction<br/> 6.2. Average score/change in satisfaction </p> </section> <section id="CD009831-sec-0038"> <h6 class="title">7. Quality of life</h6> <p>7.1. Clinically important change in quality of life<br/> 7.2. Average score/change of the quality of life score </p> </section> <section id="CD009831-sec-0039"> <h6 class="title">8. Service utilisation</h6> <p>8.1. Days in hospital<br/> 8.2. Admitted </p> </section> <section id="CD009831-sec-0040"> <h6 class="title">9. Functioning</h6> <p>9.1. Days requiring a sick certificate<br/> 9.2. Employed<br/> 9.3. Clinically important change in general functioning </p> </section> <section id="CD009831-sec-0041"> <h6 class="title">10. Economic outcomes</h6> <p>10.1. Average change in total cost of medical and mental health care<br/> 10.2. Total indirect and direct costs </p> </section> <section id="CD009831-sec-0042"> <h6 class="title">11. 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD009831-bbs2-0188" title="SchünemannHJ , OxmanAD , BrozekJ , GlasziouP , JaeschkeR , VistGE , et al. Grading Quality of Evidence and Strength of Recommendations for Diagnostic Tests and Strategies. BMJ2008;336:1106‐10. ">Schünemann 2008</a>) and used GRADEPRO to import data from RevMan v5 to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study, the magnitude of effect of the examined interventions, and the sum of available data on all outcomes that we rated as important to patient‐care and decision making. </p> <p>We anticipated including the following main outcomes in a 'Summary of findings' table.</p> <p> <ul id="CD009831-list-0001"> <li> <p>Clinically important response to treatment</p> </li> <li> <p>Acceptability of treatment ‐ leaving the study early due to any reason</p> </li> <li> <p>Overall efficacy of treatment ‐ leaving the study early due to inefficacy</p> </li> <li> <p>Tolerability of treatment ‐ leaving the study early due to adverse effects</p> </li> <li> <p>Adverse effects ‐ number of participants with at least one adverse effect</p> </li> <li> <p>Adverse effects ‐ number of participants with extrapyramidal/movement disorder</p> </li> <li> <p>Quality of life ‐ improved to an important extent</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD009831-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <p>No language restriction was applied within the limitations of the search tools to avoid the problem of 'language bias' (<a href="./references#CD009831-bbs2-0146" title="EggerM , Zellweger‐ZähnerT , SchneiderM , JunkerC , LengelerC , AntesG . Language bias in randomised controlled trials published in English and German. Lancet1997;350:326‐9. ">Egger 1997b</a>). </p> <section id="CD009831-sec-0044"> <h4 class="title">Electronic searches</h4> <section id="CD009831-sec-0045"> <h5 class="title">1. Cochrane Schizophrenia Group’s Trials Register</h5> <p>In October 2011 and July 2012, the Trials Search Co‐ordinator (TSC) searched the Cochrane Schizophrenia Group’s Registry of Trials using the following search strategy: </p> <p>(*haloperi* or *R‐1625 or *haldol* or *alased* or *aloperidi* or *bioperido* or *buterid* or *ceree* or *dozic* or *duraperido* or *fortuna* or *serena* or *serenel* or *seviu* or *sigaperid* or *sylad* or *zafri*) in Interventions of STUDY </p> <p>The Cochrane Schizophrenia Group’s Registry of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> </section> </section> <section id="CD009831-sec-0046"> <h4 class="title">Searching other resources</h4> <section id="CD009831-sec-0047"> <h5 class="title">1. Reference searching</h5> <p>We inspected the references of all identified studies for more trials.</p> </section> <section id="CD009831-sec-0048"> <h5 class="title">2. Previous reviews</h5> <p>We searched the publication lists of the previous conventional reviews by <a href="./references#CD009831-bbs2-0166" title="KleinDF , DavisJM . Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins, 1969. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969. ">Klein 1969</a> and <a href="./references#CD009831-bbs2-0140" title="DavisJM , BarterJT , KaneJM . Antipsychotic drugs. Comprehensive Textbook of Psychiatry. Baltimore: Williams and Wilkins, 1989. ">Davis 1989</a>, but if we identified other relevant reviews, these were also searched for publications fulfilling the inclusion criteria. </p> </section> <section id="CD009831-sec-0049"> <h5 class="title">3. Personal contact</h5> <p>We tried to contact the first author of each included study for missing information.</p> </section> <section id="CD009831-sec-0050"> <h5 class="title">4. Drug companies</h5> <p>We contacted the original manufacturers of haloperidol and asked them for further relevant studies and for missing information on identified studies. </p> </section> </section> </section> <section id="CD009831-sec-0051"> <h3 class="title" id="CD009831-sec-0051">Data collection and analysis</h3> <section id="CD009831-sec-0052"> <h4 class="title">Selection of studies</h4> <p>Review author MD inspected all abstracts of studies identified as above and identified potentially relevant reports. In addition, to ensure reliability, a second review author (MS) inspected a random sample of these abstracts, comprising 25% of the total. Where disagreement occurred this was resolved by discussion, or where there was still doubt, the full article was acquired for further inspection. The full articles of relevant reports were acquired for reassessment and carefully inspected for a final decision on inclusion (see <a href="#CD009831-sec-0023">Criteria for considering studies for this review</a>). Once the full articles were obtained, in turn MD and MS inspected all full reports and independently decided whether they met inclusion criteria. MD and MS were not blinded to the names of the authors, institutions, or journal of publication. Where difficulties or disputes arose, we asked review author SL for help and if it was impossible to decide, these studies were added to those awaiting assessment and the authors of the papers contacted for clarification. </p> </section> <section id="CD009831-sec-0053"> <h4 class="title">Data extraction and management</h4> <section id="CD009831-sec-0054"> <h5 class="title">1. Extraction</h5> <p>At least two review authors (MD, MS, CL) independently extracted data from all selected trials. When disagreement arose, we resolved it by discussion with a third review author (SL). Where this was not possible, we contacted the study authors to resolve the dilemma. </p> </section> <section id="CD009831-sec-0055"> <h5 class="title">2. Management</h5> <section id="CD009831-sec-0056"> <h6 class="title">2.1 Forms</h6> <p>Data were extracted on standard simple forms that were piloted based on a random sample of 10 studies. </p> </section> <section id="CD009831-sec-0057"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if: (a) the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD009831-bbs2-0179" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and (b) the measuring instrument was not written or modified by one of the trialists for that particular trial. Ideally, the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). As this is not often reported clearly, we noted in <a href="#CD009831-sec-0095">Description of studies</a> if this was not the case. </p> </section> <section id="CD009831-sec-0058"> <h6 class="title">2.3. Endpoint versus change data</h6> <p>There are advantages to both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. Endpoint and change data were combined in the analysis as we used mean differences (MD) rather than standardised mean differences (SMD) throughout (<a href="./references#CD009831-bbs2-0158" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>, Chapter 9.4.5.2). </p> </section> <section id="CD009831-sec-0059"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: (a) data from studies of at least 200 participants were entered in the analysis irrespective of the following rules, because skewed data pose less of a problem in large studies; (b) endpoint data: when a scale starts from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation (SD). If this value was lower than 1, it strongly suggested a skew and the study was excluded. If this ratio was higher than 1 but below 2, there is suggestion of skew. We entered the study and tested whether its inclusion or exclusion substantially changed the results. If the ratio was larger than 2 the study was included, because skew is less likely (<a href="./references#CD009831-bbs2-0130" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="./references#CD009831-bbs2-0158" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). (c) change data: when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We entered the study, because change data tend to be less skewed and because excluding studies would also lead to bias, because not all the available information was used. </p> </section> <section id="CD009831-sec-0060"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week, or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD009831-sec-0061"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>If possible, efforts were made to convert outcome measures to dichotomous data. This could be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD009831-bbs2-0183" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD009831-bbs2-0163" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD009831-bbs2-0171" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . What does the PANSS mean?. Schizophrenia Research2005;79:231‐8. ">Leucht 2005a</a>; <a href="./references#CD009831-bbs2-0172" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> </section> </section> <section id="CD009831-sec-0062"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Again at least two review authors (MD, MS, CL) worked independently to assess risk of bias by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009831-bbs2-0158" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) to assess trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting. </p> <p>If the raters disagreed, the final rating was made by consensus, with the involvement of another member of the review group (SL). Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. Non‐concurrence in quality assessment was reported, but if disputes arose as to which category a trial was to be allocated, again, resolution was made by discussion. </p> <p>The level of risk of bias was noted in both the text of the review and in the <a href="./full#CD009831-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD009831-sec-0063"> <h4 class="title">Measures of treatment effect</h4> <section id="CD009831-sec-0064"> <h5 class="title">1. Dichotomous data</h5> <p>For binary outcomes, we calculated a standard estimation of the random‐effects (<a href="./references#CD009831-bbs2-0142" title="Der‐SimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">Der‐Simonian 1986</a>) risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD009831-bbs2-0136" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54:405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD009831-bbs2-0141" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). This misinterpretation then leads to an overestimate of the impression of the effect. Where possible, efforts were made to convert outcome measures to dichotomous data. </p> </section> <section id="CD009831-sec-0065"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated mean difference (MD) between groups. MDs were based on the random‐effects model as this takes into account any differences between studies, even if there is no statistically significant heterogeneity. We did not calculate standardised mean differences (SMD) measures. There was one exception to this rule, however. In the case of where scales were of such similarity to allow pooling, we calculated the SMD and, whenever possible, transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD009831-sec-0066"> <h4 class="title">Unit of analysis issues</h4> <section id="CD009831-sec-0067"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD009831-bbs2-0143" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance is overestimated. This causes type I errors (<a href="./references#CD009831-bbs2-0135" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD009831-bbs2-0154" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>Where clustering was not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. Where clustering had been incorporated into the analysis of primary studies, we presented these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. If a cluster study had been appropriately analysed taking into account intra‐class correlation co‐efficient and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique, where the natural logarithm of the effect estimate (and standard errors) for all included trials for that outcome would be calculated and entered into <a href="http://www.ims.cochrane.org/revman" target="_blank">RevMan</a> along with the log of the effect estimate (and standard errors) from the cluster randomised trial(s). We would have used methods described in section 7.7.7.2 and 7.7.7.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009831-bbs2-0158" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) to obtain standard errors. </p> </section> <section id="CD009831-sec-0068"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological, or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD009831-bbs2-0147" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31:140‐9. ">Elbourne 2002</a>). As both effects are very likely in schizophrenia, randomised cross‐over studies were eligible, but only data up to the point of the first cross‐over. </p> </section> <section id="CD009831-sec-0069"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>If a trial investigated more than two treatment arms we only used data from these study arms that evaluated the antipsychotics drugs of interest for this systematic review. If two dose groups were analysed and data were binary, these were simply added and combined within the two‐by‐two table. If these data were continuous, we combined data following the formula in section 7.7.3.8 (Combining groups) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. </p> </section> </section> <section id="CD009831-sec-0070"> <h4 class="title">Dealing with missing data</h4> <section id="CD009831-sec-0071"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD009831-bbs2-0201" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33:254‐7. ">Xia 2009</a>). The loss to follow‐up in randomised schizophrenia trials is often considerable calling the validity of the results into question. Nevertheless, it is unclear which degree of attrition leads to a high degree of bias. We did not exclude trials from outcomes on the basis of the percentage of participants completing them. We did, however, use the 'Risk of bias' tool described above to indicate potential bias when more than 25% of the participants left the studies prematurely, when the reasons for attrition differed between the intervention and the control group, and when no appropriate imputation strategies were applied. </p> </section> <section id="CD009831-sec-0072"> <h5 class="title">2. Dichotomous data</h5> <p>Data were presented on a 'once‐randomised‐always‐analyse' basis, assuming an 'intention‐to‐treat' (ITT) analysis. If the authors applied such a strategy, we used their results. If the original authors presented only the results of the per‐protocol or completer population, we assumed that those participants lost to follow‐up would have had the same percentage of events as those who remained in the study. </p> </section> <section id="CD009831-sec-0073"> <h5 class="title">3. Continuous data</h5> <section id="CD009831-sec-0074"> <h6 class="title">3.1 General</h6> <p>Intention‐to‐treat data (ITT) were used when available. We anticipated that in some studies, in order to do an ITT analysis, the method of last observation carried forward (LOCF) was employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD009831-bbs2-0170" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59:1001‐5. ">Leon 2006</a>; <a href="./references#CD009831-bbs2-0174" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). Therefore, where LOCF data have been used in the analysis, they have been indicated in the review. </p> </section> <section id="CD009831-sec-0075"> <h6 class="title">3.2 Missing standard deviations</h6> <p>If standard deviations (SDs) were not reported, we primarily tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either 'P' value or 't' value available for differences in mean, we calculated them according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009831-bbs2-0158" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>): When only the SE was reported, SDs were calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009831-bbs2-0158" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, ranges or other statistics. If these formulae did not apply, we calculated the SDs according to a validated imputation method, which is based on the SDs of the other included studies (<a href="./references#CD009831-bbs2-0151" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59:7‐10. ">Furukawa 2006</a>). </p> </section> </section> </section> <section id="CD009831-sec-0076"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD009831-sec-0077"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies without any comparison to judge clinical heterogeneity.</p> <p>We simply inspected all studies for clearly outlying situations or people which we had not predicted would arise. Where such situations or participant groups arose, these were fully discussed. </p> </section> <section id="CD009831-sec-0078"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, these were fully discussed. </p> </section> <section id="CD009831-sec-0079"> <h5 class="title">3. Statistical</h5> <section id="CD009831-sec-0080"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD009831-sec-0081"> <h6 class="title">3.2 Employing the I<sup>2</sup>statistic </h6> <p>Heterogeneity between studies was investigated by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> 'P' value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD009831-bbs2-0158" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'P' value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). </p> <p>We interpreted an I<sup>2</sup> estimate greater than or equal to 50% accompanied by a statistically significant Chi<sup>2</sup> statistic, as evidence of substantial levels of heterogeneity (Section 9.5.2 ‐ <a href="./references#CD009831-bbs2-0158" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, reasons for heterogeneity were explored. </p> </section> </section> </section> <section id="CD009831-sec-0082"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD009831-sec-0083"> <h5 class="title">1. Protocol versus full study</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009831-bbs2-0158" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). We tried to locate protocols of included randomised trials. If the protocol was available, outcomes in the protocol and in the published report were compared. If the protocol was not available, outcomes listed in the methods section of the trial report were compared with the reported results. </p> </section> <section id="CD009831-sec-0084"> <h5 class="title">2. Funnel plots</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD009831-bbs2-0145" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997a</a>). These are again described in Section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009831-bbs2-0158" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> </section> <section id="CD009831-sec-0085"> <h4 class="title">Data synthesis</h4> <p>We employed a random‐effects model for analyses (<a href="./references#CD009831-bbs2-0142" title="Der‐SimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">Der‐Simonian 1986</a>). We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. Therefore, the random‐effects model is usually more conservative in terms of statistical significance, although as a disadvantage, it puts added weight onto smaller studies, which can either inflate or deflate the effect size. Therefore, we examined in a sensitivity analysis whether using a fixed‐effect model markedly changed the results of the primary outcome. </p> </section> <section id="CD009831-sec-0086"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD009831-sec-0087"> <h5 class="title">1. Subgroup analysis</h5> <p>We examined the subgroups of people with a first episode of schizophrenia and patients with treatment‐resistant schizophrenia (failure of response to at least one previous pharmacotherapy with antipsychotics in adequate dose and duration) to determine if their results for primary outcomes substantively differed from other participant groups'. Furthermore, we performed a stratification according to the different first‐generation antipsychotics administered as active comparator agent to haloperidol. </p> </section> <section id="CD009831-sec-0088"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, this was reported. First, we investigated whether data had been entered correctly. Second, if the data were correct, we evaluated whether there were obvious reasons that caused the heterogeneity in the relevant studies. If we found appropriate reasons (e.g. different methods), we removed these trials from the pooled data analysis. If we did not find any obvious reason, the data of these studies were pooled but heterogeneity was thoroughly discussed. </p> <p>Additional potential causes of high heterogeneity were explored by performing a random‐effects restricted maximum‐likelihood meta‐regression of the primary outcome. The following potential effect modifiers of the primary outcome were addressed: schizophrenia severity at baseline (BPRS or PANSS total score at baseline), haloperidol dose, comparator dose, ratio of haloperidol and comparator dose, study duration, pharmaceutical sponsor. We are aware that subgroup analyses are observational by nature and therefore consider the results to be exploratory and not explanatory. </p> </section> </section> <section id="CD009831-sec-0089"> <h4 class="title">Sensitivity analysis</h4> <p>All sensitivity analyses were applied only for the primary outcome.</p> <section id="CD009831-sec-0090"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcome we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then all data were employed from these studies. </p> </section> <section id="CD009831-sec-0091"> <h5 class="title">2. Implication of non double‐blind trials</h5> <p>We excluded trials in a sensitivity analysis if they were not double‐blind.</p> </section> <section id="CD009831-sec-0092"> <h5 class="title">3. Exclusion of cross‐over‐trials</h5> <p>We removed cross‐over‐trials in a sensitivity analysis to detect any substantive difference when these studies were not included in the analysis of the primary outcome. </p> </section> <section id="CD009831-sec-0093"> <h5 class="title">4. Fixed‐effect versus random‐effects models</h5> <p>A sensitivity analysis was carried out to clarify, whether the use of a fixed‐effect model resulted in a substantial difference in the primary outcome compared to the random‐effects model. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009831-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009831-sec-0094"></div> <section id="CD009831-sec-0095"> <h3 class="title">Description of studies</h3> <p>For substantive description of studies please see <a href="./references#CD009831-sec-0219" title="">Characteristics of included studies</a> and <a href="./references#CD009831-sec-0220" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD009831-sec-0096"> <h4 class="title">Results of the search</h4> <p>The electronic literature search identified a total of 2944 references, of which 158 citations were closely inspected. Sixty‐three studies (87 citations) were included and 64 studies (71 citations) were excluded. We did not identify any studies awaiting classification or ongoing studies (<a href="#CD009831-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009831-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009831-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009831-sec-0097"> <h4 class="title">Included studies</h4> <p>Sixty‐three trials published between 1962 and 1993 were included in this systematic review. Most of the studies were in English; six in Japanese (<a href="./references#CD009831-bbs2-0031" title="ItoH , AnnoH , FujiiY , HasegawaY , IkegamiH , IshigookaJ , et al. Clinical evaluation of bromperidol, a new investigational butyrophenone derivative, in schizophrenia, a double‐blind comparison of bromperidol and haloperidol. Rinsho Hyoka (Clinical Evaluation)1985;13:105‐36. ItohH . A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double‐ blind technique. Psychopharmacology Bulletin1985;21:120‐2. ">Itoh 1985</a>; <a href="./references#CD009831-bbs2-0034" title="KodamaH , SaraiK , NakaharaT . The clinical efficacy of bromperidol for schizophrenia: comparison with haloperidol by the double‐blind method. Igaku to Yakugaku1984;12:269‐86. ">Kodama 1984</a>; <a href="./references#CD009831-bbs2-0035" title="KuriharaM , ItoH , KatoN . Clinical evaluation of clocapramine (clofekton) in schizophrenia: a double blind comparison of clocapramine, haloperidol and perphenazine. Rinsho Seishin Igaku (Japanese Journal of Clinical Psychiatry)1983;12:519‐38. ">Kurihara 1983</a>; <a href="./references#CD009831-bbs2-0040" title="MoriA , KazamatsuriH , KanenoS , KamijimaK , KariyaT , MurasakiM , et al. A double‐blind comparison of a new benzamide compound YM 09151 with haloperidol in the treatment of schizophrenia. Rinsho Hyoka1989;17:349‐77. ">Mori 1989</a>; <a href="./references#CD009831-bbs2-0043" title="NishimatuO , HorigudchiJ , AkitaK , NomuraS , SaraiK , KodamaH . Comparison of the clinical efficacy of methylperidol (luvatren) and haloperidol for schizophrenia by the double‐blind method. Seishin Igaku (Clinical Psychiatry)1975;4:973‐85. ">Nishimatu 1975</a>; <a href="./references#CD009831-bbs2-0045" title="OkudaO , AkaueY , OkishioY . The efficacy of sulpiride in the treatment of schizophrenia by the double‐blind method. Japanese Pharmacology and Therapeutics [Yakuri to Chiryo]1979;7:439‐58. ">Okuda 1979</a>), three in Italian (<a href="./references#CD009831-bbs2-0007" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95:1109‐25. ">Cocchi 1971</a>; <a href="./references#CD009831-bbs2-0019" title="GermanaB , RapisardaV . Clinical therapeutic experience with bromperidol ‐ a double‐blind study [Esperienze clinico terapeutiche con bromperidolo ‐ prova in doppio cieco e in chiaro]. Rivista di Psichiatria1990;4:233‐5. ">Germana 1990</a>; <a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a>), two in French (<a href="./references#CD009831-bbs2-0010" title="DarondelA , BalthazardJC , BrunJP . A double‐blind comparison between pipotiazine and haloperidol [Bilan d'une etude controlee a double insu pipotiazine versus haloperidol]. Psychologie Medicale1981;13:171‐80. ">Darondel 1981</a>; <a href="./references#CD009831-bbs2-0020" title="GiordanaJY , FrenayS . Comparative study of pipotiazine (in its non‐esterified form) and of haloperidol in acute or subacute psychotic states [Etude comparative de la pipothiazine (dans sa forme non esterifiee) et de l'haloperidol au cours d'etats psychotiques aigus et subaigus]. Psychologie Medicale1984;16:1803‐15. ">Giordana 1984</a>), two in Spanish (<a href="./references#CD009831-bbs2-0005" title="BuenoJR . A double‐blind comparative clinical trial with loxapine succinate and haloperidol in the treatment of Schizophrenia [Ensaio clinico comparativo e duplo‐cego com succina de loxapina e haloperidol no tratamento da esquizofrenia]. Folha Medica1979;78:47‐52. ">Bueno 1979</a>; <a href="./references#CD009831-bbs2-0016" title="FuentenebroF , EscobarJI , KellerJ , Lopez de OchoaEF , VazquezC . Prediction of the therapeutic response to neuroleptics in schizophrenia [Prediccion de la respuesta al tratamiento neuroleptico en la esquizofrenia]. Psiquis Revista de Psiquiatria, Psicologia y Psicosomatica1989;10:22‐8. ">Fuentenebro 1989</a>), and one study in German (<a href="./references#CD009831-bbs2-0038" title="MattkeDJ , MombourW , GlotznerFL . The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research [Erfassung neuroleptisch bedingter extrapyramidaler Syndrome in einem psychopharmakologischen Forschungsprojekt]. Pharmakopsychiatrie und Neuropsychopharmakologie1975;1:36‐44. MattkeDJ , WisuschilW . A method for studying pupilomotorics under the influence of neuroleptic medication [Eine Methode zur Untersuchung der Pupillomotorik unter dem Einfluss neuroleptischer Medikation]. Arzneimittelforschung1976;26:946‐50. ">Mattke 1976</a>). </p> <section id="CD009831-sec-0098"> <h5 class="title">1. Study design</h5> <p>All studies were randomised ("implied randomisation" in 12 trials) and most applied double‐blind methodology. Sixty studies were conducted using a parallel group design whereas three were designed as cross‐over studies (<a href="./references#CD009831-bbs2-0018" title="GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersenE , NielsenH . Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross‐over study of therapeutic effectiveness,side effects and plasma concentrations. [article in french]. Semaine des Hopitaux1985;61:1309‐16. GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersonE , NielsenH . Sulpiride and haloperidol in schizophrenia: a double‐blind cross‐over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry1985;147:283‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol in the treatment of schizophrenia: A brief preliminary report [article in danish]. Nordisk Psykiatrisk Tidsskrift1984;38:223‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica. Supplementum1984;311:31‐41. ">Gerlach 1985</a>; <a href="./references#CD009831-bbs2-0054" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993;87:86‐91. ">Shalev 1993</a>; <a href="./references#CD009831-bbs2-0057" title="StewartA , LafaveHG , SegoviaG . Haloperidol ‐ new addition to the drug treatment of schizophrenia. Behavioral Neuropsychiatry1969;1:23‐8. ">Stewart 1969</a>). Further details regarding methodological issues are displayed in the sections on allocation and blinding. </p> </section> <section id="CD009831-sec-0099"> <h5 class="title">2. Trial duration</h5> <p>Fifty‐seven studies evaluated a short‐term trial duration (up to 12 weeks) whereas five studies (<a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>; <a href="./references#CD009831-bbs2-0009" title="CosarB , CandansayarS , TanerE , IsikE . Comparison of efficacy of clozapine, sulpiride, chlorpromazine and haloperidol in chronic schizophrenic patients therapy. European Neuropsychopharmacology1999;9:287. ">Cosar 1999</a>; <a href="./references#CD009831-bbs2-0013" title="EngelhardtDM , RudorferL , RosenB . Haloperidol and thiothixene in the long‐term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment. Journal of Clinical Psychiatry1978;39:834‐40. ">Engelhardt 1978</a>; <a href="./references#CD009831-bbs2-0046" title="PaprockiJ , Barcala PeixotoMP , AndradeNM . A controlled double‐blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients. Psychopharmacology Bulletin1976;12:32‐4. ">Paprocki 1976</a>; <a href="./references#CD009831-bbs2-0058" title="TejaJS , GreyWH , ClumJM , WarrenC . Tranquilizers or anti‐depressants for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry1975;9:241‐7. ">Teja 1975</a>) investigated a medium‐term period (from more than 12 weeks to 26 weeks). One trial was carried out over a long‐term period (&gt; 26 weeks) (<a href="./references#CD009831-bbs2-0042" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics ‐ a comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a>). </p> </section> <section id="CD009831-sec-0100"> <h5 class="title">3. Participants</h5> <p>The 63 included trials comprised a total of 3675 participants. One study examined children (<a href="./references#CD009831-bbs2-0015" title="FaretraG , DooherL , DowlingJ . Comparison of haloperidol and fluphenazine in disturbed children. American Journal of Psychiatry1970;126:1670‐3. ">Faretra 1970</a>) and two trials adolescents (<a href="./references#CD009831-bbs2-0049" title="PoolD , BloomW , MielkeDH , RonigerJJJr , GallantDM . A controlled evaluation of loxitane in seventy‐five adolescent schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1976;19:99‐104. ">Pool 1976</a>; <a href="./references#CD009831-bbs2-0062" title="VersianiM , daSilvaJA , FrotaLH , MundimFD . Double‐blind comparison between loxapine and haloperidol in the treatment of adolescent schizophrenic patients. Current Therapeutic Research1978;24:559‐66. ">Versiani 1978</a>). Forty‐six studies included only participants with schizophrenia or schizophrenia‐like psychosis. The remaining trials also enrolled persons with other diagnoses or ambiguities regarding the diagnoses remained. These studies were included because at least 75% of the whole trial sample had schizophrenia or a schizophrenia‐like psychosis. <a href="./references#CD009831-bbs2-0047" title="ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica1983;3:354‐64. ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychotic episodes [article in french]. Acta Psychiatrica Belgica1982;82:617‐31. ">Parent 1983</a> included 40 participants, of which only 21 were diagnosed with schizophrenia or schizophrenia‐like psychosis, but the data used in this analysis refer exclusively to the 21 persons with schizophrenic disorders. </p> <p>In 14 trials the diagnoses of the participants were based on international classification systems. One study applied the DSM‐II (<a href="./references#CD009831-bbs2-0004" title="BrannenJO , McEvoyJP , WilsonWH , PetrieWM , BanTA , BerneySA , et al. A double‐blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatria1981;14:139‐40. ">Brannen 1981</a>), six trials the DSM‐III (<a href="./references#CD009831-bbs2-0012" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993;29:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009831-bbs2-0014" title="EscobarJI , MannJJ , KellerJ , WilkinsJ , MasonB , MillsMJ . Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Journal of Clinical Psychiatry1985;46:15‐9. ">Escobar 1985</a>; <a href="./references#CD009831-bbs2-0016" title="FuentenebroF , EscobarJI , KellerJ , Lopez de OchoaEF , VazquezC . Prediction of the therapeutic response to neuroleptics in schizophrenia [Prediccion de la respuesta al tratamiento neuroleptico en la esquizofrenia]. Psiquis Revista de Psiquiatria, Psicologia y Psicosomatica1989;10:22‐8. ">Fuentenebro 1989</a>; <a href="./references#CD009831-bbs2-0042" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics ‐ a comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a>; <a href="./references#CD009831-bbs2-0054" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993;87:86‐91. ">Shalev 1993</a>; <a href="./references#CD009831-bbs2-0060" title="TuasonVB . A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Journal of Clinical Psychiatry1986;47:126‐9. ">Tuason 1986</a>), two the DSM‐III‐R (<a href="./references#CD009831-bbs2-0033" title="KinonBJ , KaneJM , ChakosM , MunneR . Possible predictors of neuroleptic‐resistant schizophrenic relapse ‐ influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacology Bulletin1993;29:365‐9. KinonBJ , KaneJM , JohnsC , PerovichR , IsmiM , KoreenA , et al. Treatment of neuroleptic‐resistant schizophrenic relapse. Psychopharmacology Bulletin1993;29:309‐14. ">Kinon 1993</a>; <a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a>), and one the DSM‐IV (<a href="./references#CD009831-bbs2-0009" title="CosarB , CandansayarS , TanerE , IsikE . Comparison of efficacy of clozapine, sulpiride, chlorpromazine and haloperidol in chronic schizophrenic patients therapy. European Neuropsychopharmacology1999;9:287. ">Cosar 1999</a>). In three investigations, participants were diagnosed according to ICD‐8 (<a href="./references#CD009831-bbs2-0025" title="HaasS , BeckmannH . Pimozide and haloperidol in a double‐blind study in acutely schizophrenic patients [Pimozid und Haloperidol im Doppelblind‐Versuch bei akut schizophrenen Patienten]. Arzneimittelforschung1982;32:888. HaasS , BeckmannH . Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria1982;15:70‐4. ">Haas 1982</a>; <a href="./references#CD009831-bbs2-0038" title="MattkeDJ , MombourW , GlotznerFL . The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research [Erfassung neuroleptisch bedingter extrapyramidaler Syndrome in einem psychopharmakologischen Forschungsprojekt]. Pharmakopsychiatrie und Neuropsychopharmakologie1975;1:36‐44. MattkeDJ , WisuschilW . A method for studying pupilomotorics under the influence of neuroleptic medication [Eine Methode zur Untersuchung der Pupillomotorik unter dem Einfluss neuroleptischer Medikation]. Arzneimittelforschung1976;26:946‐50. ">Mattke 1976</a>; <a href="./references#CD009831-bbs2-0041" title="NedopilN , RutherE . Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatria1981;14:205‐7. ">Nedopil 1981</a>) and <a href="./references#CD009831-bbs2-0002" title="BaastrupPC , AlhforsUG , BjerkenstedtL , DenckerSJ , FensboC , GravemA , et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica1993;87:48‐58. FensboC . Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients ‐ a controlled multicenter study [Zuclopenthixol acetat, haloperidol og zuclopenthixol i behandling af akut psykotiske patienter. En kontrolleret multicenterundersogelse]. Nordisk Psykiatrisk Tidsskrift1990;44:295‐7. ">Baastrup 1993</a> used the ICD‐9 as diagnostic criterion. </p> </section> <section id="CD009831-sec-0101"> <h5 class="title">4. Sample size</h5> <p>The number of participants included in each study ranged from 18 (<a href="./references#CD009831-bbs2-0021" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3:315‐20. GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46:4‐7. ">Glazer 1990</a>; <a href="./references#CD009831-bbs2-0051" title="RubinR . A double‐blind comparison of the onset of activity of haloperidol and trifluoperazine. Alabama Journal of Medical Sciences1971;8:414‐8. ">Rubin 1971</a>) to 206 (<a href="./references#CD009831-bbs2-0031" title="ItoH , AnnoH , FujiiY , HasegawaY , IkegamiH , IshigookaJ , et al. Clinical evaluation of bromperidol, a new investigational butyrophenone derivative, in schizophrenia, a double‐blind comparison of bromperidol and haloperidol. Rinsho Hyoka (Clinical Evaluation)1985;13:105‐36. ItohH . A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double‐ blind technique. Psychopharmacology Bulletin1985;21:120‐2. ">Itoh 1985</a>). </p> </section> <section id="CD009831-sec-0102"> <h5 class="title">5. Setting</h5> <p>Thirty‐nine trials included exclusively inpatients and six studies (<a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>; <a href="./references#CD009831-bbs2-0013" title="EngelhardtDM , RudorferL , RosenB . Haloperidol and thiothixene in the long‐term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment. Journal of Clinical Psychiatry1978;39:834‐40. ">Engelhardt 1978</a>; <a href="./references#CD009831-bbs2-0021" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3:315‐20. GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46:4‐7. ">Glazer 1990</a>; <a href="./references#CD009831-bbs2-0036" title="LuckeyWT , SchieleBC . A comparison of haloperidol and trifluoperazine. (A double‐blind, controlled study on chronic schizophrenic outpatients). Diseases of the Nervous System1967;28:181‐6. ">Luckey 1967</a>; <a href="./references#CD009831-bbs2-0042" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics ‐ a comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a>; <a href="./references#CD009831-bbs2-0059" title="TobinJM , RobinsonGM . Double blind comparison of haloperidol and thiothixene with after care treatment evaluation in psychiatric outpatients with schizophrenia. Psychiatric Journal of the University of Ottowa1980;5:168‐74. ">Tobin 1980</a>) exclusively outpatient participants. <a href="./references#CD009831-bbs2-0020" title="GiordanaJY , FrenayS . Comparative study of pipotiazine (in its non‐esterified form) and of haloperidol in acute or subacute psychotic states [Etude comparative de la pipothiazine (dans sa forme non esterifiee) et de l'haloperidol au cours d'etats psychotiques aigus et subaigus]. Psychologie Medicale1984;16:1803‐15. ">Giordana 1984</a> as well as <a href="./references#CD009831-bbs2-0034" title="KodamaH , SaraiK , NakaharaT . The clinical efficacy of bromperidol for schizophrenia: comparison with haloperidol by the double‐blind method. Igaku to Yakugaku1984;12:269‐86. ">Kodama 1984</a> included both inpatients and outpatients. Four studies described the inclusion of mostly inpatients (<a href="./references#CD009831-bbs2-0032" title="KariyaT , ShimazonoY , ItohH , MoriA , MurasakiM , SuganoK , et al. A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double‐blind technique. Journal of International Medical Research1983;11:66‐77. KariyaT , ShimazonoY , YamashitaI . Comparison of clinical effects of timiperone and haloperidol on schizophrenia using double‐blind technique. Seishin Igaku (Clinical Psychiatry)1981;10:1281‐301. ">Kariya 1983</a>; <a href="./references#CD009831-bbs2-0035" title="KuriharaM , ItoH , KatoN . Clinical evaluation of clocapramine (clofekton) in schizophrenia: a double blind comparison of clocapramine, haloperidol and perphenazine. Rinsho Seishin Igaku (Japanese Journal of Clinical Psychiatry)1983;12:519‐38. ">Kurihara 1983</a>; <a href="./references#CD009831-bbs2-0040" title="MoriA , KazamatsuriH , KanenoS , KamijimaK , KariyaT , MurasakiM , et al. A double‐blind comparison of a new benzamide compound YM 09151 with haloperidol in the treatment of schizophrenia. Rinsho Hyoka1989;17:349‐77. ">Mori 1989</a>; <a href="./references#CD009831-bbs2-0043" title="NishimatuO , HorigudchiJ , AkitaK , NomuraS , SaraiK , KodamaH . Comparison of the clinical efficacy of methylperidol (luvatren) and haloperidol for schizophrenia by the double‐blind method. Seishin Igaku (Clinical Psychiatry)1975;4:973‐85. ">Nishimatu 1975</a>). In <a href="./references#CD009831-bbs2-0014" title="EscobarJI , MannJJ , KellerJ , WilkinsJ , MasonB , MillsMJ . Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Journal of Clinical Psychiatry1985;46:15‐9. ">Escobar 1985</a>, the participants were hospitalised at least during the injectable phase of the trial and in <a href="./references#CD009831-bbs2-0056" title="SpinaE , DeDomenicoP , BonanzingaM , D'AgostinoMA , GittoC , DiRosaAE , et al. A double‐blind comparative study of bromperidol versus haloperidol in schizophrenic patients. New Trends in Experimental and Clinical Psychiatry1992;7:67‐71. ">Spina 1992</a>, they had to be inpatients for at least the first four weeks of treatment. Similarly, in <a href="./references#CD009831-bbs2-0008" title="CocitoE , AmbrosiniG , ArataA , BevilacquaP , TortoraE . Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol. Arzneimittelforschung1970;20:1119‐25. ">Cocito 1970</a>, the participants had to be inpatients at least for the beginning of the trial. There was no information regarding the setting for the remaining nine trials examined in this systematic review (<a href="./references#CD009831-bbs2-0009" title="CosarB , CandansayarS , TanerE , IsikE . Comparison of efficacy of clozapine, sulpiride, chlorpromazine and haloperidol in chronic schizophrenic patients therapy. European Neuropsychopharmacology1999;9:287. ">Cosar 1999</a>; <a href="./references#CD009831-bbs2-0012" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993;29:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009831-bbs2-0016" title="FuentenebroF , EscobarJI , KellerJ , Lopez de OchoaEF , VazquezC . Prediction of the therapeutic response to neuroleptics in schizophrenia [Prediccion de la respuesta al tratamiento neuroleptico en la esquizofrenia]. Psiquis Revista de Psiquiatria, Psicologia y Psicosomatica1989;10:22‐8. ">Fuentenebro 1989</a>; <a href="./references#CD009831-bbs2-0031" title="ItoH , AnnoH , FujiiY , HasegawaY , IkegamiH , IshigookaJ , et al. Clinical evaluation of bromperidol, a new investigational butyrophenone derivative, in schizophrenia, a double‐blind comparison of bromperidol and haloperidol. Rinsho Hyoka (Clinical Evaluation)1985;13:105‐36. ItohH . A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double‐ blind technique. Psychopharmacology Bulletin1985;21:120‐2. ">Itoh 1985</a>; <a href="./references#CD009831-bbs2-0037" title="MalfroidM , HensL , RoosenP , DomR . Double‐blind‐ evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients. Acta Psychiatrica Belgica1978;78:147‐54. ">Malfroid 1978</a>; <a href="./references#CD009831-bbs2-0038" title="MattkeDJ , MombourW , GlotznerFL . The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research [Erfassung neuroleptisch bedingter extrapyramidaler Syndrome in einem psychopharmakologischen Forschungsprojekt]. Pharmakopsychiatrie und Neuropsychopharmakologie1975;1:36‐44. MattkeDJ , WisuschilW . A method for studying pupilomotorics under the influence of neuroleptic medication [Eine Methode zur Untersuchung der Pupillomotorik unter dem Einfluss neuroleptischer Medikation]. Arzneimittelforschung1976;26:946‐50. ">Mattke 1976</a>; <a href="./references#CD009831-bbs2-0048" title="BuresE , PoldingerW . Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double‐blind research [Einleitende Worte zum Austausch der Erfahrungen über die klinische Wirkung von Bromperidol. Mitteilung über eigene Ergebnisse im offenen und Doppelblindversuch]. International Pharmacopsychiatry1978;13:45‐52. PöldingerW . Clinical experiences in an open and a double‐blind trial. Acta Psychiatrica Belgica1978;78:96‐101. PöldingerW , BuresE , HaageH . Double‐blind study with two butyrophenone derivatives: bromperidol vs. haloperidol. International Pharmacopsychiatry1977;12:184‐92. ">Pöldinger 1977</a>; <a href="./references#CD009831-bbs2-0057" title="StewartA , LafaveHG , SegoviaG . Haloperidol ‐ new addition to the drug treatment of schizophrenia. Behavioral Neuropsychiatry1969;1:23‐8. ">Stewart 1969</a>; <a href="./references#CD009831-bbs2-0061" title="UlmarG , EdlerR , HagenM . Trifluperidol vs haloperidol – a double‐blind trial. Proceedings of the 17th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1990 Sep 10‐14; Kyoto, Japan. 1990:296. ">Ulmar 1990</a>). </p> </section> <section id="CD009831-sec-0103"> <h5 class="title">6. Interventions</h5> <p>According to the predefined inclusion criteria all included trials compared haloperidol with another first‐generation antipsychotic drug. One trial compared haloperidol with benperidol (<a href="./references#CD009831-bbs2-0041" title="NedopilN , RutherE . Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatria1981;14:205‐7. ">Nedopil 1981</a>), nine with bromperidol (<a href="./references#CD009831-bbs2-0004" title="BrannenJO , McEvoyJP , WilsonWH , PetrieWM , BanTA , BerneySA , et al. A double‐blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatria1981;14:139‐40. ">Brannen 1981</a>; <a href="./references#CD009831-bbs2-0011" title="DenijsEL . Clinical evaluation of bromperidol versus haloperidol in psychotic patients. International Pharmacopsychiatry1980;15:309‐17. ">Denijs 1980</a>; <a href="./references#CD009831-bbs2-0019" title="GermanaB , RapisardaV . Clinical therapeutic experience with bromperidol ‐ a double‐blind study [Esperienze clinico terapeutiche con bromperidolo ‐ prova in doppio cieco e in chiaro]. Rivista di Psichiatria1990;4:233‐5. ">Germana 1990</a>; <a href="./references#CD009831-bbs2-0031" title="ItoH , AnnoH , FujiiY , HasegawaY , IkegamiH , IshigookaJ , et al. Clinical evaluation of bromperidol, a new investigational butyrophenone derivative, in schizophrenia, a double‐blind comparison of bromperidol and haloperidol. Rinsho Hyoka (Clinical Evaluation)1985;13:105‐36. ItohH . A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double‐ blind technique. Psychopharmacology Bulletin1985;21:120‐2. ">Itoh 1985</a>; <a href="./references#CD009831-bbs2-0034" title="KodamaH , SaraiK , NakaharaT . The clinical efficacy of bromperidol for schizophrenia: comparison with haloperidol by the double‐blind method. Igaku to Yakugaku1984;12:269‐86. ">Kodama 1984</a>; <a href="./references#CD009831-bbs2-0037" title="MalfroidM , HensL , RoosenP , DomR . Double‐blind‐ evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients. Acta Psychiatrica Belgica1978;78:147‐54. ">Malfroid 1978</a>; <a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a>; <a href="./references#CD009831-bbs2-0048" title="BuresE , PoldingerW . Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double‐blind research [Einleitende Worte zum Austausch der Erfahrungen über die klinische Wirkung von Bromperidol. Mitteilung über eigene Ergebnisse im offenen und Doppelblindversuch]. International Pharmacopsychiatry1978;13:45‐52. PöldingerW . Clinical experiences in an open and a double‐blind trial. Acta Psychiatrica Belgica1978;78:96‐101. PöldingerW , BuresE , HaageH . Double‐blind study with two butyrophenone derivatives: bromperidol vs. haloperidol. International Pharmacopsychiatry1977;12:184‐92. ">Pöldinger 1977</a>; <a href="./references#CD009831-bbs2-0056" title="SpinaE , DeDomenicoP , BonanzingaM , D'AgostinoMA , GittoC , DiRosaAE , et al. A double‐blind comparative study of bromperidol versus haloperidol in schizophrenic patients. New Trends in Experimental and Clinical Psychiatry1992;7:67‐71. ">Spina 1992</a>), two with clopenthixol (<a href="./references#CD009831-bbs2-0027" title="HeikkiläL , LaitinenJ , VartiainenH . Cis(Z)‐clopenthixol and haloperidol in chronic schizophrenic patients ‐ a double‐blind clinical multicentre investigation. Acta Psychiatrica Scandinavica1981;294(Suppl. 1):30‐8. ">Heikkilä 1981</a>; <a href="./references#CD009831-bbs2-0053" title="SerafetinidesEA . Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry1973;8:214‐6. SerafetinidesEA . Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System1973;34:190‐1. SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973;7:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972;154:31‐42. SerafetinidesEA , WillisD . A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry1973;8:245‐7. SerafetinidesEA , WillisD , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Disease1972;155:366‐9. ">Serafetinides 1972</a>), two with droperidol (<a href="./references#CD009831-bbs2-0007" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95:1109‐25. ">Cocchi 1971</a>; <a href="./references#CD009831-bbs2-0008" title="CocitoE , AmbrosiniG , ArataA , BevilacquaP , TortoraE . Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol. Arzneimittelforschung1970;20:1119‐25. ">Cocito 1970</a>), one with flupenthixol (<a href="./references#CD009831-bbs2-0047" title="ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica1983;3:354‐64. ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychotic episodes [article in french]. Acta Psychiatrica Belgica1982;82:617‐31. ">Parent 1983</a>), three with fluphenazine (<a href="./references#CD009831-bbs2-0015" title="FaretraG , DooherL , DowlingJ . Comparison of haloperidol and fluphenazine in disturbed children. American Journal of Psychiatry1970;126:1670‐3. ">Faretra 1970</a>; <a href="./references#CD009831-bbs2-0026" title="HallWB , VestreND , SchieleBC , ZimmermannR . A controlled comparison of haloperidol and fluphenazine in chronic treatment‐resistant schizophrenics. Diseases of the Nervous System1968;29:405‐8. ">Hall 1968</a>; <a href="./references#CD009831-bbs2-0033" title="KinonBJ , KaneJM , ChakosM , MunneR . Possible predictors of neuroleptic‐resistant schizophrenic relapse ‐ influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacology Bulletin1993;29:365‐9. KinonBJ , KaneJM , JohnsC , PerovichR , IsmiM , KoreenA , et al. Treatment of neuroleptic‐resistant schizophrenic relapse. Psychopharmacology Bulletin1993;29:309‐14. ">Kinon 1993</a>), seven with loxapine (<a href="./references#CD009831-bbs2-0005" title="BuenoJR . A double‐blind comparative clinical trial with loxapine succinate and haloperidol in the treatment of Schizophrenia [Ensaio clinico comparativo e duplo‐cego com succina de loxapina e haloperidol no tratamento da esquizofrenia]. Folha Medica1979;78:47‐52. ">Bueno 1979</a>; <a href="./references#CD009831-bbs2-0038" title="MattkeDJ , MombourW , GlotznerFL . The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research [Erfassung neuroleptisch bedingter extrapyramidaler Syndrome in einem psychopharmakologischen Forschungsprojekt]. Pharmakopsychiatrie und Neuropsychopharmakologie1975;1:36‐44. MattkeDJ , WisuschilW . A method for studying pupilomotorics under the influence of neuroleptic medication [Eine Methode zur Untersuchung der Pupillomotorik unter dem Einfluss neuroleptischer Medikation]. Arzneimittelforschung1976;26:946‐50. ">Mattke 1976</a>; <a href="./references#CD009831-bbs2-0046" title="PaprockiJ , Barcala PeixotoMP , AndradeNM . A controlled double‐blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients. Psychopharmacology Bulletin1976;12:32‐4. ">Paprocki 1976</a>; <a href="./references#CD009831-bbs2-0049" title="PoolD , BloomW , MielkeDH , RonigerJJJr , GallantDM . A controlled evaluation of loxitane in seventy‐five adolescent schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1976;19:99‐104. ">Pool 1976</a>; <a href="./references#CD009831-bbs2-0052" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: a double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: a double‐blind comparison with haloperidol and placebo in acute schizophrenics [article in french]. Psychologie Médicale1979;11:1533‐40. ">Selman 1976</a>; <a href="./references#CD009831-bbs2-0060" title="TuasonVB . A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Journal of Clinical Psychiatry1986;47:126‐9. ">Tuason 1986</a>; <a href="./references#CD009831-bbs2-0062" title="VersianiM , daSilvaJA , FrotaLH , MundimFD . Double‐blind comparison between loxapine and haloperidol in the treatment of adolescent schizophrenic patients. Current Therapeutic Research1978;24:559‐66. ">Versiani 1978</a>), one with methylperidol (<a href="./references#CD009831-bbs2-0043" title="NishimatuO , HorigudchiJ , AkitaK , NomuraS , SaraiK , KodamaH . Comparison of the clinical efficacy of methylperidol (luvatren) and haloperidol for schizophrenia by the double‐blind method. Seishin Igaku (Clinical Psychiatry)1975;4:973‐85. ">Nishimatu 1975</a>), one with nemonapride (<a href="./references#CD009831-bbs2-0040" title="MoriA , KazamatsuriH , KanenoS , KamijimaK , KariyaT , MurasakiM , et al. A double‐blind comparison of a new benzamide compound YM 09151 with haloperidol in the treatment of schizophrenia. Rinsho Hyoka1989;17:349‐77. ">Mori 1989</a>), one with mesoridazine (<a href="./references#CD009831-bbs2-0063" title="EatonEM , BuskJ , MaloneyMP , SloaneRB , WhippleK , WhiteK . Hemispheric dysfunction in schizophrenia: assessment by visual perception tasks. Psychiatry Research1979;1:325‐32. WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981;16:34‐8. ">White 1981</a>), four with molindone (<a href="./references#CD009831-bbs2-0012" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993;29:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009831-bbs2-0016" title="FuentenebroF , EscobarJI , KellerJ , Lopez de OchoaEF , VazquezC . Prediction of the therapeutic response to neuroleptics in schizophrenia [Prediccion de la respuesta al tratamiento neuroleptico en la esquizofrenia]. Psiquis Revista de Psiquiatria, Psicologia y Psicosomatica1989;10:22‐8. ">Fuentenebro 1989</a>; <a href="./references#CD009831-bbs2-0014" title="EscobarJI , MannJJ , KellerJ , WilkinsJ , MasonB , MillsMJ . Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Journal of Clinical Psychiatry1985;46:15‐9. ">Escobar 1985</a>; <a href="./references#CD009831-bbs2-0021" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3:315‐20. GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46:4‐7. ">Glazer 1990</a>), three with perphenazine (<a href="./references#CD009831-bbs2-0023" title="GoldsteinBJ , BrauzerB , ClydeDJ , CaldwellJM . The differential prediction of response to two anti‐psychotic drugs. Psychosomatics1969;10:193‐7. ">Goldstein 1969</a>; <a href="./references#CD009831-bbs2-0035" title="KuriharaM , ItoH , KatoN . Clinical evaluation of clocapramine (clofekton) in schizophrenia: a double blind comparison of clocapramine, haloperidol and perphenazine. Rinsho Seishin Igaku (Japanese Journal of Clinical Psychiatry)1983;12:519‐38. ">Kurihara 1983</a>; <a href="./references#CD009831-bbs2-0054" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993;87:86‐91. ">Shalev 1993</a>), three with pimozide (<a href="./references#CD009831-bbs2-0024" title="GowardmanM , BarrerB , BrownRA . Pimozide (R6238) in chronic schizophrenia: double‐blind trial. New Zealand Medical Journal1973;78:487‐91. ">Gowardman 1973</a>; <a href="./references#CD009831-bbs2-0025" title="HaasS , BeckmannH . Pimozide and haloperidol in a double‐blind study in acutely schizophrenic patients [Pimozid und Haloperidol im Doppelblind‐Versuch bei akut schizophrenen Patienten]. Arzneimittelforschung1982;32:888. HaasS , BeckmannH . Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria1982;15:70‐4. ">Haas 1982</a>; <a href="./references#CD009831-bbs2-0055" title="SilverstoneT , CooksonJ , BallR , ChinCN , JacobsD , LaderS , et al. The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. Journal of Psychiatric Research1984;18:255‐68. ">Silverstone 1984</a>), three with pipotiazine (<a href="./references#CD009831-bbs2-0003" title="BechelliLP , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently‐hospitalized acute schizophrenic patients. Brazilian Journal of Medical and Biological Research1983;16:305‐11. ">Bechelli 1983</a>; <a href="./references#CD009831-bbs2-0010" title="DarondelA , BalthazardJC , BrunJP . A double‐blind comparison between pipotiazine and haloperidol [Bilan d'une etude controlee a double insu pipotiazine versus haloperidol]. Psychologie Medicale1981;13:171‐80. ">Darondel 1981</a>; <a href="./references#CD009831-bbs2-0020" title="GiordanaJY , FrenayS . Comparative study of pipotiazine (in its non‐esterified form) and of haloperidol in acute or subacute psychotic states [Etude comparative de la pipothiazine (dans sa forme non esterifiee) et de l'haloperidol au cours d'etats psychotiques aigus et subaigus]. Psychologie Medicale1984;16:1803‐15. ">Giordana 1984</a>), one with propericuazine (<a href="./references#CD009831-bbs2-0042" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics ‐ a comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a>), five with sulpiride (<a href="./references#CD009831-bbs2-0006" title="CassanoGB , CastrogiovanniP , ContiL . The computer diagnosis in a multicenter study of psychoactive agents. Psychopharmacology Bulletin1976;12:22‐4. CassanoGB , CastrogiovanniP , ContiL , BonolloL . Sulpiride ‐ an antipsychotic agent: comparative trial vs. haloperidol. Psychopharmacology Bulletin1977;13:41‐3. CassanoGB , CastrogiovanniP , ContiL , BonolloL . Sulpiride versus haloperidol in schizophrenia: a double‐blind comparative trial. Current Therapy Research, Clinical and Experimental1975;17:189‐201. CastrogiovanniP , CassanoGB , ContiL , MagginiC , BonolloL , SarteschiP . An automated diagnostic process (PDA) in clinical psychopharmacology. An exemplification of its use in a sulpiride versus haloperidol comparative trial. International Pharmacopsychiatry1976;11:74‐83. ">Cassano 1975</a>; <a href="./references#CD009831-bbs2-0009" title="CosarB , CandansayarS , TanerE , IsikE . Comparison of efficacy of clozapine, sulpiride, chlorpromazine and haloperidol in chronic schizophrenic patients therapy. European Neuropsychopharmacology1999;9:287. ">Cosar 1999</a>; <a href="./references#CD009831-bbs2-0018" title="GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersenE , NielsenH . Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross‐over study of therapeutic effectiveness,side effects and plasma concentrations. [article in french]. Semaine des Hopitaux1985;61:1309‐16. GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersonE , NielsenH . Sulpiride and haloperidol in schizophrenia: a double‐blind cross‐over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry1985;147:283‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol in the treatment of schizophrenia: A brief preliminary report [article in danish]. Nordisk Psykiatrisk Tidsskrift1984;38:223‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica. Supplementum1984;311:31‐41. ">Gerlach 1985</a>; <a href="./references#CD009831-bbs2-0045" title="OkudaO , AkaueY , OkishioY . The efficacy of sulpiride in the treatment of schizophrenia by the double‐blind method. Japanese Pharmacology and Therapeutics [Yakuri to Chiryo]1979;7:439‐58. ">Okuda 1979</a>; <a href="./references#CD009831-bbs2-0050" title="Rama RaoV , BaileyJ , BishopM , CoppenA . A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology1981;73:77‐80. ">Rama Rao 1981</a>), one with thiopropazate (<a href="./references#CD009831-bbs2-0029" title="HollisterLE , OverallJE , CaffeyEJr , BennettJL , MeyerF , KimbellIJr , et al. Controlled comparison of Haloperidol with thiopropazate in newly admitted schizophrenics. Journal of Nervous and Mental Disorders1962;135:544‐9. ">Hollister 1962</a>), five with thiothixene (<a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>; <a href="./references#CD009831-bbs2-0013" title="EngelhardtDM , RudorferL , RosenB . Haloperidol and thiothixene in the long‐term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment. Journal of Clinical Psychiatry1978;39:834‐40. ">Engelhardt 1978</a>; <a href="./references#CD009831-bbs2-0030" title="HowardJS . Haloperidol for chronically hospitalized psychotics: a double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a>; <a href="./references#CD009831-bbs2-0058" title="TejaJS , GreyWH , ClumJM , WarrenC . Tranquilizers or anti‐depressants for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry1975;9:241‐7. ">Teja 1975</a>; <a href="./references#CD009831-bbs2-0059" title="TobinJM , RobinsonGM . Double blind comparison of haloperidol and thiothixene with after care treatment evaluation in psychiatric outpatients with schizophrenia. Psychiatric Journal of the University of Ottowa1980;5:168‐74. ">Tobin 1980</a>), one with timiperone (<a href="./references#CD009831-bbs2-0032" title="KariyaT , ShimazonoY , ItohH , MoriA , MurasakiM , SuganoK , et al. A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double‐blind technique. Journal of International Medical Research1983;11:66‐77. KariyaT , ShimazonoY , YamashitaI . Comparison of clinical effects of timiperone and haloperidol on schizophrenia using double‐blind technique. Seishin Igaku (Clinical Psychiatry)1981;10:1281‐301. ">Kariya 1983</a>), six with trifluoperazine (<a href="./references#CD009831-bbs2-0022" title="GoldsteinBJ , ClydeDJ . Haloperidol in controlling the symptoms of acute psychoses. Part II. A double‐blind evaluation of haloperidol and trifluoperazine. Current Therapeutic Research, Clinical and Experimental1966;8:236‐40. ">Goldstein 1966</a>; <a href="./references#CD009831-bbs2-0036" title="LuckeyWT , SchieleBC . A comparison of haloperidol and trifluoperazine. (A double‐blind, controlled study on chronic schizophrenic outpatients). Diseases of the Nervous System1967;28:181‐6. ">Luckey 1967</a>; <a href="./references#CD009831-bbs2-0044" title="O'BrienCP , DiGiacomoJN , WebbW . Management of hostile, suspicious patients ‐ trifluoperazine versus haloperidol. Diseases of the Nervous System1974;35:75‐8. ">O´Brien 1974</a>; <a href="./references#CD009831-bbs2-0051" title="RubinR . A double‐blind comparison of the onset of activity of haloperidol and trifluoperazine. Alabama Journal of Medical Sciences1971;8:414‐8. ">Rubin 1971</a>; <a href="./references#CD009831-bbs2-0057" title="StewartA , LafaveHG , SegoviaG . Haloperidol ‐ new addition to the drug treatment of schizophrenia. Behavioral Neuropsychiatry1969;1:23‐8. ">Stewart 1969</a>; <a href="./references#CD009831-bbs2-0058" title="TejaJS , GreyWH , ClumJM , WarrenC . Tranquilizers or anti‐depressants for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry1975;9:241‐7. ">Teja 1975</a>), two with trifluperidol (<a href="./references#CD009831-bbs2-0017" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(Suppl. 1):53‐7. PrattJP , BishopMP , GallantDM . Trifluperidol and haloperidol in the treatment of acute schizophrenia. American Journal of Psychiatry1964;121:592‐4. ">Gallant 1967</a>; <a href="./references#CD009831-bbs2-0061" title="UlmarG , EdlerR , HagenM . Trifluperidol vs haloperidol – a double‐blind trial. Proceedings of the 17th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1990 Sep 10‐14; Kyoto, Japan. 1990:296. ">Ulmar 1990</a>), and two with zuclopenthixol (<a href="./references#CD009831-bbs2-0002" title="BaastrupPC , AlhforsUG , BjerkenstedtL , DenckerSJ , FensboC , GravemA , et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica1993;87:48‐58. FensboC . Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients ‐ a controlled multicenter study [Zuclopenthixol acetat, haloperidol og zuclopenthixol i behandling af akut psykotiske patienter. En kontrolleret multicenterundersogelse]. Nordisk Psykiatrisk Tidsskrift1990;44:295‐7. ">Baastrup 1993</a>; <a href="./references#CD009831-bbs2-0028" title="HeikkiläL , ElianderH , VartiainenH , TurunenM , PedersenV . Zuclopenthixol and haloperidol in patients with acute psychotic states. A double‐blind, multi‐centre study. Current Medical Research Opinion1992;12:594‐603. ">Heikkilä 1992</a>). </p> <p>A fixed dose or dose scheme was applied in six studies (<a href="./references#CD009831-bbs2-0007" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95:1109‐25. ">Cocchi 1971</a>; <a href="./references#CD009831-bbs2-0010" title="DarondelA , BalthazardJC , BrunJP . A double‐blind comparison between pipotiazine and haloperidol [Bilan d'une etude controlee a double insu pipotiazine versus haloperidol]. Psychologie Medicale1981;13:171‐80. ">Darondel 1981</a>; <a href="./references#CD009831-bbs2-0033" title="KinonBJ , KaneJM , ChakosM , MunneR . Possible predictors of neuroleptic‐resistant schizophrenic relapse ‐ influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacology Bulletin1993;29:365‐9. KinonBJ , KaneJM , JohnsC , PerovichR , IsmiM , KoreenA , et al. Treatment of neuroleptic‐resistant schizophrenic relapse. Psychopharmacology Bulletin1993;29:309‐14. ">Kinon 1993</a>; <a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a>; <a href="./references#CD009831-bbs2-0041" title="NedopilN , RutherE . Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatria1981;14:205‐7. ">Nedopil 1981</a>; <a href="./references#CD009831-bbs2-0042" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics ‐ a comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a>). In most of the included trials flexible doses of antipsychotic agents could be administered. The mean final doses of haloperidol ranged from 6.6 mg/day (<a href="./references#CD009831-bbs2-0048" title="BuresE , PoldingerW . Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double‐blind research [Einleitende Worte zum Austausch der Erfahrungen über die klinische Wirkung von Bromperidol. Mitteilung über eigene Ergebnisse im offenen und Doppelblindversuch]. International Pharmacopsychiatry1978;13:45‐52. PöldingerW . Clinical experiences in an open and a double‐blind trial. Acta Psychiatrica Belgica1978;78:96‐101. PöldingerW , BuresE , HaageH . Double‐blind study with two butyrophenone derivatives: bromperidol vs. haloperidol. International Pharmacopsychiatry1977;12:184‐92. ">Pöldinger 1977</a>) to 30.4 mg/day (<a href="./references#CD009831-bbs2-0004" title="BrannenJO , McEvoyJP , WilsonWH , PetrieWM , BanTA , BerneySA , et al. A double‐blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatria1981;14:139‐40. ">Brannen 1981</a>). In the long‐term study by <a href="./references#CD009831-bbs2-0042" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics ‐ a comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a> evaluating maintenance pharmacotherapy, no participant received more than 6 mg/day haloperidol. The maximum allowed dose of haloperidol that could be administered was 100 mg/day in the research projects of <a href="./references#CD009831-bbs2-0060" title="TuasonVB . A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Journal of Clinical Psychiatry1986;47:126‐9. ">Tuason 1986</a> and <a href="./references#CD009831-bbs2-0063" title="EatonEM , BuskJ , MaloneyMP , SloaneRB , WhippleK , WhiteK . Hemispheric dysfunction in schizophrenia: assessment by visual perception tasks. Psychiatry Research1979;1:325‐32. WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981;16:34‐8. ">White 1981</a>. </p> </section> <section id="CD009831-sec-0104"> <h5 class="title">7. Outcomes</h5> <section id="CD009831-sec-0105"> <h6 class="title">7.1 Clinically important response to treatment</h6> <p>The primary outcome "clinically important response to treatment" was reported only by a limited number of the included studies (n = 40). We prespecified a reduction of at least 50% in the PANSS or BPRS as a relevant cut‐off to define clinically important response to treatment. Only the study by <a href="./references#CD009831-bbs2-0034" title="KodamaH , SaraiK , NakaharaT . The clinical efficacy of bromperidol for schizophrenia: comparison with haloperidol by the double‐blind method. Igaku to Yakugaku1984;12:269‐86. ">Kodama 1984</a> provided data to calculate the 50% threshold of the BPRS. In all other cases, we had to employ the definition of the original studies, which was mainly based on the categorisation according to the Clinical Global Impression Scale (CGI, <a href="./references#CD009831-bbs2-0155" title="GuyW . ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale). Rockville: National Institute of Mental Health, 1976. ">Guy 1976</a>). We used a CGI rating of at least "much improved" to assume clinically important response to treatment. </p> </section> <section id="CD009831-sec-0106"> <h6 class="title">7.2 Rating scales</h6> <p>Different rating scales were applied to assess clinical response and adverse effects. Details of scales that provided usable data are shown below. Reasons for exclusion of data from other rating instruments are provided under "outcomes" in the <a href="./references#CD009831-sec-0219" title="">Characteristics of included studies</a> table. </p> <section id="CD009831-sec-0107"> <p><b>7.2.1 Global state</b></p> <p>7.2.1.1 Clinical Global Impression ‐ CGI (<a href="./references#CD009831-bbs2-0155" title="GuyW . ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale). Rockville: National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This rating instrument is commonly employed in studies on schizophrenia and enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven‐point scoring system is usually used with low scores indicating decreased severity and/or greater recovery. <a href="./references#CD009831-bbs2-0014" title="EscobarJI , MannJJ , KellerJ , WilkinsJ , MasonB , MillsMJ . Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Journal of Clinical Psychiatry1985;46:15‐9. ">Escobar 1985</a>, <a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a>, <a href="./references#CD009831-bbs2-0056" title="SpinaE , DeDomenicoP , BonanzingaM , D'AgostinoMA , GittoC , DiRosaAE , et al. A double‐blind comparative study of bromperidol versus haloperidol in schizophrenic patients. New Trends in Experimental and Clinical Psychiatry1992;7:67‐71. ">Spina 1992</a>, and <a href="./references#CD009831-bbs2-0063" title="EatonEM , BuskJ , MaloneyMP , SloaneRB , WhippleK , WhiteK . Hemispheric dysfunction in schizophrenia: assessment by visual perception tasks. Psychiatry Research1979;1:325‐32. WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981;16:34‐8. ">White 1981</a> reported data from this scale. </p> </section> <section id="CD009831-sec-0108"> <p><b>7.2.2 Mental state</b></p> <p>7.2.2.1 Brief Psychiatric Rating Scale ‐ BPRS (<a href="./references#CD009831-bbs2-0183" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>)<br/> This brief rating scale is used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 18 items, and each item can be defined on a seven‐point scale varying from "not present" (1) to "extremely severe" (7). Scores range between 18 and 126. Twenty‐four studies (<a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>; <a href="./references#CD009831-bbs2-0003" title="BechelliLP , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently‐hospitalized acute schizophrenic patients. Brazilian Journal of Medical and Biological Research1983;16:305‐11. ">Bechelli 1983</a>; <a href="./references#CD009831-bbs2-0004" title="BrannenJO , McEvoyJP , WilsonWH , PetrieWM , BanTA , BerneySA , et al. A double‐blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatria1981;14:139‐40. ">Brannen 1981</a>; <a href="./references#CD009831-bbs2-0010" title="DarondelA , BalthazardJC , BrunJP . A double‐blind comparison between pipotiazine and haloperidol [Bilan d'une etude controlee a double insu pipotiazine versus haloperidol]. Psychologie Medicale1981;13:171‐80. ">Darondel 1981</a>; <a href="./references#CD009831-bbs2-0012" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993;29:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009831-bbs2-0018" title="GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersenE , NielsenH . Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross‐over study of therapeutic effectiveness,side effects and plasma concentrations. [article in french]. Semaine des Hopitaux1985;61:1309‐16. GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersonE , NielsenH . Sulpiride and haloperidol in schizophrenia: a double‐blind cross‐over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry1985;147:283‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol in the treatment of schizophrenia: A brief preliminary report [article in danish]. Nordisk Psykiatrisk Tidsskrift1984;38:223‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica. Supplementum1984;311:31‐41. ">Gerlach 1985</a>; <a href="./references#CD009831-bbs2-0025" title="HaasS , BeckmannH . Pimozide and haloperidol in a double‐blind study in acutely schizophrenic patients [Pimozid und Haloperidol im Doppelblind‐Versuch bei akut schizophrenen Patienten]. Arzneimittelforschung1982;32:888. HaasS , BeckmannH . Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria1982;15:70‐4. ">Haas 1982</a>; <a href="./references#CD009831-bbs2-0026" title="HallWB , VestreND , SchieleBC , ZimmermannR . A controlled comparison of haloperidol and fluphenazine in chronic treatment‐resistant schizophrenics. Diseases of the Nervous System1968;29:405‐8. ">Hall 1968</a>; <a href="./references#CD009831-bbs2-0027" title="HeikkiläL , LaitinenJ , VartiainenH . Cis(Z)‐clopenthixol and haloperidol in chronic schizophrenic patients ‐ a double‐blind clinical multicentre investigation. Acta Psychiatrica Scandinavica1981;294(Suppl. 1):30‐8. ">Heikkilä 1981</a>; <a href="./references#CD009831-bbs2-0028" title="HeikkiläL , ElianderH , VartiainenH , TurunenM , PedersenV . Zuclopenthixol and haloperidol in patients with acute psychotic states. A double‐blind, multi‐centre study. Current Medical Research Opinion1992;12:594‐603. ">Heikkilä 1992</a>; <a href="./references#CD009831-bbs2-0029" title="HollisterLE , OverallJE , CaffeyEJr , BennettJL , MeyerF , KimbellIJr , et al. Controlled comparison of Haloperidol with thiopropazate in newly admitted schizophrenics. Journal of Nervous and Mental Disorders1962;135:544‐9. ">Hollister 1962</a>; <a href="./references#CD009831-bbs2-0031" title="ItoH , AnnoH , FujiiY , HasegawaY , IkegamiH , IshigookaJ , et al. Clinical evaluation of bromperidol, a new investigational butyrophenone derivative, in schizophrenia, a double‐blind comparison of bromperidol and haloperidol. Rinsho Hyoka (Clinical Evaluation)1985;13:105‐36. ItohH . A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double‐ blind technique. Psychopharmacology Bulletin1985;21:120‐2. ">Itoh 1985</a>; <a href="./references#CD009831-bbs2-0033" title="KinonBJ , KaneJM , ChakosM , MunneR . Possible predictors of neuroleptic‐resistant schizophrenic relapse ‐ influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacology Bulletin1993;29:365‐9. KinonBJ , KaneJM , JohnsC , PerovichR , IsmiM , KoreenA , et al. Treatment of neuroleptic‐resistant schizophrenic relapse. Psychopharmacology Bulletin1993;29:309‐14. ">Kinon 1993</a>; <a href="./references#CD009831-bbs2-0036" title="LuckeyWT , SchieleBC . A comparison of haloperidol and trifluoperazine. (A double‐blind, controlled study on chronic schizophrenic outpatients). Diseases of the Nervous System1967;28:181‐6. ">Luckey 1967</a>; <a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a>; <a href="./references#CD009831-bbs2-0047" title="ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica1983;3:354‐64. ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychotic episodes [article in french]. Acta Psychiatrica Belgica1982;82:617‐31. ">Parent 1983</a>; <a href="./references#CD009831-bbs2-0050" title="Rama RaoV , BaileyJ , BishopM , CoppenA . A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology1981;73:77‐80. ">Rama Rao 1981</a>; <a href="./references#CD009831-bbs2-0052" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: a double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: a double‐blind comparison with haloperidol and placebo in acute schizophrenics [article in french]. Psychologie Médicale1979;11:1533‐40. ">Selman 1976</a>; <a href="./references#CD009831-bbs2-0053" title="SerafetinidesEA . Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry1973;8:214‐6. SerafetinidesEA . Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System1973;34:190‐1. SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973;7:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972;154:31‐42. SerafetinidesEA , WillisD . A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry1973;8:245‐7. SerafetinidesEA , WillisD , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Disease1972;155:366‐9. ">Serafetinides 1972</a>; <a href="./references#CD009831-bbs2-0056" title="SpinaE , DeDomenicoP , BonanzingaM , D'AgostinoMA , GittoC , DiRosaAE , et al. A double‐blind comparative study of bromperidol versus haloperidol in schizophrenic patients. New Trends in Experimental and Clinical Psychiatry1992;7:67‐71. ">Spina 1992</a>; <a href="./references#CD009831-bbs2-0059" title="TobinJM , RobinsonGM . Double blind comparison of haloperidol and thiothixene with after care treatment evaluation in psychiatric outpatients with schizophrenia. Psychiatric Journal of the University of Ottowa1980;5:168‐74. ">Tobin 1980</a>; <a href="./references#CD009831-bbs2-0060" title="TuasonVB . A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Journal of Clinical Psychiatry1986;47:126‐9. ">Tuason 1986</a>; <a href="./references#CD009831-bbs2-0062" title="VersianiM , daSilvaJA , FrotaLH , MundimFD . Double‐blind comparison between loxapine and haloperidol in the treatment of adolescent schizophrenic patients. Current Therapeutic Research1978;24:559‐66. ">Versiani 1978</a>; <a href="./references#CD009831-bbs2-0063" title="EatonEM , BuskJ , MaloneyMP , SloaneRB , WhippleK , WhiteK . Hemispheric dysfunction in schizophrenia: assessment by visual perception tasks. Psychiatry Research1979;1:325‐32. WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981;16:34‐8. ">White 1981</a>) reported data from the BPRS scale. </p> <p>7.2.2.2 Montgomery Rating Score ‐ MRS (<a href="./references#CD009831-bbs2-0181" title="MontgomerySA , TaylorP , MontgomeryD . Development of a schizophrenia scale sensitive to change. Neuropsychopharmacology1978;17:1061‐2. ">Montgomery 1978</a>)<br/> The MRS consists of 12 items and allows an evaluation in terms of schizophrenic first rank symptoms. <a href="./references#CD009831-bbs2-0055" title="SilverstoneT , CooksonJ , BallR , ChinCN , JacobsD , LaderS , et al. The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. Journal of Psychiatric Research1984;18:255‐68. ">Silverstone 1984</a> provided data from this scale. </p> <p>7.2.2.3 Rating Scale for Quantification of Psychotic Symptom Severity ‐ RSQPSS (<a href="./references#CD009831-bbs2-0153" title="GoodrichW . Rating Scale for Quantification of Psychotic Symptom Severity (RSQPSS). American Journal of Psychiatry1953;110:334. ">Goodrich 1953</a>)<br/> The RSQPSS allows a methodical exploration of physical conditions (appetite, sleep, body weight, psychosomatic symptoms), sensorium (orientation, state of intellectual functions relative to schizophrenic deficiency), behaviour (personal care, activity, abnormal language, behaviour), emotional status (mood, tension, affectivity), and mental content (hallucination, delusion). A total sum score (final rating) ranging from 2.0 (security ward) to 4.0 (possible discharge from mental hospital) provides an overall evaluation of severity. The study by <a href="./references#CD009831-bbs2-0008" title="CocitoE , AmbrosiniG , ArataA , BevilacquaP , TortoraE . Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol. Arzneimittelforschung1970;20:1119‐25. ">Cocito 1970</a> reported data from this scale. </p> <p>7.2.2.4 Scale for the Assessment of Positive Symptoms ‐ SAPS (<a href="./references#CD009831-bbs2-0132" title="AndreasenNC . The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: The University of Iowa, 1983. ">Andreasen 1983</a>)<br/> This six‐point scale contains a global rating of the following positive symptoms: hallucinations, delusions, bizarre behaviour, and conceptual disorganisation. High scores indicate a high magnitude of symptoms. <a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a> provided data from this scale. </p> <p>7.2.2.5 Scale for the Assessment of Negative Symptoms ‐ SANS (<a href="./references#CD009831-bbs2-0133" title="AndreasenNC . Scale for the assessment of negative symptoms. British Journal of Psychiatry1989;155:53‐8. ">Andreasen 1989</a>)<br/> This scale was designed to assess negative symptoms in schizophrenic conditions. These negative symptoms include alogia, affective blunting, avolition‐apathy, anhedonia‐associality, and attention impairment. As in the SAPS, higher scores in this six‐point scale are associated with more severe symptoms. <a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a> reported data from this scale. </p> <p>7.2.2.6 Hamilton Depression Rating Scale ‐ HAM‐D (<a href="./references#CD009831-bbs2-0156" title="Hamilton , M . A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56‐62. ">Hamilton 1960</a>)<br/> The HAM‐D (<a href="./references#CD009831-bbs2-0156" title="Hamilton , M . A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56‐62. ">Hamilton 1960</a>) is a well‐established 17‐item scale for the measurement of depression and is sensitive to change. <a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>, <a href="./references#CD009831-bbs2-0012" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993;29:249‐55. ">Dufresne 1993</a>, and <a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a> trials provided data concerning the HAM‐D. </p> <p>7.2.2.7 AMDP (<a href="./references#CD009831-bbs2-0131" title="AMDP . Das AMDP‐System. Manual zur Dokumentation psychiatrischer Befunde. 8. Göttingen: Hogrefe, 2007. ">AMDP 2007</a>)<br/> The AMDP system consists of a glossary of psychopathological symptoms (AMDP manual) and rating scales. Altogether, these instruments provide standardised diagnostic findings. <a href="./references#CD009831-bbs2-0020" title="GiordanaJY , FrenayS . Comparative study of pipotiazine (in its non‐esterified form) and of haloperidol in acute or subacute psychotic states [Etude comparative de la pipothiazine (dans sa forme non esterifiee) et de l'haloperidol au cours d'etats psychotiques aigus et subaigus]. Psychologie Medicale1984;16:1803‐15. ">Giordana 1984</a> and <a href="./references#CD009831-bbs2-0041" title="NedopilN , RutherE . Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatria1981;14:205‐7. ">Nedopil 1981</a> allocated data in terms of the AMDP system. </p> </section> <section id="CD009831-sec-0109"> <p><b>7.2.3 Behaviour</b></p> <p>7.2.3.1 Nurses Observation Scale for Inpatient Evaluation ‐ NOSIE (<a href="./references#CD009831-bbs2-0159" title="HonigfeldG , GillisRD , KlettCJ . Nurses' observation scale for inpatient evaluation: a new scale for measuring improvement in chronic schizophrenia. Journal of Clinical Psychology1965;21:65‐71. ">Honigfeld 1965</a>)<br/> The NOSIE is an 80‐item scale with items rated on a five‐point scale from zero (not present) to four (always present). Ratings are based on behaviour over the previous three days. The seven headings are social competence, social interest, personal neatness, co‐operation, irritability, manifest psychosis, and psychotic depression. The total score ranges from zero to 320 with high scores indicating a poor outcome. <a href="./references#CD009831-bbs2-0004" title="BrannenJO , McEvoyJP , WilsonWH , PetrieWM , BanTA , BerneySA , et al. A double‐blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatria1981;14:139‐40. ">Brannen 1981</a>, <a href="./references#CD009831-bbs2-0027" title="HeikkiläL , LaitinenJ , VartiainenH . Cis(Z)‐clopenthixol and haloperidol in chronic schizophrenic patients ‐ a double‐blind clinical multicentre investigation. Acta Psychiatrica Scandinavica1981;294(Suppl. 1):30‐8. ">Heikkilä 1981</a>, and <a href="./references#CD009831-bbs2-0053" title="SerafetinidesEA . Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry1973;8:214‐6. SerafetinidesEA . Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System1973;34:190‐1. SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973;7:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972;154:31‐42. SerafetinidesEA , WillisD . A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry1973;8:245‐7. SerafetinidesEA , WillisD , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Disease1972;155:366‐9. ">Serafetinides 1972</a> reported data from this scale. </p> <p>7.2.3.2 Wing`s Ward Behaviour Scale (<a href="./references#CD009831-bbs2-0200" title="WingJK . A simple and reliable subclassification of chronic schizophrenia. Journal of Mental Science1961;107:862‐76. ">Wing 1961</a>)<br/> The Wing`s Ward Behaviour Scale comprises two subscales measuring social withdrawal (e.g. slowness, underactivity, or lack of conversation) and social embarrassing behaviour (e.g. threats of violence or odd mannerisms). The Wing`s Ward Behaviour Scale requires senior nurses as informants. <a href="./references#CD009831-bbs2-0050" title="Rama RaoV , BaileyJ , BishopM , CoppenA . A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology1981;73:77‐80. ">Rama Rao 1981</a> provided data from this scale. </p> </section> <section id="CD009831-sec-0110"> <p><b>7.2.4 Adverse effects</b></p> <p>Adverse effects (death, at least one adverse effect, at least one movement disorder, akathisia, akinesia, dyskinesia, dystonia, rigor, tardive dyskinesia, tremor, use of antiparkinson medication, hypotension, sedation, weight gain) were reported in a dichotomous manner in terms of the number of participants who experienced the relevant adverse effect. </p> </section> <section id="CD009831-sec-0111"> <p><b>7.2.5 Missing outcomes</b></p> <p>No data were available for the outcomes "satisfaction with care", "quality of life", "service utilisation", "functioning", and economic consequences of treatment. </p> </section> </section> </section> </section> <section id="CD009831-sec-0112"> <h4 class="title">Excluded studies</h4> <p>We excluded 64 trials (see <a href="./references#CD009831-sec-0220" title="">Characteristics of excluded studies</a> table). Twenty‐eight studies were excluded because they were not appropriately randomised. In 10 trials the participants did not receive oral medication within the first week and in seven studies fewer than 75% of participants suffered from schizophrenia and/or schizophrenia‐like psychoses and data were not provided separately for people with schizophrenic disorders. Six trials were performed applying a cross‐over study design without providing data separately up to the point of first cross‐over and six studies administered an intervention in the control group that does not meet the inclusion criteria. Three research projects evaluated augmentation strategies and in two trials there was no information regarding the diagnoses of the participants available. One citation was a review and in one study after four days of parenteral administration of the investigated agents, only responders were switched to oral medication. </p> </section> </section> <section id="CD009831-sec-0113"> <h3 class="title">Risk of bias in included studies</h3> <p>For graphical representations of our judgements of risk of bias please refer to <a href="#CD009831-fig-0002">Figure 2</a> and <a href="#CD009831-fig-0003">Figure 3</a>. Full details of judgements for every single included study are presented in the 'Risk of bias' tables within the section <a href="./references#CD009831-sec-0219" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD009831-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009831-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD009831-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009831-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>Briefly, all studies were randomised, but only three of them described an adequate random sequence generation procedure. No study indicated adequate concealment of allocation. The risk for a performance bias was low in 40 studies and for detection bias in 10 trials. The risk of bias for incomplete outcome data reporting (attrition bias) was judged to be low in 18 trials, unclear in 28, and high in 17. Three of the 63 included studies appeared to be free of selective reporting and in 33 trials we found evidence for a high risk of other biases. </p> <section id="CD009831-sec-0114"> <h4 class="title">Allocation</h4> <p><a href="./references#CD009831-bbs2-0013" title="EngelhardtDM , RudorferL , RosenB . Haloperidol and thiothixene in the long‐term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment. Journal of Clinical Psychiatry1978;39:834‐40. ">Engelhardt 1978</a> used a computer‐generated randomisation scheme for sequence generation and <a href="./references#CD009831-bbs2-0018" title="GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersenE , NielsenH . Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross‐over study of therapeutic effectiveness,side effects and plasma concentrations. [article in french]. Semaine des Hopitaux1985;61:1309‐16. GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersonE , NielsenH . Sulpiride and haloperidol in schizophrenia: a double‐blind cross‐over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry1985;147:283‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol in the treatment of schizophrenia: A brief preliminary report [article in danish]. Nordisk Psykiatrisk Tidsskrift1984;38:223‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica. Supplementum1984;311:31‐41. ">Gerlach 1985</a> randomised referring to a random number table. In <a href="./references#CD009831-bbs2-0020" title="GiordanaJY , FrenayS . Comparative study of pipotiazine (in its non‐esterified form) and of haloperidol in acute or subacute psychotic states [Etude comparative de la pipothiazine (dans sa forme non esterifiee) et de l'haloperidol au cours d'etats psychotiques aigus et subaigus]. Psychologie Medicale1984;16:1803‐15. ">Giordana 1984</a> the participants were drawn by lots into two groups of treatment. These trials were given the quality score "low risk of bias". No further details on the randomisation method were provided in the remaining 60 studies. In 12 publications no randomisation was mentioned (<a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>; <a href="./references#CD009831-bbs2-0005" title="BuenoJR . A double‐blind comparative clinical trial with loxapine succinate and haloperidol in the treatment of Schizophrenia [Ensaio clinico comparativo e duplo‐cego com succina de loxapina e haloperidol no tratamento da esquizofrenia]. Folha Medica1979;78:47‐52. ">Bueno 1979</a>; <a href="./references#CD009831-bbs2-0016" title="FuentenebroF , EscobarJI , KellerJ , Lopez de OchoaEF , VazquezC . Prediction of the therapeutic response to neuroleptics in schizophrenia [Prediccion de la respuesta al tratamiento neuroleptico en la esquizofrenia]. Psiquis Revista de Psiquiatria, Psicologia y Psicosomatica1989;10:22‐8. ">Fuentenebro 1989</a>; <a href="./references#CD009831-bbs2-0025" title="HaasS , BeckmannH . Pimozide and haloperidol in a double‐blind study in acutely schizophrenic patients [Pimozid und Haloperidol im Doppelblind‐Versuch bei akut schizophrenen Patienten]. Arzneimittelforschung1982;32:888. HaasS , BeckmannH . Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria1982;15:70‐4. ">Haas 1982</a>; <a href="./references#CD009831-bbs2-0027" title="HeikkiläL , LaitinenJ , VartiainenH . Cis(Z)‐clopenthixol and haloperidol in chronic schizophrenic patients ‐ a double‐blind clinical multicentre investigation. Acta Psychiatrica Scandinavica1981;294(Suppl. 1):30‐8. ">Heikkilä 1981</a>; <a href="./references#CD009831-bbs2-0031" title="ItoH , AnnoH , FujiiY , HasegawaY , IkegamiH , IshigookaJ , et al. Clinical evaluation of bromperidol, a new investigational butyrophenone derivative, in schizophrenia, a double‐blind comparison of bromperidol and haloperidol. Rinsho Hyoka (Clinical Evaluation)1985;13:105‐36. ItohH . A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double‐ blind technique. Psychopharmacology Bulletin1985;21:120‐2. ">Itoh 1985</a>; <a href="./references#CD009831-bbs2-0038" title="MattkeDJ , MombourW , GlotznerFL . The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research [Erfassung neuroleptisch bedingter extrapyramidaler Syndrome in einem psychopharmakologischen Forschungsprojekt]. Pharmakopsychiatrie und Neuropsychopharmakologie1975;1:36‐44. MattkeDJ , WisuschilW . A method for studying pupilomotorics under the influence of neuroleptic medication [Eine Methode zur Untersuchung der Pupillomotorik unter dem Einfluss neuroleptischer Medikation]. Arzneimittelforschung1976;26:946‐50. ">Mattke 1976</a>; <a href="./references#CD009831-bbs2-0044" title="O'BrienCP , DiGiacomoJN , WebbW . Management of hostile, suspicious patients ‐ trifluoperazine versus haloperidol. Diseases of the Nervous System1974;35:75‐8. ">O´Brien 1974</a>; <a href="./references#CD009831-bbs2-0057" title="StewartA , LafaveHG , SegoviaG . Haloperidol ‐ new addition to the drug treatment of schizophrenia. Behavioral Neuropsychiatry1969;1:23‐8. ">Stewart 1969</a>; <a href="./references#CD009831-bbs2-0059" title="TobinJM , RobinsonGM . Double blind comparison of haloperidol and thiothixene with after care treatment evaluation in psychiatric outpatients with schizophrenia. Psychiatric Journal of the University of Ottowa1980;5:168‐74. ">Tobin 1980</a>; <a href="./references#CD009831-bbs2-0061" title="UlmarG , EdlerR , HagenM . Trifluperidol vs haloperidol – a double‐blind trial. Proceedings of the 17th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1990 Sep 10‐14; Kyoto, Japan. 1990:296. ">Ulmar 1990</a>; <a href="./references#CD009831-bbs2-0063" title="EatonEM , BuskJ , MaloneyMP , SloaneRB , WhippleK , WhiteK . Hemispheric dysfunction in schizophrenia: assessment by visual perception tasks. Psychiatry Research1979;1:325‐32. WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981;16:34‐8. ">White 1981</a>). Because the trials were described as "double‐blind", we implied that the studies were randomised. All these studies were rated with "unclear risk of bias". None of the included trials used a 'cluster randomisation'. </p> <p>Regarding concealment of allocation, no study provided enough information to permit judgement of "low risk of bias" as well as "high risk of bias" in the quality score. </p> </section> <section id="CD009831-sec-0115"> <h4 class="title">Blinding</h4> <p>Performance‐Bias: Most of the included studies were declared as "double‐blind". In 19 trials the authors provided no further information concerning the mechanism of blinding ("unclear risk of bias"), while 40 provided information to allow judgement with "low risk of bias" in the quality tool. Most of these studies used at least identically appearing capsules for blinding. Three trials <i>(</i><a href="./references#CD009831-bbs2-0002" title="BaastrupPC , AlhforsUG , BjerkenstedtL , DenckerSJ , FensboC , GravemA , et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica1993;87:48‐58. FensboC . Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients ‐ a controlled multicenter study [Zuclopenthixol acetat, haloperidol og zuclopenthixol i behandling af akut psykotiske patienter. En kontrolleret multicenterundersogelse]. Nordisk Psykiatrisk Tidsskrift1990;44:295‐7. ">Baastrup 1993</a>; <a href="./references#CD009831-bbs2-0041" title="NedopilN , RutherE . Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatria1981;14:205‐7. ">Nedopil 1981</a>; <a href="./references#CD009831-bbs2-0047" title="ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica1983;3:354‐64. ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychotic episodes [article in french]. Acta Psychiatrica Belgica1982;82:617‐31. ">Parent 1983</a><i>)</i> were non‐blind and in <a href="./references#CD009831-bbs2-0060" title="TuasonVB . A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Journal of Clinical Psychiatry1986;47:126‐9. ">Tuason 1986</a> the personnel administering the study medications was not blinded (classified as "high risk of bias"). </p> <p>Detection‐Bias: 51 publications did not provide enough information to allow classification of "high" or "low risk of bias". In 10 trials, we assessed a "low risk of bias" for a detection‐bias (<a href="./references#CD009831-bbs2-0014" title="EscobarJI , MannJJ , KellerJ , WilkinsJ , MasonB , MillsMJ . Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Journal of Clinical Psychiatry1985;46:15‐9. ">Escobar 1985</a>; <a href="./references#CD009831-bbs2-0015" title="FaretraG , DooherL , DowlingJ . Comparison of haloperidol and fluphenazine in disturbed children. American Journal of Psychiatry1970;126:1670‐3. ">Faretra 1970</a>; <a href="./references#CD009831-bbs2-0018" title="GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersenE , NielsenH . Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross‐over study of therapeutic effectiveness,side effects and plasma concentrations. [article in french]. Semaine des Hopitaux1985;61:1309‐16. GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersonE , NielsenH . Sulpiride and haloperidol in schizophrenia: a double‐blind cross‐over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry1985;147:283‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol in the treatment of schizophrenia: A brief preliminary report [article in danish]. Nordisk Psykiatrisk Tidsskrift1984;38:223‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica. Supplementum1984;311:31‐41. ">Gerlach 1985</a>; <a href="./references#CD009831-bbs2-0024" title="GowardmanM , BarrerB , BrownRA . Pimozide (R6238) in chronic schizophrenia: double‐blind trial. New Zealand Medical Journal1973;78:487‐91. ">Gowardman 1973</a>; <a href="./references#CD009831-bbs2-0026" title="HallWB , VestreND , SchieleBC , ZimmermannR . A controlled comparison of haloperidol and fluphenazine in chronic treatment‐resistant schizophrenics. Diseases of the Nervous System1968;29:405‐8. ">Hall 1968</a>; <a href="./references#CD009831-bbs2-0041" title="NedopilN , RutherE . Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatria1981;14:205‐7. ">Nedopil 1981</a>; <a href="./references#CD009831-bbs2-0049" title="PoolD , BloomW , MielkeDH , RonigerJJJr , GallantDM . A controlled evaluation of loxitane in seventy‐five adolescent schizophrenic patients. Current Therapeutic Research, Clinical and Experimental1976;19:99‐104. ">Pool 1976</a>; <a href="./references#CD009831-bbs2-0052" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: a double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: a double‐blind comparison with haloperidol and placebo in acute schizophrenics [article in french]. Psychologie Médicale1979;11:1533‐40. ">Selman 1976</a>; <a href="./references#CD009831-bbs2-0059" title="TobinJM , RobinsonGM . Double blind comparison of haloperidol and thiothixene with after care treatment evaluation in psychiatric outpatients with schizophrenia. Psychiatric Journal of the University of Ottowa1980;5:168‐74. ">Tobin 1980</a>; <a href="./references#CD009831-bbs2-0060" title="TuasonVB . A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Journal of Clinical Psychiatry1986;47:126‐9. ">Tuason 1986</a>), while two studies appeared to have a "high risk" regarding this bias <i>(</i><a href="./references#CD009831-bbs2-0002" title="BaastrupPC , AlhforsUG , BjerkenstedtL , DenckerSJ , FensboC , GravemA , et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica1993;87:48‐58. FensboC . Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients ‐ a controlled multicenter study [Zuclopenthixol acetat, haloperidol og zuclopenthixol i behandling af akut psykotiske patienter. En kontrolleret multicenterundersogelse]. Nordisk Psykiatrisk Tidsskrift1990;44:295‐7. ">Baastrup 1993</a>; <a href="./references#CD009831-bbs2-0047" title="ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica1983;3:354‐64. ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychotic episodes [article in french]. Acta Psychiatrica Belgica1982;82:617‐31. ">Parent 1983</a>)<i>.</i> </p> </section> <section id="CD009831-sec-0116"> <h4 class="title">Incomplete outcome data</h4> <p>The overall‐attrition (participants who left the trials early for any indication) was low (&lt; 10%) in 18 trials (rated as "low risk of bias") and moderate (10% to 25%) in 10 studies. Moderate attrition was classified as "unclear risk of bias" because in all relevant trials the authors of the original studies did not provide sufficient information to judge if the analysis‐methods were appropriate to deal with the missing data. In 17 trials the attrition could be considered as high (&gt; 25%) (rated as "high risk of bias") and 18 studies did not address this outcome (judged as "unclear risk of bias"). In most of the research projects completers‐analyses were applied. </p> </section> <section id="CD009831-sec-0117"> <h4 class="title">Selective reporting</h4> <p>The outcome‐data reporting was incomplete in 46 studies (rated as "high risk of bias"). In particular, standard deviations were often not indicated and had to be imputed from the other trials. In several instances the data had to be estimated from figures, which led to imprecision. Two trials appeared to be free of selective reporting (<a href="./references#CD009831-bbs2-0008" title="CocitoE , AmbrosiniG , ArataA , BevilacquaP , TortoraE . Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol. Arzneimittelforschung1970;20:1119‐25. ">Cocito 1970</a>; <a href="./references#CD009831-bbs2-0010" title="DarondelA , BalthazardJC , BrunJP . A double‐blind comparison between pipotiazine and haloperidol [Bilan d'une etude controlee a double insu pipotiazine versus haloperidol]. Psychologie Medicale1981;13:171‐80. ">Darondel 1981</a>) and were rated with "low risk of bias" in the quality score. </p> </section> <section id="CD009831-sec-0118"> <h4 class="title">Other potential sources of bias</h4> <p>Three investigations appeared to be free of other potential sources of bias and received the rating "low risk of bias" (<a href="./references#CD009831-bbs2-0052" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: a double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: a double‐blind comparison with haloperidol and placebo in acute schizophrenics [article in french]. Psychologie Médicale1979;11:1533‐40. ">Selman 1976</a>; <a href="./references#CD009831-bbs2-0053" title="SerafetinidesEA . Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry1973;8:214‐6. SerafetinidesEA . Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System1973;34:190‐1. SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973;7:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972;154:31‐42. SerafetinidesEA , WillisD . A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry1973;8:245‐7. SerafetinidesEA , WillisD , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Disease1972;155:366‐9. ">Serafetinides 1972</a>; <a href="./references#CD009831-bbs2-0056" title="SpinaE , DeDomenicoP , BonanzingaM , D'AgostinoMA , GittoC , DiRosaAE , et al. A double‐blind comparative study of bromperidol versus haloperidol in schizophrenic patients. New Trends in Experimental and Clinical Psychiatry1992;7:67‐71. ">Spina 1992</a>). In 27 studies the "risk of bias" was considered as "unclear" due to a lack of available information in the publications. Thus, there was insufficient information to assess whether an important "risk of bias" exists<i>.</i> <br/> The remaining 33 studies were characterised by a "high risk of bias" in terms of other potential sources of bias. The reasons for rating "high risk of bias" are displayed in more detail in the <a href="./references#CD009831-sec-0219" title="">Characteristics of included studies</a> table for every included trial. </p> </section> </section> <section id="CD009831-sec-0119"> <h3 class="title" id="CD009831-sec-0119">Effects of interventions</h3> <p>See: <a href="./full#CD009831-tbl-0001"><b>Summary of findings for the main comparison</b> Haloperidol versus first‐generation antipsychotics for schizophrenia (short term)</a>; <a href="./full#CD009831-tbl-0002"><b>Summary of findings 2</b> Haloperidol versus first‐generation antipsychotics for schizophrenia (medium term)</a> </p> <p>We analysed dichotomous outcomes with risk ratios (RR) and continuous outcomes with mean differences (MD), both with the associated 95% confidence intervals (CI) </p> <section id="CD009831-sec-0120"> <h4 class="title">1. Primary outcome: Clinically important response to treatment</h4> <section id="CD009831-sec-0121"> <h5 class="title">1.1 Overall symptoms of schizophrenia (short term)</h5> <p>Four‐hundred and thirty out of 1045 (41.1%) participants in the pooled haloperidol group compared to 497 out of 1087 (45.7%) in the pooled group of the other first‐generation antipsychotics met the predefined criteria for the achievement of clinically important response to treatment. The pooled risk ratio (RR) revealed no statistically significant between‐group difference (40 RCTs, n = 2132, RR 0.93 CI 0.87 to 1.00). </p> </section> <section id="CD009831-sec-0122"> <h5 class="title">1.2 Overall symptoms of schizophrenia (medium term)</h5> <p>Statistically significant less patients in the haloperidol group than in the control group achieved clinically important response to treatment (1 RCT, n = 80, RR 0.51 CI 0.37 to 0.69). </p> </section> </section> <section id="CD009831-sec-0123"> <h4 class="title">2. Global state</h4> <section id="CD009831-sec-0124"> <h5 class="title">2.1 Mean Clinical Global Impression (CGI) score at endpoint (short term)</h5> <p>There was no statistically significant difference (4 RCTs, n = 151, MD ‐0.07 CI ‐0.39 to 0.25). The standard deviations had to be imputed for three trials (<a href="./references#CD009831-bbs2-0014" title="EscobarJI , MannJJ , KellerJ , WilkinsJ , MasonB , MillsMJ . Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Journal of Clinical Psychiatry1985;46:15‐9. ">Escobar 1985</a>; <a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a>; <a href="./references#CD009831-bbs2-0056" title="SpinaE , DeDomenicoP , BonanzingaM , D'AgostinoMA , GittoC , DiRosaAE , et al. A double‐blind comparative study of bromperidol versus haloperidol in schizophrenic patients. New Trends in Experimental and Clinical Psychiatry1992;7:67‐71. ">Spina 1992</a>). </p> </section> </section> <section id="CD009831-sec-0125"> <h4 class="title">3. Mental state general</h4> <section id="CD009831-sec-0126"> <h5 class="title">3.1 Mean Brief Psychiatric Rating Scale (BPRS) total score at endpoint (short term)</h5> <p>There was no statistically significant difference (23 RCTs, n = 998, MD 0.37 CI ‐1.66 to 2.39). The standard deviations had to be imputed for 12 trials (<a href="./references#CD009831-bbs2-0004" title="BrannenJO , McEvoyJP , WilsonWH , PetrieWM , BanTA , BerneySA , et al. A double‐blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatria1981;14:139‐40. ">Brannen 1981</a>; <a href="./references#CD009831-bbs2-0012" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993;29:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009831-bbs2-0018" title="GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersenE , NielsenH . Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross‐over study of therapeutic effectiveness,side effects and plasma concentrations. [article in french]. Semaine des Hopitaux1985;61:1309‐16. GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersonE , NielsenH . Sulpiride and haloperidol in schizophrenia: a double‐blind cross‐over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry1985;147:283‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol in the treatment of schizophrenia: A brief preliminary report [article in danish]. Nordisk Psykiatrisk Tidsskrift1984;38:223‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica. Supplementum1984;311:31‐41. ">Gerlach 1985</a>; <a href="./references#CD009831-bbs2-0025" title="HaasS , BeckmannH . Pimozide and haloperidol in a double‐blind study in acutely schizophrenic patients [Pimozid und Haloperidol im Doppelblind‐Versuch bei akut schizophrenen Patienten]. Arzneimittelforschung1982;32:888. HaasS , BeckmannH . Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria1982;15:70‐4. ">Haas 1982</a>; <a href="./references#CD009831-bbs2-0026" title="HallWB , VestreND , SchieleBC , ZimmermannR . A controlled comparison of haloperidol and fluphenazine in chronic treatment‐resistant schizophrenics. Diseases of the Nervous System1968;29:405‐8. ">Hall 1968</a>; <a href="./references#CD009831-bbs2-0027" title="HeikkiläL , LaitinenJ , VartiainenH . Cis(Z)‐clopenthixol and haloperidol in chronic schizophrenic patients ‐ a double‐blind clinical multicentre investigation. Acta Psychiatrica Scandinavica1981;294(Suppl. 1):30‐8. ">Heikkilä 1981</a>; <a href="./references#CD009831-bbs2-0029" title="HollisterLE , OverallJE , CaffeyEJr , BennettJL , MeyerF , KimbellIJr , et al. Controlled comparison of Haloperidol with thiopropazate in newly admitted schizophrenics. Journal of Nervous and Mental Disorders1962;135:544‐9. ">Hollister 1962</a>; <a href="./references#CD009831-bbs2-0036" title="LuckeyWT , SchieleBC . A comparison of haloperidol and trifluoperazine. (A double‐blind, controlled study on chronic schizophrenic outpatients). Diseases of the Nervous System1967;28:181‐6. ">Luckey 1967</a>; <a href="./references#CD009831-bbs2-0052" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: a double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research, Clinical and Experimental1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: a double‐blind comparison with haloperidol and placebo in acute schizophrenics [article in french]. Psychologie Médicale1979;11:1533‐40. ">Selman 1976</a>; <a href="./references#CD009831-bbs2-0053" title="SerafetinidesEA . Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry1973;8:214‐6. SerafetinidesEA . Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System1973;34:190‐1. SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973;7:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972;154:31‐42. SerafetinidesEA , WillisD . A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry1973;8:245‐7. SerafetinidesEA , WillisD , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. II. The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Disease1972;155:366‐9. ">Serafetinides 1972</a>; <a href="./references#CD009831-bbs2-0059" title="TobinJM , RobinsonGM . Double blind comparison of haloperidol and thiothixene with after care treatment evaluation in psychiatric outpatients with schizophrenia. Psychiatric Journal of the University of Ottowa1980;5:168‐74. ">Tobin 1980</a>; <a href="./references#CD009831-bbs2-0062" title="VersianiM , daSilvaJA , FrotaLH , MundimFD . Double‐blind comparison between loxapine and haloperidol in the treatment of adolescent schizophrenic patients. Current Therapeutic Research1978;24:559‐66. ">Versiani 1978</a>). An I² value of 91% accompanied by a statistically significant Chi<sup>2</sup> statistic indicated a substantial level of heterogeneity. </p> </section> <section id="CD009831-sec-0127"> <h5 class="title">3.2 Mean Brief Psychiatric Rating Scale (BPRS) total score at endpoint (medium term)</h5> <p>Because of missing standard deviations for the trial that contributed data to this outcome, no effect size could be calculated. No validated imputation method could be applied to obtain the missing standard deviations. </p> </section> <section id="CD009831-sec-0128"> <h5 class="title">3.3 Mean Montgomery Rating Score (MRS) at endpoint (short term)</h5> <p>Because of missing standard deviations for the trial that contributed data to this outcome, no effect size could be calculated. No validated imputation method could be applied to obtain the missing standard deviations. </p> </section> <section id="CD009831-sec-0129"> <h5 class="title">3.4 Mean Rating Scale for Quantification of Psychotic Symptom Severity (RSQPSS) at 60 days (short term) </h5> <p>There was no statistically significant difference (1 RCT, n = 12, MD 0.00 CI ‐0.04 to 0.04). </p> </section> </section> <section id="CD009831-sec-0130"> <h4 class="title">4. Mental state specific</h4> <section id="CD009831-sec-0131"> <h5 class="title">4.1 Depersonalisation ‐ AMDP at endpoint (short term)</h5> <p>There was a statistically significant difference in favour of the other first‐generation antipsychotics (1 RCT, n = 30, MD 1.30 CI 0.62 to 1.98). </p> </section> <section id="CD009831-sec-0132"> <h5 class="title">4.2 Depressive symptoms ‐ Hamilton Depression Rating Scale (HAM‐D) score at endpoint (short term) </h5> <p>There was no statistically significant difference (2 RCTs, n = 62, MD ‐0.46 CI ‐1.23 to 0.32). The standard deviations for <a href="./references#CD009831-bbs2-0012" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993;29:249‐55. ">Dufresne 1993</a> had to be imputed. </p> </section> <section id="CD009831-sec-0133"> <h5 class="title">4.3 Depressive symptoms ‐ Hamilton Depression Rating Scale (HAM‐D) score at endpoint (medium term) </h5> <p>Because of missing standard deviations for all trials that contributed data to this outcome, no effect size could be calculated. No validated imputation method could be applied to obtain the missing standard deviations. </p> </section> <section id="CD009831-sec-0134"> <h5 class="title">4.4 Negative Symptoms ‐ Scale for the Assessment of Negative Symptoms (SANS) score at endpoint (short term) </h5> <p>There was no statistically significant difference (1 RCT, n = 40, MD 0.30 CI ‐2.13 to 2.73). </p> </section> <section id="CD009831-sec-0135"> <h5 class="title">4.5 Positive symptoms ‐ Conceptual disorganisation ‐ AMDP at endpoint (short term)</h5> <p>There was a statistically significant difference in favour of the other first‐generation antipsychotics (1 RCT, n = 30, MD 3.00 CI 2.07 to 3.93). </p> </section> <section id="CD009831-sec-0136"> <h5 class="title">4.6 Positive symptoms ‐ Delusional symptoms ‐ AMDP at endpoint (short term)</h5> <p>There was a statistically significant difference in favour of the other first‐generation antipsychotics (1 RCT, n = 30, MD 3.30 CI 2.13 to 4.47). </p> </section> <section id="CD009831-sec-0137"> <h5 class="title">4.7 Positive symptoms ‐ Positive symptoms (overall) measured by the Scale for the Assessment of Positive Symptoms (SAPS) score at endpoint (short term) </h5> <p>There was a statistically significant difference in favour of haloperidol (1 RCT, n = 40, MD ‐14.70 CI ‐17.42 to ‐11.98). </p> </section> <section id="CD009831-sec-0138"> <h5 class="title">4.8 Positive symptoms‐ Hallucinatory symptoms ‐ AMDP at endpoint (short term)</h5> <p>The data of both studies were skewed and could therefore only be presented in an "other data" table. </p> </section> <section id="CD009831-sec-0139"> <h5 class="title">4.9 Positive symptoms ‐ Paranoid symptoms ‐ AMDP at endpoint (short term)</h5> <p>The data of the study were skewed and could therefore only be presented in an "other data" table. </p> </section> </section> <section id="CD009831-sec-0140"> <h4 class="title">5. Behaviour</h4> <section id="CD009831-sec-0141"> <h5 class="title">5.1 Mean Nurses Observation Scale for Inpatient Evaluation (NOSIE) score at endpoint (short term) </h5> <p>Because of missing standard deviations for all trials that contributed data to this outcome, no effect size could be calculated. No validated imputation method could be applied to obtain the missing standard deviations. </p> </section> <section id="CD009831-sec-0142"> <h5 class="title">5.2 Mean Wing`s Ward Behaviour Scale score at endpoint (short term)</h5> <p>There was no statistically significant difference (1 RCT, n = 30, MD ‐1.27 CI ‐4.51 to 1.97). </p> </section> </section> <section id="CD009831-sec-0143"> <h4 class="title">6. Leaving the study early</h4> <section id="CD009831-sec-0144"> <h5 class="title">6.1 Due to any reason as a measure of overall acceptability (short term)</h5> <p>There was no statistically significant difference (28 RCTs, n = 1299, RR 1.04 CI 0.87 to 1.24). </p> </section> <section id="CD009831-sec-0145"> <h5 class="title">6.2 Due to any reason as a measure of overall acceptability (medium term)</h5> <p>There was no statistically significant difference (2 RCTs, n = 137, RR 1.02 CI 0.75 to 1.38). </p> </section> <section id="CD009831-sec-0146"> <h5 class="title">6.3 Due to inefficacy of treatment as a measure of overall efficacy (short term)</h5> <p>There was no statistically significant difference (13 RCTs, n = 507, RR 0.93 CI 0.40 to 2.16). </p> </section> <section id="CD009831-sec-0147"> <h5 class="title">6.4 Due to adverse effects as a measure of overall tolerability (short term)</h5> <p>There was no statistically significant difference (16 RCTs, n = 640, RR 1.00 CI 0.42 to 2.35). </p> </section> <section id="CD009831-sec-0148"> <h5 class="title">6.5 Due to adverse effects as a measure of overall tolerability (medium term)</h5> <p>There was no statistically significant difference (1 RCT, n = 80, RR not estimable).</p> </section> </section> <section id="CD009831-sec-0149"> <h4 class="title">7. Adverse effects general</h4> <section id="CD009831-sec-0150"> <h5 class="title">7.1 Number of participants with at least one adverse effect (short term)</h5> <p>There was no statistically significant difference (10 RCTs, n = 693, RR 1.06 CI 0.94 to 1.20). </p> <p><b>7.2 Number of participants with at least one adverse effect (medium term)</b> <br/> There was no statistically significant difference (2 RCTs, n = 137, RR 1.07 CI 0.58 to 1.97). An I² value of 86% accompanied by a statistically significant Chi<sup>2</sup> statistic indicated a substantial level of heterogeneity. </p> </section> </section> <section id="CD009831-sec-0151"> <h4 class="title">8. Adverse effects specific</h4> <section id="CD009831-sec-0152"> <h5 class="title">8.1 Extrapyramidal side effects: number of participants with akathisia (short term)</h5> <p>There was no statistically significant difference (22 RCTs, n = 1648, RR 1.05 CI 0.89 to 1.24). </p> </section> <section id="CD009831-sec-0153"> <h5 class="title">8.2 Extrapyramidal side effects: number of participants with akathisia (medium term)</h5> <p>There was a statistically significant difference in favour of the haloperidol group (1 RCT, n = 57, RR 0.31 CI 0.16 to 0.60). </p> </section> <section id="CD009831-sec-0154"> <h5 class="title">8.3 Extrapyramidal side effects: number of participants with akinesia (short term)</h5> <p>There was no statistically significant difference (2 RCTs, n = 235, RR 0.92 CI 0.31 to 2.68). </p> </section> <section id="CD009831-sec-0155"> <h5 class="title">8.4 Extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (short term) </h5> <p>There was no statistically significant difference (17 RCTs, n = 998, RR 1.12 CI 0.95 to 1.31). </p> </section> <section id="CD009831-sec-0156"> <h5 class="title">8.5 Extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (medium term) </h5> <p>There was no statistically significant difference (1 RCT, n = 80, RR 1.04 CI 0.62 to 1.75). </p> </section> <section id="CD009831-sec-0157"> <h5 class="title">8.6 Extrapyramidal side effects: number of participants with dyskinesia (short term)</h5> <p>There was no statistically significant difference (11 RCTs, n = 807, RR 0.81 CI 0.48 to 1.35). </p> </section> <section id="CD009831-sec-0158"> <h5 class="title">8.7 Extrapyramidal side effects: number of participants with dystonia (short term)</h5> <p>There was no statistically significant difference (15 RCTs, n = 1035, RR 1.34 CI 0.95 to 1.88). </p> </section> <section id="CD009831-sec-0159"> <h5 class="title">8.8 Extrapyramidal side effects: number of participants with rigor (short term)</h5> <p>There was no statistically significant difference (13 RCTs, n = 940, RR 1.01 CI 0.81 to 1.26). </p> </section> <section id="CD009831-sec-0160"> <h5 class="title">8.9 Extrapyramidal side effects: number of participants with rigor (medium term)</h5> <p>There was no statistically significant difference (1 RCT, n = 57, RR 0.97 CI 0.39 to 2.40). </p> </section> <section id="CD009831-sec-0161"> <h5 class="title">8.10 Extrapyramidal side effects: number of participants with tardive dyskinesia (short term) </h5> <p>There was no statistically significant difference (2 RCTs, n = 207, RR 0.48 CI 0.06 to 3.57). </p> </section> <section id="CD009831-sec-0162"> <h5 class="title">8.11 Extrapyramidal side effects: number of participants with tardive dyskinesia (medium term) </h5> <p>There was no statistically significant difference (1 RCT, n = 80, RR not estimable).</p> </section> <section id="CD009831-sec-0163"> <h5 class="title">8.12 Extrapyramidal side effects: number of participants with tremor (short term)</h5> <p>There was no statistically significant difference (15 RCTs, n = 828, RR 1.00 CI 0.72 to 1.40). </p> </section> <section id="CD009831-sec-0164"> <h5 class="title">8.13 Extrapyramidal side effects: number of participants with tremor (medium term)</h5> <p>There was no statistically significant difference (1 RCT, n = 57, RR 0.80 CI 0.28 to 2.34). </p> </section> <section id="CD009831-sec-0165"> <h5 class="title">8.14 Extrapyramidal side effects: number of participants with use of antiparkinson medication (short term) </h5> <p>There was no statistically significant difference (21 RCTs, n = 949, RR 1.04 CI 0.89 to 1.20). </p> </section> <section id="CD009831-sec-0166"> <h5 class="title">8.15 Number of participants with death (short term)</h5> <p>There was no statistically significant difference (1 RCT, n = 50, RR 0.33 CI 0.01 to 7.81). </p> </section> <section id="CD009831-sec-0167"> <h5 class="title">8.16 Number of participants with hypotension (short term)</h5> <p>There was no statistically significant difference (14 RCTs, n = 580, RR 1.10 CI 0.31 to 3.91). </p> </section> <section id="CD009831-sec-0168"> <h5 class="title">8.17 Number of participants with sedation (short term)</h5> <p>There was no statistically significant difference (5 RCTs, n = 306, RR 0.72 CI 0.45 to 1.18). </p> </section> <section id="CD009831-sec-0169"> <h5 class="title">8.18 Number of participants with weight gain (short term)</h5> <p>There was no statistically significant difference (6 RCTs, n = 262, RR 0.67 CI 0.21 to 2.15). An I² value of 58% accompanied by a statistically significant Chi<sup>2</sup> statistic indicated a substantial level of heterogeneity. </p> </section> <section id="CD009831-sec-0170"> <h5 class="title">8.19 Number of participants with weight gain (medium term)</h5> <p>There was no statistically significant difference (1 RCT, n = 57, RR 0.48 CI 0.05 to 5.03). </p> </section> </section> <section id="CD009831-sec-0171"> <h4 class="title">9. Sensitivity analyses</h4> <p>All sensitivity analyses were performed only for the primary outcome (clinically important response to treatment). </p> <section id="CD009831-sec-0172"> <h5 class="title">9.1 Implication of randomisation</h5> <p>In 12 publications randomisation was not mentioned (<a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>; <a href="./references#CD009831-bbs2-0005" title="BuenoJR . A double‐blind comparative clinical trial with loxapine succinate and haloperidol in the treatment of Schizophrenia [Ensaio clinico comparativo e duplo‐cego com succina de loxapina e haloperidol no tratamento da esquizofrenia]. Folha Medica1979;78:47‐52. ">Bueno 1979</a>; <a href="./references#CD009831-bbs2-0016" title="FuentenebroF , EscobarJI , KellerJ , Lopez de OchoaEF , VazquezC . Prediction of the therapeutic response to neuroleptics in schizophrenia [Prediccion de la respuesta al tratamiento neuroleptico en la esquizofrenia]. Psiquis Revista de Psiquiatria, Psicologia y Psicosomatica1989;10:22‐8. ">Fuentenebro 1989</a>; <a href="./references#CD009831-bbs2-0025" title="HaasS , BeckmannH . Pimozide and haloperidol in a double‐blind study in acutely schizophrenic patients [Pimozid und Haloperidol im Doppelblind‐Versuch bei akut schizophrenen Patienten]. Arzneimittelforschung1982;32:888. HaasS , BeckmannH . Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria1982;15:70‐4. ">Haas 1982</a>; <a href="./references#CD009831-bbs2-0027" title="HeikkiläL , LaitinenJ , VartiainenH . Cis(Z)‐clopenthixol and haloperidol in chronic schizophrenic patients ‐ a double‐blind clinical multicentre investigation. Acta Psychiatrica Scandinavica1981;294(Suppl. 1):30‐8. ">Heikkilä 1981</a>; <a href="./references#CD009831-bbs2-0031" title="ItoH , AnnoH , FujiiY , HasegawaY , IkegamiH , IshigookaJ , et al. Clinical evaluation of bromperidol, a new investigational butyrophenone derivative, in schizophrenia, a double‐blind comparison of bromperidol and haloperidol. Rinsho Hyoka (Clinical Evaluation)1985;13:105‐36. ItohH . A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double‐ blind technique. Psychopharmacology Bulletin1985;21:120‐2. ">Itoh 1985</a>; <a href="./references#CD009831-bbs2-0038" title="MattkeDJ , MombourW , GlotznerFL . The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research [Erfassung neuroleptisch bedingter extrapyramidaler Syndrome in einem psychopharmakologischen Forschungsprojekt]. Pharmakopsychiatrie und Neuropsychopharmakologie1975;1:36‐44. MattkeDJ , WisuschilW . A method for studying pupilomotorics under the influence of neuroleptic medication [Eine Methode zur Untersuchung der Pupillomotorik unter dem Einfluss neuroleptischer Medikation]. Arzneimittelforschung1976;26:946‐50. ">Mattke 1976</a>; <a href="./references#CD009831-bbs2-0044" title="O'BrienCP , DiGiacomoJN , WebbW . Management of hostile, suspicious patients ‐ trifluoperazine versus haloperidol. Diseases of the Nervous System1974;35:75‐8. ">O´Brien 1974</a>; <a href="./references#CD009831-bbs2-0057" title="StewartA , LafaveHG , SegoviaG . Haloperidol ‐ new addition to the drug treatment of schizophrenia. Behavioral Neuropsychiatry1969;1:23‐8. ">Stewart 1969</a>; <a href="./references#CD009831-bbs2-0059" title="TobinJM , RobinsonGM . Double blind comparison of haloperidol and thiothixene with after care treatment evaluation in psychiatric outpatients with schizophrenia. Psychiatric Journal of the University of Ottowa1980;5:168‐74. ">Tobin 1980</a>; <a href="./references#CD009831-bbs2-0061" title="UlmarG , EdlerR , HagenM . Trifluperidol vs haloperidol – a double‐blind trial. Proceedings of the 17th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1990 Sep 10‐14; Kyoto, Japan. 1990:296. ">Ulmar 1990</a>; <a href="./references#CD009831-bbs2-0063" title="EatonEM , BuskJ , MaloneyMP , SloaneRB , WhippleK , WhiteK . Hemispheric dysfunction in schizophrenia: assessment by visual perception tasks. Psychiatry Research1979;1:325‐32. WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981;16:34‐8. ">White 1981</a>). Because the trials were described as "double‐blind" we implied that the studies were randomised. Removing these studies from the statistical analyses did not alter the meta‐analytic findings in terms of statistically significant differences between groups. </p> </section> <section id="CD009831-sec-0173"> <h5 class="title">9.2 Exclusion of cross‐over‐trials</h5> <p>Removing the cross‐over trials (<a href="./references#CD009831-bbs2-0018" title="GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersenE , NielsenH . Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross‐over study of therapeutic effectiveness,side effects and plasma concentrations. [article in french]. Semaine des Hopitaux1985;61:1309‐16. GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersonE , NielsenH . Sulpiride and haloperidol in schizophrenia: a double‐blind cross‐over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry1985;147:283‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol in the treatment of schizophrenia: A brief preliminary report [article in danish]. Nordisk Psykiatrisk Tidsskrift1984;38:223‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica. Supplementum1984;311:31‐41. ">Gerlach 1985</a>; <a href="./references#CD009831-bbs2-0054" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993;87:86‐91. ">Shalev 1993</a>; <a href="./references#CD009831-bbs2-0057" title="StewartA , LafaveHG , SegoviaG . Haloperidol ‐ new addition to the drug treatment of schizophrenia. Behavioral Neuropsychiatry1969;1:23‐8. ">Stewart 1969</a>) did not change the meta‐analytic results in terms of statistically significant differences between groups. </p> </section> <section id="CD009831-sec-0174"> <h5 class="title">9.3 Implication of non double‐blind trials</h5> <p>Exclusion of the non double‐blind trials (<a href="./references#CD009831-bbs2-0002" title="BaastrupPC , AlhforsUG , BjerkenstedtL , DenckerSJ , FensboC , GravemA , et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica1993;87:48‐58. FensboC . Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients ‐ a controlled multicenter study [Zuclopenthixol acetat, haloperidol og zuclopenthixol i behandling af akut psykotiske patienter. En kontrolleret multicenterundersogelse]. Nordisk Psykiatrisk Tidsskrift1990;44:295‐7. ">Baastrup 1993</a>; <a href="./references#CD009831-bbs2-0041" title="NedopilN , RutherE . Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatria1981;14:205‐7. ">Nedopil 1981</a>; <a href="./references#CD009831-bbs2-0047" title="ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica1983;3:354‐64. ParentM , ToussaintC . Flupenthixol versus haloperidol in acute psychotic episodes [article in french]. Acta Psychiatrica Belgica1982;82:617‐31. ">Parent 1983</a>) and the studies with unclear blinding (<a href="./references#CD009831-bbs2-0009" title="CosarB , CandansayarS , TanerE , IsikE . Comparison of efficacy of clozapine, sulpiride, chlorpromazine and haloperidol in chronic schizophrenic patients therapy. European Neuropsychopharmacology1999;9:287. ">Cosar 1999</a>; <a href="./references#CD009831-bbs2-0054" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993;87:86‐91. ">Shalev 1993</a>; <a href="./references#CD009831-bbs2-0060" title="TuasonVB . A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. Journal of Clinical Psychiatry1986;47:126‐9. ">Tuason 1986</a>) did not convert the meta‐analytic findings regarding statistically significant between‐group differences. </p> </section> <section id="CD009831-sec-0175"> <h5 class="title">9.4 Fixed‐effect versus random‐effects model</h5> <p>Applying a fixed‐effect model instead of a random‐effects approach did alter the meta‐analytic findings in terms of statistically significant differences between groups disfavouring haloperidol (40 RCTs, n = 2132, RR 0.90 CI 0.82 to 0.98). </p> </section> </section> <section id="CD009831-sec-0176"> <h4 class="title">10. Subgroup analyses</h4> <p>All subgroup analyses were performed only for the primary outcome (clinically important response to treatment). </p> <section id="CD009831-sec-0177"> <h5 class="title">10.1 Stratification according to the different first‐generation antipsychotics</h5> <p>Concerning the short‐term trials, a statistically significant difference between haloperidol and another antipsychotic drug administered as active comparator to haloperidol was only assessable for nemonapride which was significantly more effective than haloperidol in achieving clinically important response to treatment (1 RCT, n = 167, RR 0.55 CI 0.33 to 0.93). When analysing the studies with medium duration, thiothixene was significantly more effective than haloperidol (1 RCT, n = 80, RR 0.51 CI 0.37 to 0.69). </p> </section> <section id="CD009831-sec-0178"> <h5 class="title">10.2 Trials investigating participants with treatment‐resistant schizophrenia</h5> <p>Four short‐term trials examined participants with treatment‐resistant schizophrenia (<a href="./references#CD009831-bbs2-0033" title="KinonBJ , KaneJM , ChakosM , MunneR . Possible predictors of neuroleptic‐resistant schizophrenic relapse ‐ influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacology Bulletin1993;29:365‐9. KinonBJ , KaneJM , JohnsC , PerovichR , IsmiM , KoreenA , et al. Treatment of neuroleptic‐resistant schizophrenic relapse. Psychopharmacology Bulletin1993;29:309‐14. ">Kinon 1993</a>; <a href="./references#CD009831-bbs2-0026" title="HallWB , VestreND , SchieleBC , ZimmermannR . A controlled comparison of haloperidol and fluphenazine in chronic treatment‐resistant schizophrenics. Diseases of the Nervous System1968;29:405‐8. ">Hall 1968</a>; <a href="./references#CD009831-bbs2-0030" title="HowardJS . Haloperidol for chronically hospitalized psychotics: a double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a>; <a href="./references#CD009831-bbs2-0058" title="TejaJS , GreyWH , ClumJM , WarrenC . Tranquilizers or anti‐depressants for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry1975;9:241‐7. ">Teja 1975</a>). There was no statistically significant difference between the pooled study groups of these trials in terms of the primary outcome (3 RCTs, n = 130, RR 1.46 CI 0.66 to 3.23). We could not detect any significant difference between the studies that investigated treatment‐resistant participants and the remaining trials (test for subgroup differences: P = 0.26). </p> </section> <section id="CD009831-sec-0179"> <h5 class="title">10.3 Trials investigating participants with a first episode of schizophrenia</h5> <p>No study described the major inclusion criteria of participants with a first‐episode of schizophrenia. Therefore, this a priori planned subgroup analysis could not be conducted. </p> </section> </section> <section id="CD009831-sec-0180"> <h4 class="title">11. Assessment of heterogeneity</h4> <p>Statistical tests revealed substantial levels of heterogeneity (defined by an I<sup>2</sup> greater than or equal to 50% accompanied by a statistically significant Chi<sup>2</sup> test) for the outcomes "mental state general: mean BPRS total score at endpoint (short‐trial duration)", "adverse effects: number of participants with at least one adverse effect (medium‐trial duration)", and "adverse effects: number of participants with weight gain (short‐trial duration)". Possible reasons for the occurrence of substantial heterogeneity in the three outcomes are described in the context of the discussion. </p> </section> <section id="CD009831-sec-0181"> <h4 class="title">12. Publication Bias</h4> <p>In the funnel plot the risk ratios of the studies are plotted against the standard errors (referring to the primary outcome) (<a href="#CD009831-fig-0004">Figure 4</a>). Based on the largely symmetrical arrangement of the single trials around the pooled effect size as equivalence line, there is no evidence for the presence of publication bias. </p> <div class="figure" id="CD009831-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, outcome: 1.1 Global state: 1. Clinically important response." data-id="CD009831-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, outcome: 1.1 Global state: 1. Clinically important response. </p> </div> </div> </div> </section> <section id="CD009831-sec-0182"> <h4 class="title">13. 'Summary of findings' table</h4> <p>The results of six outcomes ‐ "clinically important response to treatment", "leaving the study early due to any reason", "leaving the study early due to inefficacy", "leaving the study early due to adverse effects", "number of participants with at least one adverse effect", and "number of participants with at least one movement disorder" ‐ were considered more closely in a 'Summary of findings' table (see <a href="./full#CD009831-tbl-0001">summary of findings Table for the main comparison</a> for the studies with short duration and <a href="./full#CD009831-tbl-0002">summary of findings Table 2</a> for the trials with medium duration). The judgements derived from this instrument were taken into account for the discussion section of this systematic review. In none of the included studies did we find data for the predefined outcome "quality of life". This might be caused by the fact that the single original trials were conducted a number of years ago (published between 1962 and 1993). At that time, there was a stronger focus primarily on efficacy‐related outcomes, whereas in the last few years, attention has been directed more intensively to outcomes such as "quality of life". </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009831-sec-0183" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009831-sec-0183">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009831-sec-0248">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009831-sec-0183"></div> <section id="CD009831-sec-0184"> <h3 class="title" id="CD009831-sec-0184">Summary of main results</h3> <section id="CD009831-sec-0185"> <h4 class="title">1. General</h4> <p>The present systematic review includes 63 randomised controlled trials (involving 3675 participants) that compared haloperidol with another first‐generation antipsychotic drug (with the exception of the low‐potency antipsychotics chlorpromazine, chlorprothixene, levopromazine, mesoridazine, perazine, prochlorpromazine, and thioridazine that have been examined in another Cochrane Review (<a href="./references#CD009831-bbs2-0193" title="TardyM , HuhnM , KisslingW , EngelRR , LeuchtS . Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009268] ">Tardy 2011a</a>). Despite heterogeneity regarding the trial designs employed in the single original studies and the fact that the predefined outcomes were often incompletely reported, the results of the meta‐analytic calculations demonstrated consistently that there is no statistically significant difference between haloperidol and the other first‐generation antipsychotics in terms of overall efficacy, acceptability, and tolerability. As it is unfortunately typical for trials determining conventional antipsychotics in schizophrenia, the methods of randomisation, allocation concealment, and blinding were frequently not reported. </p> </section> <section id="CD009831-sec-0186"> <h4 class="title">2. Clinically important response to treatment</h4> <p>Based on the data of 40 short‐term trials, we could not demonstrate any statistically significant difference in the achievement of clinically important response to treatment between haloperidol and the pooled group of the other first‐generation antipsychotic agents. In this context it must be considered that statistically significant difference in disfavour of haloperidol occurred in the sensitivity analysis applying a fixed‐effect model instead of a random‐effects approach. Investigating the studies with medium‐trial duration, the group of the other first‐generation antipsychotics was statistically significantly more effective than haloperidol in achieving treatment response. Because evidence for this outcome is based on only one trial (<a href="./references#CD009831-bbs2-0013" title="EngelhardtDM , RudorferL , RosenB . Haloperidol and thiothixene in the long‐term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment. Journal of Clinical Psychiatry1978;39:834‐40. ">Engelhardt 1978</a>), no empirical conclusions can be stated. </p> </section> <section id="CD009831-sec-0187"> <h4 class="title">3. Global state</h4> <p>There was no statistically significant difference between haloperidol and the other first‐generation antipsychotic drugs assessing the mean CGI at endpoint. The analysis was limited by the fact that the standard deviations had to be imputed for three of four trials that contributed data to this outcome. </p> </section> <section id="CD009831-sec-0188"> <h4 class="title">4. Mental state</h4> <p>Results regarding the participants' mental state were rarely reported and difficult to interpret, because different scales were applied. The widely used rating scale was the BPRS. Analysing the mean BPRS total score at endpoint, we did not detect any statistically significant between‐group differences. However, the results were highly heterogenous for the short‐term studies (I² = 97%) and for 12 of 23 trials standard deviations had to be imputed from the mean of the other studies. No statistically significant differences could be identified for the Montgomery Rating Score (MRS) and the Rating Scale for Quantification of Psychotic Symptom Severity (RSQPSS) score. </p> <p>Regarding the specific mental state, a statistically significant superiority of haloperidol in reducing positive symptoms (measured by the SAPS) but not negative symptoms (SANS) could be verified. These findings were based on only one trial (<a href="./references#CD009831-bbs2-0039" title="MauriM , CassanoGB , CanovaL , CocconcelliC , FaravelliC , KemaliD , et al. Schizophrenic disorder in active phase: double‐blind study between bromperidol and haloperidol [Disturbo schizofrenico in fase attiva: studio in doppia cecita tra Bromperidolo e Aloperidolo]. Giornale di Neuropsicofarmacologia1994;16:187‐93. ">Mauri 1994</a>). There was no statistically significant difference between haloperidol and the other first‐generation antipsychotic drugs in terms of improving depressive symptoms (HAM‐D). Two trials evaluated schizophrenic symptoms by using the ADMP system (<a href="./references#CD009831-bbs2-0020" title="GiordanaJY , FrenayS . Comparative study of pipotiazine (in its non‐esterified form) and of haloperidol in acute or subacute psychotic states [Etude comparative de la pipothiazine (dans sa forme non esterifiee) et de l'haloperidol au cours d'etats psychotiques aigus et subaigus]. Psychologie Medicale1984;16:1803‐15. ">Giordana 1984</a>; <a href="./references#CD009831-bbs2-0041" title="NedopilN , RutherE . Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatria1981;14:205‐7. ">Nedopil 1981</a>). The assessments revealed statistically significant difference in disfavour of haloperidol in terms of delusional symptoms, depersonalisation, and conceptual disorganisation. </p> </section> <section id="CD009831-sec-0189"> <h4 class="title">5. Behaviour</h4> <p>Neither the assessment of the NOSIE score nor the Wing`s Ward Behaviour Scale showed any significant superiority of any study group. The analyses were limited by the fact that only four trials reported usable data on the behavioural state and three of them provided no standard deviations avoiding the calculation of the mean difference as effect size. </p> </section> <section id="CD009831-sec-0190"> <h4 class="title">6. Leaving the study early</h4> <p>Altogether, 343 out of 1436 participants (24 %) terminated the studies prematurely due to any reason without any statistically significant difference between haloperidol and the pooled group of the other first‐generation antipsychotics. This result was consistent irrespectively of the trial duration (short‐ or medium‐trial duration). When specific reasons for leaving the study early, adverse effects or inefficacy of treatment, were indicated, there was again no significant difference between the study groups. Therefore, these findings suggest a comparable overall acceptability, overall efficacy, and overall tolerability of haloperidol and the various other first‐generation antipsychotics investigated in this systematic review. </p> </section> <section id="CD009831-sec-0191"> <h4 class="title">7. Adverse effects</h4> <p>There was no statistically significant difference between haloperidol and the other first‐generation antipsychotic drugs, neither in terms of "at least one adverse effect", "at least one extrapyramidal/movement disorder", nor in terms of the specific adverse effects akathisia, akinesia, dyskinesia, dystonia, rigor, tardive dyskinesia, tremor, use of antiparkinson medication, death, hypotension, sedation, and weight gain. There was only one exception: significantly more participants in the other first‐generation antipsychotic group than in the haloperidol group experienced akathisia when analysing only the studies with medium‐trial duration. Because evidence for this outcome is based on only one trial, no empirical meta‐analytic conclusions can be stated. The incomplete reporting of adverse effects considerably limits the interpretation of these findings. Many comparisons for the single specific side effects were based on only one or two individual trials (for example, akathisia, akinesia, rigor, tardive dyskinesia, and death). Especially, there were not enough data available to appraise the risk profile of the pharmacotherapy in the long‐term treatment. In the same way, we found no data investigating adherence to the pharmacological treatment with the evaluated antipsychotic drugs. Future research projects are needed to assess this aspect of pharmacological treatment. </p> </section> <section id="CD009831-sec-0192"> <h4 class="title">8. Missing outcomes</h4> <p>No included trial provided data that measured the a priori defined outcomes "satisfaction with care", "quality of life", "service utilisation", "functioning", and economic outcomes. Further clinical trials should consider these outcomes to allow an overall appraisal of a benefit‐risk‐ratio of a psychopharmacological intervention. </p> </section> <section id="CD009831-sec-0193"> <h4 class="title">9. Subgroup analyses</h4> <p>Stratification according to the different antipsychotic drugs administered as comparator to haloperidol revealed that only a medication with nemonapride yielded a significantly higher effect size than haloperidol in terms of the primary outcome when analysing the short‐term trials. Regarding the studies with medium‐trial duration, thiothixene was statistically significantly superior to haloperidol. Because each of both findings is based on only one trial, no treatment recommendations can be deduced from the result of the meta‐analytic calculations. </p> </section> <section id="CD009831-sec-0194"> <h4 class="title">10. Sensitivity analyses</h4> <p>The findings of the primary outcome did alter statistically significantly in disfavour of haloperidol if a fixed‐effect model instead of a random‐effects approach was applied but the direction of the effect was still the same. Thus, the interpretations of the results are not challenged. Exclusion of the studies with implied randomisation, non double‐blind mechanism, and cross‐over trial design did not convert the meta‐analytic findings in terms of statistically significant between‐group differences. </p> </section> <section id="CD009831-sec-0195"> <h4 class="title">11. Heterogeneity</h4> <p>Substantial levels of heterogeneity were identified regarding the outcomes "mental state general: mean BPRS total score at endpoint (short term)" (I² = 97%), "adverse effects: number of participants with at least one adverse effect (medium term)" (I² = 86%), and "adverse effects: number of participants with weight gain (short term)" (I² = 58%). Concerning the continuous outcome "mental state general: mean BPRS total score at endpoint (short term)", the standard deviations had to be imputed for 12 of 23 trials. These imputations probably biased the pooled analysis and can be regarded as possible explanation for the high heterogeneity. As the number of trials (n = 2) and participants (n = 137) is still low for the outcome "adverse effects: number of participants with at least one adverse effect (medium term)", a part of this heterogeneity may be caused by this issue alone. In terms of the outcome "adverse effects: number of participants with weight gain (short term)", the difference between the various first‐generation antipsychotic drugs administered in the control groups of the included trials could be a possible reason for the substantial level of heterogeneity. </p> </section> </section> <section id="CD009831-sec-0196"> <h3 class="title" id="CD009831-sec-0196">Overall completeness and applicability of evidence</h3> <p>The 63 included studies were carried out in various settings (e.g. in‐ and outpatients), with different populations (e.g. participants in remission, participants with an acute schizophrenic episode, treatment‐resistant participants) and methods (e.g. outcome variables, diagnostic instruments). Because of this clinical and methodological diversity, we believe that the evidence is quite complete and applicable to routine care. Other limitations regarding this systematic review must be considered, for example, the trials were usually characterised by small sample sizes (medium sample size: 58 participants) and the outcomes were often incompletely reported thus not allowing their inclusion in the meta‐analytic calculations. In many cases missing standard deviations had to be imputed from the mean of the other studies. Because of variable trial designs and application of different outcome scales, pooling of the results was often impossible. Therefore, many comparisons were underpowered. One reason for the methodological diversity is probably that the studies were carried out during a long period of time (from 1962 to 1993). </p> </section> <section id="CD009831-sec-0197"> <h3 class="title" id="CD009831-sec-0197">Quality of the evidence</h3> <p>All included trials were randomised and most of them were described as being double‐blind but details were often not presented. Therefore, it appears unclear whether the studies were adequately randomised, whether treatment allocation was really concealed, and whether sufficient blinding could be assured over the whole trial period. Only in 18 out of 63 studies was the overall degree of attrition classified as being low (&lt; 10%). Forty‐six of the 63 included trials were characterised by selective reporting, especially in terms of standard deviations. In 33 trials potential sources of bias such as extreme baseline imbalances etc. occurred<i>.</i> In summary, the overall quality of the studies according to these criteria can be regarded as low. </p> </section> <section id="CD009831-sec-0198"> <h3 class="title" id="CD009831-sec-0198">Potential biases in the review process</h3> <p>In general, it must be considered that meta‐analyses combine similar but not identical trials. The heterogeneous designs of the original studies (see <a href="#CD009831-sec-0196">Overall completeness and applicability of evidence</a>) remain a critical issue concerning the interpretation of meta‐analytic findings. In this systematic review, we a priori decided to pool all first‐generation antipsychotics that were used as comparator drugs to haloperidol. This is justified for efficacy‐related outcomes because most antipsychotic compounds do not differ in efficacy and if differences exist between some antipsychotic drugs, these are not considerable (<a href="./references#CD009831-bbs2-0139" title="DavisJM , GarverDL . Neuroleptics: clinical use in psychiatry. In: L.Iversen , SIversen , S.Snyder editor(s). Handbook of Psychopharmacology. New York: Plenum Press, 1978. ">Davis 1978</a>; <a href="./references#CD009831-bbs2-0166" title="KleinDF , DavisJM . Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins, 1969. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969. ">Klein 1969</a>; <a href="./references#CD009831-bbs2-0176" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta‐analysis comparing second‐generation and first‐generation antipsychotics for schizophrenia. Lancet2009;373:31‐41. ">Leucht 2009</a>). The decision to pool all studies irrespectively of the antipsychotic drug administered as comparator to haloperidol is more problematic for adverse effects because antipsychotics differ to a large extent in this regard. For example, the so‐called mid‐potency antipsychotic agents (described by a lower affinity to dopamine‐D2‐receptors than high‐potency antipsychotics) are typically characterised by more anticholinergic (e.g. dry mouth and obstipation), antiadrenergic (e.g. orthostatic dysregulation), and antihistaminic (e.g. sedation and weight gain) adverse effects compared to the so‐called high‐potency antipsychotics, which are usually associated with a higher number of movement disorders than low‐potency antipsychotics. Thus, any differences in a specific adverse effect between haloperidol and the pooled study group of other first‐generation antipsychotics cannot be generalised to all first‐generation antipsychotic drugs. </p> <p>The study search was mainly based on the trial register of the Cochrane Schizophrenia Group, which primarily contains published literature. It is possible that unpublished studies we are not aware of exist. Therefore, a possibility of publication bias is present although the symmetrical funnel plot did not provide any evidence of the presence of publication bias. </p> <p>We applied a random‐effects model for our meta‐analytic calculations to consider variability between the included studies (<a href="./references#CD009831-bbs2-0160" title="HufW , KalcherK , PailG , FriedrichME , FilzmoserP , KasperS . Meta‐analysis: fact or fiction? How to interpret meta‐analyses. World Journal of Biological Psychiatry2011;12:188‐200. ">Huf 2011</a>). The random‐effects approach does not assume that the populations from which the different trials are derived are comparable. This technique emphasizes the results from smaller trials and it is these studies that are likely to be most prone to bias. In this context, it must be taken into account that applying a fixed‐effect model instead of a random‐effects approach in a sensitivity analysis of the primary outcome generated statistically significant between‐group differences in disfavour of haloperidol without any alteration of the direction of the effect. </p> <p>A major limitation of our meta‐analysis in terms of the methodology of the included original trials is that haloperidol was evaluated as active comparator drug in most of the studies. Therefore, the other first‐generation antipsychotics that were the control group in our systematic review were the drugs of interest in the original trials. Within this context it must be referred to the possibility of an industry sponsorship bias. </p> </section> <section id="CD009831-sec-0199"> <h3 class="title" id="CD009831-sec-0199">Agreements and disagreements with other studies or reviews</h3> <p>In the present systematic review, we determined the efficacy, acceptability, and tolerability of haloperidol compared with other first‐generation antipsychotics with the exception of the low‐potency antipsychotics chlorpromazine, chlorprothixene, levopromazine, mesoridazine, perazine, prochlorpromazine, and thioridazine. We did not examine these compounds because they have been evaluated in other Cochrane Reviews (<a href="./references#CD009831-bbs2-0175" title="LeuchtC , KitzmantelM , KaneJ , LeuchtS , ChuaWLLC . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2] ">Leucht 2008</a>; <a href="./references#CD009831-bbs2-0193" title="TardyM , HuhnM , KisslingW , EngelRR , LeuchtS . Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009268] ">Tardy 2011a</a>). Similar to our findings, there were also no statistically significant differences between haloperidol and the investigated conventional antipsychotics. </p> <p>Our main results are also in accordance with the findings of previous narrative, unsystematic reviews of <a href="./references#CD009831-bbs2-0139" title="DavisJM , GarverDL . Neuroleptics: clinical use in psychiatry. In: L.Iversen , SIversen , S.Snyder editor(s). Handbook of Psychopharmacology. New York: Plenum Press, 1978. ">Davis 1978</a> and <a href="./references#CD009831-bbs2-0166" title="KleinDF , DavisJM . Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins, 1969. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969. ">Klein 1969</a> suggesting that there are no differences in terms of efficacy between the various first‐generation antipsychotic drugs. Applying a systematic approach and clearly better methodology, we could verify these findings in terms of the standard reference antipsychotic drug haloperidol that is characterised by comparable efficacy with that of the other first‐generation antipsychotics </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009831-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009831-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009831-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009831-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, outcome: 1.1 Global state: 1. Clinically important response." data-id="CD009831-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, outcome: 1.1 Global state: 1. Clinically important response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 1 Global state: 1. Clinically important response." data-id="CD009831-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 1 Global state: 1. Clinically important response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 2 Global state: 2. Average score (CGI, endpoint, short term, high = poor)." data-id="CD009831-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 2 Global state: 2. Average score (CGI, endpoint, short term, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 3 Mental state: 1. General ‐ a. Average score (BPRS total, endpoint, high = poor)." data-id="CD009831-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 3 Mental state: 1. General ‐ a. Average score (BPRS total, endpoint, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 4 Mental state: 1. General ‐ b. Average score ‐ short term (various scales, endpoint, high = poor)." data-id="CD009831-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 4 Mental state: 1. General ‐ b. Average score ‐ short term (various scales, endpoint, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 5 Mental state: 2. Specific ‐ a. Depersonalisation average score ‐ short term (AMDP, high = poor)." data-id="CD009831-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 5 Mental state: 2. Specific ‐ a. Depersonalisation average score ‐ short term (AMDP, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 6 Mental state: 2. Specific ‐ b. Depressive symptoms average score (HAM‐D, high = poor)." data-id="CD009831-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 6 Mental state: 2. Specific ‐ b. Depressive symptoms average score (HAM‐D, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 7 Mental state: 2. Specific ‐ c. Negative symptoms average score ‐ short term (SANS, endpoint, high = poor)." data-id="CD009831-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 7 Mental state: 2. Specific ‐ c. Negative symptoms average score ‐ short term (SANS, endpoint, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 8 Mental state: 2. Specific ‐ d.i. Positive symptom average score ‐ short term." data-id="CD009831-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 8 Mental state: 2. Specific ‐ d.i. Positive symptom average score ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0013"> <p> <div class="table" id="CD009831-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (n)</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>hallucinatory symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Giordana 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Giordana 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nedopil 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nedopil 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>paranoid symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nedopil 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nedopil 1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 9 Mental state: 2. Specific ‐ d.ii. Positive symptoms average score ‐ short term (AMDP, skewed or incomplete data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0013">Navigate to figure in review</a></div> </div> <div class="figure" id="CD009831-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 10 Behaviour: 1a. Average score ‐ short term (NOSIE, endpoint, high = poor)." data-id="CD009831-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 10 Behaviour: 1a. Average score ‐ short term (NOSIE, endpoint, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 11 Behaviour: 1b. Average score ‐ short term (Wing’s Ward Behaviour Scale, endpoint, high = poor)." data-id="CD009831-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 11 Behaviour: 1b. Average score ‐ short term (Wing’s Ward Behaviour Scale, endpoint, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 12 Leaving the study early: 1. Due to any reason ‐ as a measure of overall acceptability." data-id="CD009831-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 12 Leaving the study early: 1. Due to any reason ‐ as a measure of overall acceptability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 13 Leaving the study early: 2. Due to inefficacy of treatment ‐ as a measure of overall efficacy (short term)." data-id="CD009831-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 13 Leaving the study early: 2. Due to inefficacy of treatment ‐ as a measure of overall efficacy (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 14 Leaving the study early: 3. Due to adverse events ‐ as a measure of overall tolerability." data-id="CD009831-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 14 Leaving the study early: 3. Due to adverse events ‐ as a measure of overall tolerability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 15 Adverse effects: 1. General ‐ at least one adverse effect." data-id="CD009831-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 15 Adverse effects: 1. General ‐ at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 16 Adverse effects: 2. Specific ‐ a. Movement disorders." data-id="CD009831-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 16 Adverse effects: 2. Specific ‐ a. Movement disorders. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 17 Adverse effects: 2. Specific ‐ b. Various." data-id="CD009831-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS, Outcome 17 Adverse effects: 2. Specific ‐ b. Various. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analyses, Outcome 1 Sensitivity analysis ‐ Implication of randomisation, Outcome: overall symptoms of schizophrenia (short term)." data-id="CD009831-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analyses, Outcome 1 Sensitivity analysis ‐ Implication of randomisation, Outcome: overall symptoms of schizophrenia (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analyses, Outcome 2 Sensitivity analysis ‐ Exclusion of cross‐over‐trials, Outcome: overall symptoms of schizophrenia (short term)." data-id="CD009831-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analyses, Outcome 2 Sensitivity analysis ‐ Exclusion of cross‐over‐trials, Outcome: overall symptoms of schizophrenia (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analyses, Outcome 3 Sensitivity analysis ‐ Exclusion of non double‐blind trials, Outcome: overall symptoms of schizophrenia (short term)." data-id="CD009831-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analyses, Outcome 3 Sensitivity analysis ‐ Exclusion of non double‐blind trials, Outcome: overall symptoms of schizophrenia (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analyses, Outcome 4 Sensitivity analysis ‐ Fixed versus random‐effects models, Outcome: overall symptoms of schizophrenia (short term)." data-id="CD009831-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analyses, Outcome 4 Sensitivity analysis ‐ Fixed versus random‐effects models, Outcome: overall symptoms of schizophrenia (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup analyses, Outcome 1 Subgroup analysis ‐ different antipsychotic drugs (short term)." data-id="CD009831-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Subgroup analyses, Outcome 1 Subgroup analysis ‐ different antipsychotic drugs (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup analyses, Outcome 2 Subgroup analysis ‐ different antipsychotic drugs (medium term)." data-id="CD009831-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Subgroup analyses, Outcome 2 Subgroup analysis ‐ different antipsychotic drugs (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009831-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/urn:x-wiley:14651858:media:CD009831:CD009831-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_t/tCD009831-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup analyses, Outcome 3 Subgroup analysis ‐ treatment‐resistant participants (short term)." data-id="CD009831-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Subgroup analyses, Outcome 3 Subgroup analysis ‐ treatment‐resistant participants (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/media/CDSR/CD009831/image_n/nCD009831-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD009831-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies and suggestions for relevant reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Existing review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0064" title="Al HaddadMK , KamelC , SequeriaRP , MawgoodMA . Zuclopenthixol versus haloperidol in the initial treatment of schizophrenic psychoses, affective psychoses and paranoid states: a controlled clinical trial. Arab Journal of Psychiatry1996;7:44‐54. ">Al Haddad 1996</a>, <a href="./references#CD009831-bbs2-0072" title="ChinCN , HamidAR , PhilipG , RamleeT , MahmudM , ZulkifliG , et al. A double‐blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. Medical Journal of Malaysia1998;53:365‐71. ">Chin 1998</a>, <a href="./references#CD009831-bbs2-0099" title="LamureM , ToumiM , ChabannesJP , DansetteGY , BenyayaJ , HansenK . Zuclopenthixol versus haloperidol: an observational randomised pharmacoeconomic evaluation of patients with chronic schizophrenia exhibiting acute psychosis. International Journal of Psychiatry in Clinical Practice2003;7:177‐85. ">Lamure 2003</a>, <a href="./references#CD009831-bbs2-0104" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1:541‐8. ">Lublin 1991</a>, <a href="./references#CD009831-bbs2-0106" title="MosolovSN , MolodetskikhAV , EryominAV , GraikovGM , NourislamovSV . Effect and tolerability of clopixol and haloperidol in patients with acute symptoms of schizophrenia: comparative randomised investigation. Sotsial'naia I Klinicheskaia Psikhiatria2000;10:47‐52. ">Mosolov 2000</a>, <a href="./references#CD009831-bbs2-0122" title="TaymeeyapraditU , KuasirikulS . Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. Journal of the Medical Association of Thailand2002;85:1301‐8. ">Taymeeyapradit 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus zuclopenthixol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0162" title="JayakodyK , GibsonRC , KumarA , GunadasaS . Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD000525.pub3] ">Jayakody 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0066" title="AzimaH , DurostH , ArthursD . The effect of R‐1625 (haloperidol) in mental syndromes: a multiblind study. American Journal of Psychiatry1960;117:546‐7. ">Azima 1960</a>, <a href="./references#CD009831-bbs2-0076" title="CrowTJ , MacMillanJF , JohnsonAL , JohnstoneEC . A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry1986;148:120‐7. MacMillanJF , CrowTJ , JohnsonAL , JohnstoneEC . British Journal of Psychiatry. Short‐term outcome in trial entrants and trial eligible patients1986;148:128‐33. ">Crow 1986</a>, <a href="./references#CD009831-bbs2-0081" title="DurostH , LeeH , ArthursD . An early evaluation of haloperidol. In: LehmannHE , BanTA editor(s). The Butyrophenones in Psychiatry. Quebec Psychopharmacological Research Association, 1964:70‐3. ">Durost 1964</a>, <a href="./references#CD009831-bbs2-0117" title="SimpsonGM , AngusJW , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research, Clinical and Experimental1967;9:407‐12. SimpsonGM , CooperTB , BraunGA . Further studies on the effect of butyrophenones on cholesterol synthesis in humans. Current Therapeutic Research, Clinical and Experimental1967;9:413‐8. ">Simpson 1967</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0128" title="AdamsCE , BergmanH , IrvingCB , LawrieS . Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003082.pub3] ">Adams 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0069" title="BechelliLP , Navas‐FilhoF . Short term double‐blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia. L'Encephale1986;12:121‐5. ">Bechelli 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus pipothiazine palmitate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0070" title="BoyerP , PuechAJ . Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools [Modalities d'action clinique des neuroleptiques: substances, doses, instruments de mesure utilises]. Psychiatrie and Psychobiologie1987;2:296‐305. ">Boyer 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amisulpride versus placebo // amisulpride dosage // amisulpride versus fluphenazine // amisulpride versus haloperidol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0191" title="Silveira da Mota NetoJI , SoaresBGO , Silva de LimaM . Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD001357] ">Silveira 2002</a>; <a href="./references#CD009831-bbs2-0185" title="SampfordJ , SampsonS . Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010832] ">Sampford 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0074" title="ColeJO , TsuangMM . Haloperidol in geriatrics. Psychopharmacology Bulletin1970;6:86‐8. ">Cole 1970</a>, <a href="./references#CD009831-bbs2-0087" title="GerlachJ , SimmelsgaardH . Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology1978;59:105‐12. ">Gerlach 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus thioridazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0076" title="CrowTJ , MacMillanJF , JohnsonAL , JohnstoneEC . A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry1986;148:120‐7. MacMillanJF , CrowTJ , JohnsonAL , JohnstoneEC . British Journal of Psychiatry. Short‐term outcome in trial entrants and trial eligible patients1986;148:128‐33. ">Crow 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus placebo // flupenthixol versus placebo // pimozide versus placebo // trifluoperazine versus placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0129" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3] ">Adams 2014</a>, <a href="./references#CD009831-bbs2-0190" title="ShenX , XiaJ , AdamsCE . Flupenthixol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD009777.pub2] ">Shen 2012</a>, <a href="./references#CD009831-bbs2-0182" title="MothiM , SampsonS . Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD001949.pub3] ">Mothi 2013</a>, <a href="./references#CD009831-bbs2-0167" title="KochK , MansiK , HaynesE , AdamsCE , SampsonS , FurtadoVA . Trifluoperazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010226] ">Koch 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0075" title="CostaAMN , DeLimaMS , FariaM , FilhoSR , DeOliveiraIR , DeJesus MariJ . A naturalistic, 9‐month follow‐up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. Journal of Psychopharmacology2007;21:165‐70. ">Costa 2007</a>, <a href="./references#CD009831-bbs2-0078" title="deJesus MariJ , LimaMS , CostaAN , AlexandrinoN , Rodrigues‐FilhoS , deOliveiraIR , et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomised trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. European Archives of Psychiatry and Clinical Neuroscience2004;254:356‐61. ">de Jesus Mari 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antipsychotic drug versus olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0144" title="DugganL , FentonM , RathboneJ , DardennesR , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] ">Duggan 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0085" title="FitzgeraldCH . A double‐blind comparison of haloperidol with perphenazine. Current Therapeutic Research1969;11:515‐9. ">Fitzgerald 1969</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus perphenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0157" title="HartungB , WadaM , LauxG , LeuchtS . Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews2005, (1). [DOI: 10.1002/14651858.CD003443.pub2] ">Hartung 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0097" title="KelwalaS , BanTA , BerneySA , WilsonWH . Rapid tranquilization ‐ a comparative study of thiothixene and haloperidol. Progress in Neuropsychopharmacology and Biological Psychiatry1984;8:77‐83. ">Kelwala 1984</a>, <a href="./references#CD009831-bbs2-0101" title="LevensonAJ , BurnettGB , NottinghamJD , SermasCE , ThornbyJI . Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol. Current Therapeutic Research, Clinical and Experimental1976;20:695‐700. ">Levenson 1976</a>, <a href="./references#CD009831-bbs2-0120" title="StotskyBA . Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Diseases of the Nervous System1977;38:967‐73. ">Stotsky 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus thiothixene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0101" title="LevensonAJ , BurnettGB , NottinghamJD , SermasCE , ThornbyJI . Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol. Current Therapeutic Research, Clinical and Experimental1976;20:695‐700. ">Levenson 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine versus haloperidol // fluphenazine versus thiothixene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0103" title="LovettWC , StokesDK , TaylorLB , YoungML , FreeSM , PhelanDG . Management of behavioral symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol. Journal of Clinical Psychiatry1987;48:234‐36. ">Lovett 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus trifluoperazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0110" title="PaprockiJ , VersianiM . A double‐blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Current Therapeutic Research, Clinical and Experimental1977;21:80‐100. ">Paprocki 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus loxapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0138" title="ChakrabartiA , BagnallA , ChueP , FentonM , PalaniswamyV , WongW , et al. Loxapine for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 10. [DOI: 10.1002/14651858.CD001943.pub2] ">Chakrabarti 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0113" title="ReznikI , SirotaP , PsychM . Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. Journal of Clinical Psychopharmacology2000;20:410‐6. ">Reznik 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluvoxamine plus antipsychotic drug versus antipsychotic drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0114" title="SaletuB , KufferleB , GrunbergerJ , AndererP . Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy. Pharmacopsychiatry 19;1986:434‐7. ">Saletu 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluperlapine versus haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies and suggestions for relevant reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009831-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggested design of study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, fully explicit description of methods of randomisation and allocation concealment.<br/> Blinding: blinded and independent raters.<br/> Duration: at least 52 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia (according to a diagnostic criteria).<br/> N = 300.*<br/> Age: adults.<br/> Sex: both. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Haloperidol. N = 150.</p> <p>2. Other first‐generation antipsychotic. N = 150.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global state: clinically important response to treatment, average score/change of the global state. </p> <p>General: time to all‐cause treatment failure marked by its discontinuation, relapse, general impression of clinician (CGI), carer/other, compliance with treatment, healthy days. </p> <p>Mental state: general measurement and specific domains (depressive symptoms, positive symptoms, negative symptoms) </p> <p>Leaving the study early (‘drop‐out’) due to any reason, due to inefficacy of treatment, and due to adverse events. </p> <p>Adverse events: any serious adverse event recorded.</p> <p>Service use: number of hospitalisation, days in hospital.<br/> Quality of life.<br/> Social functioning: return to everyday living for 80% of time.*<br/> Economic outcomes. </p> <p>Pharmacological interactions.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of ˜ 20% between groups for primary outcome with adequate degree of certainty. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>CGI = Clinical Global Impression.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggested design of study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009831-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Haloperidol versus first‐generation antipsychotics for schizophrenia (short term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Haloperidol versus first‐generation antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia </p> <p><b>Setting:</b> inpatients and outpatients<br/> <b>Intervention:</b> haloperidol versus other first‐generation antipsychotics (short term) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>first‐generation antipsychotic drugs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> haloperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinically important response to treatment (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.93</b> <br/> (0.87 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2132<br/> (40 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>457 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>425 per 1000</b> <br/> (398 to 457) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>532 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>495 per 1000</b> <br/> (463 to 532) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to any reason as a measure of overall acceptability (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.04</b> <br/> (0.87 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1299<br/> (28 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>209 per 1000</b> <br/> (175 to 250) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>142 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> <br/> (124 to 176) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to inefficacy of treatment as a measure of overall efficacy (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.93</b> <br/> (0.4 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>507<br/> (13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> <br/> (17 to 94) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to adverse events as a measure of overall tolerability (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1</b> <br/> (0.42 to 2.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>640<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> <br/> (13 to 73) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: number of participants with at least one adverse effect (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.06</b> <br/> (0.94 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>693<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>615 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>652 per 1000</b> <br/> (578 to 738) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>588 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> <br/> (553 to 706) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (short term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.12</b> <br/> (0.95 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>998<br/> (17 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>409 per 1000</b> <br/> (347 to 479) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>410 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>459 per 1000</b> <br/> (389 to 537) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes<sup>6</sup>. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias ‐ rated 'very serious': many studies did not report the methods for sequence generation and/or allocation concealment and were not free from selective reporting.<br/> <sup>2</sup> Inconsistency ‐ rated 'no': there was no substantial level of heterogeneity (defined by an I<sup>2</sup> greater than or equal to 50% accompanied by a statistically significant Chi<sup>2</sup> test). The direction of the effect of almost all studies was the same. Therefore, the overall results are not challenged by inconsistency. </p> <p><sup>3</sup>Publication bias ‐ rated 'undetected': based on the largely symmetrical arrangement of the trials in the funnel plot the likelihood for the presence of a publication bias can be regarded as being low. </p> <p><sup>4</sup> Imprecision ‐ rated 'very serious': the 95% confidence interval around the pooled effect size includes "no effect", "appreciable benefit", and "appreciable harm". </p> <p><sup>5</sup> Imprecision ‐ rated 'serious': the 95% confidence interval around the pooled effect size includes both "no effect" and "appreciable harm".<br/> <sup>6</sup> The basis for the assumed risk was the risk in the pooled control group of the relevant studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Haloperidol versus first‐generation antipsychotics for schizophrenia (short term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009831-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Haloperidol versus first‐generation antipsychotics for schizophrenia (medium term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Haloperidol versus first‐generation antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia </p> <p><b>Setting:</b> inpatients and outpatients<br/> <b>Intervention:</b> haloperidol versus other first‐generation antipsychotics (medium term) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>first‐generation antipsychotic drugs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>haloperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinically important response to treatment (medium term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.51</b> <br/> (0.37 to 0.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>80<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>510 per 1000</b> <br/> (370 to 690) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>510 per 1000</b> <br/> (370 to 690) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to any reason as a measure of overall acceptability (medium term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.75 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>137<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>543 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>554 per 1000</b> <br/> (407 to 749) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>548 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>559 per 1000</b> <br/> (411 to 756) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early due to adverse events as a measure of overall tolerability (medium term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: number of participants with at least one adverse effect (medium term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.07</b> <br/> (0.58 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>137<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>657 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>703 per 1000</b> <br/> (381 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>708 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>758 per 1000</b> <br/> (411 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (medium term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.04</b> <br/> (0.62 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>80<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>421 per 1000</b> <br/> (251 to 708) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>421 per 1000</b> <br/> (251 to 709) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes<sup>7</sup>. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias ‐ rated 'very serious': many studies did not report the methods for sequence generation and/or allocation concealment and were not free from selective reporting.<br/> <sup>2</sup> Risk of bias ‐ rated 'very serious': many studies did not report the methods for sequence generation and/or allocation concealment and were not free from selective reporting. High risk of bias regarding other bias in two studies (<a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>, <a href="./references#CD009831-bbs2-0013" title="EngelhardtDM , RudorferL , RosenB . Haloperidol and thiothixene in the long‐term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment. Journal of Clinical Psychiatry1978;39:834‐40. ">Engelhardt 1978</a>) and in terms of blinding in one trial (<a href="./references#CD009831-bbs2-0001" title="AbuzzahabFS , ZimmermanRL . Psychopharmacological correlates of post psychotic depression: a double‐blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry1982;43:105‐10. ">Abuzzahab 1982</a>). </p> <p><sup>3</sup> Inconsistency ‐ rated 'no': there was no substantial level of heterogeneity (defined by an I<sup>2</sup> greater than or equal to 50% accompanied by a statistically significant Chi<sup>2</sup> test). The direction of the effect of almost all studies was the same. Therefore, the overall results are not challenged by inconsistency. </p> <p><sup>4</sup> Inconsistency ‐ rated 'very serious': there was a substantial level of heterogeneity (defined by an I<sup>2</sup> greater than or equal to 50% accompanied by a statistically significant Chi<sup>2</sup> test). </p> <p><sup>5</sup> Publication bias ‐ rated 'undetected': based on the largely symmetrical arrangement of the trials in the funnel plot the likelihood for the presence of a publication bias can be regarded as being low.<br/> <sup>6</sup> Imprecision ‐ rated 'very serious': the 95% confidence interval around the pooled effect size includes "no effect", "appreciable benefit", and "appreciable harm".<br/> <sup>7</sup> The basis for the assumed risk was the risk in the pooled control group of the relevant studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Haloperidol versus first‐generation antipsychotics for schizophrenia (medium term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009831-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in this series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0175" title="LeuchtC , KitzmantelM , KaneJ , LeuchtS , ChuaWLLC . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2] ">Leucht 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol vs low‐potency first‐generation antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0193" title="TardyM , HuhnM , KisslingW , EngelRR , LeuchtS . Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009268] ">Tardy 2011a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perphenazine versus low‐potency first‐generation antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0194" title="TardyM , HuhnM , EngelRR , LeuchtS . Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD009369] ">Tardy 2011b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine versus low‐potency first‐generation antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0195" title="TardyM , HuhnM , EngelRR , LeuchtS . Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD009230] ">Tardy 2011c</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0196" title="TardyM , DoldM , EngelRR , LeuchtS . Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009396] ">Tardy 2011d</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flupenthixol versus low‐potency first‐generation antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009831-bbs2-0197" title="TardyM , DoldM , EngelRR , LeuchtS . Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD009227] ">Tardy 2011e</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in this series</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/full#CD009831-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009831-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Clinically important response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.37, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Average score (CGI, endpoint, short term, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.39, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1. General ‐ a. Average score (BPRS total, endpoint, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [‐1.66, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1. General ‐ b. Average score ‐ short term (various scales, endpoint, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 MRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 RSQPSS (at 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.04, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 2. Specific ‐ a. Depersonalisation average score ‐ short term (AMDP, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.62, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 2. Specific ‐ b. Depressive symptoms average score (HAM‐D, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.23, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 2. Specific ‐ c. Negative symptoms average score ‐ short term (SANS, endpoint, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐2.13, 2.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 2. Specific ‐ d.i. Positive symptom average score ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 conceptual disorganisation (AMDP, endpoint, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [2.07, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 delusional symptoms (AMDP, endpoint, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [2.13, 4.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 positive symptoms (SAPS, endpoint, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.7 [‐17.42, ‐11.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 2. Specific ‐ d.ii. Positive symptoms average score ‐ short term (AMDP, skewed or incomplete data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 hallucinatory symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 paranoid symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Behaviour: 1a. Average score ‐ short term (NOSIE, endpoint, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Behaviour: 1b. Average score ‐ short term (Wing’s Ward Behaviour Scale, endpoint, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.27 [‐4.51, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Leaving the study early: 1. Due to any reason ‐ as a measure of overall acceptability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.87, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.75, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Leaving the study early: 2. Due to inefficacy of treatment ‐ as a measure of overall efficacy (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.40, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Leaving the study early: 3. Due to adverse events ‐ as a measure of overall tolerability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.42, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 1. General ‐ at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.94, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.58, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 2. Specific ‐ a. Movement disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 akathisia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.89, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 akathisia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.16, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 akinesia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.31, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 at least one extrapyramidal/movement disorder ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.95, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 at least one extrapyramidal/movement disorder ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.62, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 dyskinesia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.48, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7 dystonia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.95, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8 rigor ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.81, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.9 rigor ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.39, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10 tardive dyskinesia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.06, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.11 tardive dyskinesia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.12 tremor ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.13 tremor ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.28, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.14 use of antiparkinson medication ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.89, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 2. Specific ‐ b. Various <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 death ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 hypotension ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.31, 3.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 sedation ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.45, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 weight gain ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.21, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 weight gain ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.05, 5.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">HALOPERIDOL versus FIRST‐GENERATION ANTIPSYCHOTIC DRUGS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009831-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Sensitivity analysis ‐ Implication of randomisation, Outcome: overall symptoms of schizophrenia (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sensitivity analysis ‐ Exclusion of cross‐over‐trials, Outcome: overall symptoms of schizophrenia (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Sensitivity analysis ‐ Exclusion of non double‐blind trials, Outcome: overall symptoms of schizophrenia (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sensitivity analysis ‐ Fixed versus random‐effects models, Outcome: overall symptoms of schizophrenia (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009831-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Subgroup analysis ‐ different antipsychotic drugs (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Bromperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.88, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Clopenthixol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.52, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Droperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Flupenthixol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Fluphenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.37, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Loxapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.87, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Molindone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Nemonapride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.33, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 Perphenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.7 [0.41, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 Pimozide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.74, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 Pipotiazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.39, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12 Sulpiride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.50, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13 Tiopropazate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.73, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14 Thiothixene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.70, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15 Timiperone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.57, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16 Trifluoperazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.68, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17 Trifluperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.53, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18 Zuclopenthixol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.70, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Subgroup analysis ‐ different antipsychotic drugs (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.37, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Thiothixene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.37, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Subgroup analysis ‐ treatment‐resistant participants (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Trials with treatment‐resistant participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.66, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Trials without treatment‐resistant participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009831.pub2/references#CD009831-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009831.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009831-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009831-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009831-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009831-note-0002">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009831\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009831\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009831\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009831\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009831.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009831.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009831.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009831.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009831.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729751022"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009831.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729751026"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009831.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee486995f9377',t:'MTc0MDcyOTc1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 